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Abstract 
The history of radiation therapy for the treatment of cancer began over hundred years 
ago at the turn of the nineteenth century, and today, still constitutes an important arm of 
cancer therapy. Advances in tumor imaging techniques and specialized software allow 
for three-dimensional treatment planning and dose application, and further improved the 
standard of radiotherapy. With intensity-modulated radiation therapy (IMRT), radiation 
doses can now be precisely focused on the irregularly shaped tumor area while sparing 
normal tissue.  
It is the goal of radiotherapy to deprive tumor cells of their replicative potential. 
Ionizing radiation damages cells by the introduction of DNA damage. Ionizing radiation 
induced DNA double-strand breaks in particular are most toxic for an irradiated cell. 
Even though cancer cells often exhibit an increased apoptotic threshold, they often also 
exhibit deficiencies in their DNA repair capacity or in their capability to refrain from 
cell cycle progression in presence of DNA damage. These factors increase their suscep-
tibility to radiation treatment. Importantly, proliferating cells, such as cancer cells, are 
more susceptible to DNA damage, based on the increased radiosensitivity of cells 
residing in late G2 and M phase. Furthermore, the combination of IR with conventional 
chemotherapy intends to increase DNA damage, to modulate the apoptotic threshold or 
to synchronize proliferating cells into the sensitive M phase. In recent years, greater 
understanding of tumor biology also offers the possibility of targeting “cancer-specific” 
signaling pathways. Pathways considered for targeting include signaling entities related 
to proliferation and survival or aim for synthetic lethality in combination with the 
cancer cell’s inherent deficiencies. Today, mainly two classes of molecular targeting 
agents have been approved for clinical application: monoclonal antibodies that bind and 
inhibit cell surface receptors or secreted factors, and small molecules that penetrate cells 
and are designed to interfere with the enzymatic activity of the target protein.  
Molecular targeting of cancer cells with regard to radiosensitization is the main topic of 
this thesis. The first part is dedicated to the inhibition of the epidermal growth factor 
receptor (EGFR) by a non-immunoglobulin scaffold protein, a designed ankyrin repeat 
protein (DARPin). The epidermal growth factor receptor signaling cascades are 
involved in regulation of growth, proliferation, survival and differentiation of mamma-
lian cells. Overexpression of EGFR is often found in cancers of epithelial origin and is 
associated with a malignant phenotype. EGFR inhibition in combination with radiation 
therapy has been reported to improve patient outcome, though responses of different 
tumor entities are heterogeneous and the molecular mechanism is not well understood. 
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Presently, antibody-based as well as small molecular EGFR inhibitors are in clinical 
use. 
The protein entity we used for EGFR targeting is a designed protein consisting of sever-
al assembled ankyrin repeats. The ankyrin motif, two α-helices followed by a β-turn, is 
adapted from natural ankyrin repeats that are part of protein-protein interaction 
interfaces. Mechanistically, DARPins can be selected to bind and inhibit extracellular 
targets similar to antibodies and with even superior affinity.  
In this study, we compared efficacy of EGFR inhibition by the DARPin E69_LZ3_E01 
with the efficacy of the monoclonal anti-EGFR antibody cetuximab, each agent individ-
ually and in combination with ionizing radiation. We determined the effect of EGFR 
inhibition on cell cycle distribution and proliferation in the vulvar squamous carcinoma 
cell line A431, a widely used EGFR model cell line. By means of classical and 3D 
clonogenic assays, we assessed radiosensitization upon EGFR inhibition in A431 cells. 
Furthermore, and with regard to the in vivo application, we investigated the dynamics of 
EGFR inhibition by DARPin E69_LZ3_E01 and cetuximab, and EGFR reconstitution 
and cell recovery upon retraction of the inhibitors. Finally, the DARPin E69_LZ3_E01 
was tested in a preclinical setting in A431 tumor xenografts in nude mice, as mono-
therapy and in combination with ionizing radiation, in comparison to cetuximab. 
In vitro, inhibition of the EGFR in A431 cells suppressed proliferation, which was also 
reflected in the accumulation of cells in the G1 phase of the cell cycle. The antiprolifer-
ative effect of DARPin E69_LZ3_E01 on A431 cells was more pronounced than for the 
antibody cetuximab. On the level of EGFR signaling, DARPin E69_LZ3_E01 did not 
only lead to stronger repression of EGF-stimulated activation of the downstream target 
Erk, but also to an enhanced downregulation of the EGFR. Upon removal of either 
inhibitor, cells recovered rapidly within few hours.  
In combination with radiation, we could not demonstrate a direct radiosensitization 
induced by EGFR inhibition in A431 cells in vitro. However, combined treatment of 
A431 tumor xenografts with radiation and cetuximab was superior to either modality 
alone and resulted in a complete tumor remission in 6 out of 10 animals. In contrast to a 
dense daily regimen, no tumor growth delay was induced by DARPin E69_LZ3_E01. 
The pharmacokinetic analysis of DARPin E69_LZ3_E01 revealed that the half-life of 
the pegylated DARPin, which was used for the in vivo experiment, most probably was 
not sufficient to maintain continuous receptor inhibition.  
In the second part of the thesis, radiosensitization by the knockdown of the major vault 
protein (MVP) was investigated in various human cancer cell lines. MVP is the major 
component of a big barrel-like protein complex named vault. The precise function of 
vaults, which are highest expressed in tissues chronically exposed to xenobiotics, is not 
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well known. Like EGFR, MVP is often overexpressed in cancer cells and correlates 
with poor patient outcome. Curiously, MVP is not an essential protein, as MVP-
deficient mice develop normally. Moreover, no enzymatic activity has been assigned to 
vaults, but associated proteins, like TEP1, vPARP as well as multiple vRNAs that are 
localized in the interior of vaults, may have functional roles.  
Depletion of MVP by means of siRNA sensitized the lung cancer cell line A549 and the 
colon cancer cell line HCT116 to irradiation and greatly inhibited their proliferation. 
The inhibitory effect on proliferation, however, varied greatly among additional cell 
lines tested. Strikingly, proliferation of p53-proficient cell lines was more strongly 
affected by MVP silencing than proliferation of p53-deficient cell lines. Unfortunately, 
the discrepancies among the different phenotypes induced by additional MVP-targeting 
siRNA sequences and the failure to proof the link between the MVP knockdown and the 
resulting phenotypes by rescue experiments, led us to conclude that nonspecific effects 
introduced by the siRNA technique might be the reason for the MVP knockdown 
phenotype observed.  
Consequently and despite in-depth investigations, we could not confirm the previously 
proposed link between MVP and DNA repair. Nevertheless, independently of the 
knockdown experiments, we observed that MVP expression was induced by ionizing 
radiation. An increase in MVP expression levels in response to various other stress 
stimuli was reported previously. Interestingly, we observed that this irradiation-induced 
increase of MVP was at least in part regulated in an autocrine manner. This may be the 
cause for the delayed time point of MVP-induction, we observed. Others demonstrated 
that MVP was also upregulated in senescent cells to prevent induction of apoptosis. In 
cancer cells, MVP may be upregulated in response to ionizing radiation or other stress 
stimuli, to contribute to cell death resistance. 
Zusammenfassung 
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Zusammenfassung 
Die Geschichte der klinischen Anwendung von Radiotherapie begann vor mehr als 
hundert Jahren und bildet auch heute noch eine wichtige Grundlage für die Behandlung 
von Krebserkrankungen. Grosse technische Fortschritte in Bildgebung und Software 
ermöglichen eine dreidimensionale Planung des Bestrahlungseingriffs und eine Ver-
besserung der herkömmlichen Radiotherapie. Zusammen mit modernen Bestrahlungs-
techniken wie der Intensitätsmodulierten Strahlentherapie (IMRT) wird eine genaue 
Fokussierung auch auf unregelmässig geformte Tumore gewährleistet, während das 
umliegende gesunde Gewebe geschont werden kann.  
Ziel der Radiotherapie ist es, diejenigen Tumorzellen, die die Fähigkeit haben sich zu 
teilen, abzutöten oder ihnen die Teilungsfähigkeit zu nehmen. Die Bestrahlung des 
Tumorgewebes induziert DNA Schäden, wovon Doppelstrangbrüche für die Zelle am 
schädlichsten sind. Obwohl bei malignanten Zellen der Zelltod oft verspätet ausgelöst 
wird, ist bei Krebszellen auch häufig die DNA-Reparaturkapazität beeinträchtigt, sowie 
auch die Möglichkeit in einer Phase des Zellzyklus anzuhalten um die Schäden zu 
beheben. Zudem sind proliferierende Zellen, wie es Krebszellen sind, strahlen-
empfindlicher; Zellen, die sich in der späten G2-Phase und in der M-Phase des Zell-
zyklus befinden, sind anfälliger für Strahlenschäden. Strahlentherapie wird oft mit 
konventioneller Chemotherapie kombiniert, die die Bestrahlung unterstützt, indem 
zusätzliche DNA Schäden zugefügt, der programmierte Zelltod gefördert, oder die 
Zellen in der Strahlen-sensitiven M-Phase synchronisiert werden. Zunehmendes 
Verständnis der Tumorbiologie eröffnete neue Möglichkeiten tumorspezifische Signal-
wege zu inhibieren. Zwei Klassen solcher tumorspezifischen Medikamente sind zum 
heutigen Zeitpunkt in klinischer Anwendung: Monoklonale Antikörper, die Rezeptoren 
an der Zelloberfläche binden und inhibieren und kleinmolekulare Inhibitoren, die ihre 
Wirkungen auf die enzymatische Aktivität eines Proteins innerhalb der Zelle entfalten.  
Inhalt dieser Doktorarbeit ist das Thema „Tumorspezifische Radiosensibilisierung“. Der 
erste Teil der Dissertation handelt von der Inhibition des epidermalen Wachstums-
rezeptors (EGFR) durch Nicht-Immunoglobulin-verwandte Gerüstproteine, sogenannte 
DARPins (designed ankyrin repeat proteins). EGFR ist mitverantwortlich für die 
Regulierung des Zellwachstums und der Proliferation. Der Rezeptor spielt auch eine 
Rolle für die Erhaltung der Lebensfähigkeit einer Zelle und ist an Differenzierungs-
prozessen der Zelle beteiligt. EGFR ist in epithelialen Tumoren oft überexprimiert und 
assoziiert mit aggressiven Krebsarten. Inhibition des Rezeptors in Kombination mit 
Radiotherapie erzielte gute Ergebnisse und wird in der Klinik eingesetzt, obwohl die 
molekularen Mechanismen der Wirkung nicht genau ergründet sind. Dabei werden 
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sowohl anti-EGFR Antikörper wie auch kleinmolekulare Inhibitoren gegen den Rezep-
tor verwendet.  
DARPins, die wir für die Inhibition des EGF-Rezeptors verwendeten, sind Designer-
proteine, die aus repetitiven Motiven bestehen. Ein einzelnes Motiv besteht aus zwei α-
Helices, gefolgt von einer β-Schleife und beruht auf der Struktur natürlich vorkom-
mender „Ankyrin-Repeat“ Motive, die Teil von Proteininteraktionsflächen sind. 
Ähnlich wie Antikörper, und mit zum Teil noch grösserer Affinität, können DARPins 
den extrazellulären Teil eines Zielproteins binden und diesen möglicherweise inhi-
bieren. DARPin E69_LZ3_E01 verfügt über zwei solcher EGFR-Bindungsdomänen, 
die über einen Leucin-Reissverschluss miteinander verbunden sind. Dadurch bilden sich 
Dimere, die über vier Bindungsdomänen verfügen.  
Ziel der Studie war es, die Wirksamkeit von DARPin E69_LZ3_E01 in Bezug auf 
EGFR-Inhibition und Radiosensibilisierung, mit derjenigen des monoklonalen Anti-
körpers Cetuximab zu vergleichen. Wir untersuchten den Effekt der EGFR-Inhibition 
auf die Zellzyklusverteilung der Sarkomazelllinie A431, die häufig für Studien in Bezug 
auf EGFR verwendet wird. Weiter betrachteten wir die Dynamik der EGFR-Inhibition 
und die Dynamik der Widerherstellung der ursprünglichen Funktionsfähigkeit der 
Rezeptoren nach Entfernung der Inhibitoren aus dem Zellkulturmedium. Die klonogene 
Überlebensrate in Kombination mit Bestrahlung wurde auf klassische Weise in adhä-
renten Zellen und in 3D-Zellkultur bestimmt und schlussendlich untersuchten wir die 
kombinierte Behandlung von DARPin E69_LZ3_E01 mit Bestrahlung in einem präk-
linischen Versuchsaufbau im Nacktmaus-Tumorxenograft-Modell. Zum Vergleich 
führten wir den gleichen Versuch mit Cetuximab durch. 
In der EGFR-überexprimierenden Zellenlinie A431 führte die Inhibition des EGF-
Rezeptors in Zellkultur zu einer Verminderung des Wachstums, welche sich auch in der 
Akkumulation der Zellen in der G1-Phase des Zellzyklus zeigte. DARPin 
E69_LZ3_E01 zeigte dabei eine stärkere Wirkung als der Antikörper Cetuximab. 
Zudem war die Wachstumsfaktor-induzierte Phosphorylierung von Erk, einem Folge-
protein der EGFR Signalkaskade, in den Zellen, die mit DARPins behandelt wurden, 
stärker unterdrückt. Ebenso führte die Behandlung mit DARPins im Vergleich zur 
Behandlung mit Cetuximab im Allgemeinen zu einer stärkeren Verminderung der 
Anzahl der EGF-Rezeptoren. Nach Entfernung beider Inhibitoren erholten sich die 
Zellen jeweils innerhalb weniger Stunden. 
Wir konnten keine Radiosensibilisierung durch EGFR-Inhibition in A431 Zellen nach-
weisen. Im Tierversuch zeigte Cetuximab in Kombination mit Bestrahlung eine syner-
gistische Wirkung und führte bei 6 von 10 Tieren zu einer kompletten Remission der 
Tumorxenografte. Obwohl DARPin E69_LZ3_E01 täglich initiiert wurde, konnten wir 
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keine Wirkung in Bezug auf Tumorwachstum feststellen. Eine Untersuchung der 
Pharmakokinetik zeigte jedoch, dass die pegylierte Form von DARPin E69_LZ3_E01 
eine noch immer ungenügende Serumhalbwertszeit aufweist, um eine andauernde 
Inhibition des Rezeptors zu gewährleisten.  
Im zweiten Teil der Dissertation wird das „Major Vault Protein“ (MVP) als mögliches 
Zielprotein für Radiosensibilisierung in Betracht gezogen. MVP ist der Haupt-
bestandteil eines fassähnlichen Proteinkomplexes. Die Funktion von MVP, das vor 
allem in Umwelt exponierten Geweben stark exprimiert wird, ist kaum bekannt. 
Ähnlich wie bei EGFR, ist eine Überexpression von MVP in Krebszellen mit schlech-
teren Prognosen für den Patienten assoziiert. Interessanterweise ist MVP kein essen-
tielles Gen und Knockout-Mäuse entwickeln sich normal. Dem Protein MVP, das das 
Gerüst des Proteinkomplexes bildet, konnte bislang keine enzymatische Funktion 
zugewiesen werden. Allerdings könnten andere Proteine wie TEP1, vPARP oder auch 
vRNAs, die alle fester Bestandteil des Komplexes sind, ein solche Funktion haben. 
Das Unterdrücken der MVP Expression durch Applikation von siRNA (MVP Knock-
down) führte zu einer stark verminderten Zellproliferation und zu einer Radiosensi-
bilisierung der Lungenkrebs Zelllinie A549 und der Darmkrebs Zelllinie HCT116. Der 
Einfluss auf die Zellproliferation variierte jedoch stark in ihrer Ausprägung in weiteren 
Zelllinien, die wir untersuchten. Zelllinien mit intaktem p53 Protein waren stärker 
betroffen, als Zelllinien mit einer p53-Defizienz. Allerdings zeigten sich zwischen den 
verschiedenen siRNA Sequenzen die wir für den Knockdown von MVP verwendeten 
grosse Inkonsistenzen. Zudem konnte die Verminderung der Proliferation durch die 
Expression von siRNA-resistenter MVP-mRNA nicht verhindert werden. Zusätzliche 
Experimente deuteten ebenfalls darauf hin, dass die Ausprägung des Proliferations-
Phänotyps auf unspezifischen Effekten der verwendeten siRNA Sequenzen beruhten 
könnte.  
Wir konnten zwar keine direkte Verbindung zwischen MVP und der DNA Reparatur-
maschinerie herstellen, aber konnten feststellen, dass die Expression von MVP in Folge 
von Bestrahlung erhöht wird. Eine erhöhte Expression von MVP in Folge von verschie-
denen anderen Stressfaktoren ist bereits anderweitig beschrieben worden. Interes-
santerweise stellten wir fest, dass die Induktion von MVP teilweise über sekretierte 
Faktoren reguliert wird, was auch den späten Zeitpunkt der Aufregulierung erklären 
könnte. Die MVP Expression ist in seneszenten Zellen erhöht und wirkt der Induktion 
des programmierten Zelltodes entgegen. Möglicherweise spielt MVP eine ähnliche 
Rolle in Krebszellen und trägt nach Bestrahlung oder nach Einwirkung anderer 
Stressfaktoren zur die Resistenz gegenüber dem Zelltod bei. 
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1 General Introduction 
1.1 A Brief Overview on the Prevalence of Cancer 
The term “cancer” stands for a multifaceted disease that may arise in virtually any tissue 
of the human body. Cancer is characterized by uncontrolled growth of cells that do not 
contribute to or even may impair the functionality of the tissue of origin. Cancer cells 
may spread to distant sites and compromise multiple organs. Besides cardiovascular 
diseases, cancer is a major cause of death in developed countries. However, though the 
number of annual new cases of all cancers combined shows a considerable geographical 
variation. In 2012, there were an estimated 3.45 million new cases of cancer in Europe. 
The most common cancers were breast cancer for females, followed by colorectal 
cancer, prostate cancer in men and in fourth position lung cancer; altogether these four 
cancer types account for half of the tumor burden. An overview on cancer incidences 
and mortality divided according to tissue and gender is shown in Figure 1.1. 
 
Figure 1.1 Distribution of the expected incidences and deaths for the five most common cancers 
in Europe 2012. The size of the pie charts reflects the total number of incidences or deaths 
(adapted from [1]). 
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1.2 The Development of Cancer and Possible Causes in Brief 
Cancer arises from somatic DNA mutations, though the prevalence of a cancer-relevant 
germ line mutation increases the development of malignant neoplasms [2, 3]. This 
observation and the fact that the number of cancer incidences increases with age, led to 
the suggestion that the development of cancer is a multistep process facilitated by the 
accumulation of mutations [4]. The hypothesis that cellular defects may be inherited by 
daughter cells and may lead to abnormalities in growth, already had been postulated by 
Theodor Boveri in the beginning to the 19th century, after he had observed that areas 
with abnormal growth patterns occasionally emerged from induced multipolar mitosis 
in a developing Echinus embryo (reviewed in [5]). However, not all species seem to be 
equally prone to develop cancer, and men living in different countries with different 
habits have differential risks to develop a certain cancer type, independent of the 
ethnicity. This suggests that genetic factors determine the susceptibility of developing 
cancer and that customary or environmental factors influence and favor the origination 
of certain cancer types.  
Customary and environmental factors comprise the exposure to hazardous agents, such 
as ultraviolet (UV) radiation or to chemical substances that directly introduce DNA 
damage and may lead somatic mutations that have the potential to contribute to 
malignant transformation of the affected cells. Innate defects in the DNA repair capacity 
greatly increase the occurrence of mutations and thus the chance of cancer development. 
Similarly, obtained defects in the DNA repair machinery lead to genomic instability and 
greatly influence the rate of mutations, whereas under normal circumstances DNA 
damage is repaired efficiently and the acquisition of mutations is very low. In fact, 
acquisition of mutations that lead to genomic instability has been proposed to be a 
prerequisite for tumorigenesis [6].  
Chronic inflammation, e.g. induced by exposure to asbestos, has been shown to 
positively influence the process of cancer formation by modulating enzyme activity in 
the tumor environment, and the infiltrating immune cells support tumor growth by 
releasing angiogenic, growth and survival factors [7]. Inflammatory cells such as 
macrophages produce reactive oxygen species (ROS) that can lead to additional DNA-
damage and genetic alterations. Such inflammatory responses have been shown to take 
place across a wide variety of solid tumors and together with genomic instability are 
described as “enabling characteristics”; characteristics that promote tumorigenesis (see 
Figure 1.2, section below). Certain habits act on both levels such as smoking, which is 
associated with a number of cancer types, such as cancer of the lung, the oral cavity, the 
larynx and the esophagus. Tobacco smoke contains numerous hazardous substances that 
in combination display increased mutagenic activity and contribute to acute and chronic 
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inflammatory responses, which increase the risk of cancer development. Explicitly, the 
number of years of smoking and smoking cessation influence the related cancer death 
rates [8, 9]. Alcohol consumption, another widespread habit, also influences the risk of 
cancer development in a dose-dependent manner [10], and in combination with 
smoking, the observed risk exceeds the multiplicative joint effect determined from 
either alcohol or smoking alone. [11]. 
Also viral infections have been associated with cancer formation. The human papilloma 
virus (HPV) is thought to be the major cause of cervical cancers and hepatitis B (HBV) 
and hepatitis C (HCV) viral infections may be involved in the formation of liver cancer. 
Mechanistically, viral gene products may contribute to cell survival to ensure viral 
replication, and certain viral genomes that integrate into the hosts’ genome may lead to 
deregulated protein expression [12, 13]. Moreover, persisting viral infections contribute 
to chronic inflammation, indirectly supporting carcinogenesis as described previously 
[14]. Similarly, the infection with the bacterium helicobacter pillory leads to chronic 
gastritis and is the primary cause of peptic ulcers. 
Certain risk factors that contribute to cancer development can be reduced, for example 
by the banning of known carcinogens, such as asbestos or by refraining from unprotect-
ed sunbathing or excessive alcohol consumption and so on. However, other factors can-
not be evaded like hereditary predisposition or aging processes that lead to an increased 
cancer risk. Thus, in developed countries cancer incidences certainly also have 
increased as a result of the increase in average age. 
1.3 Tumor Biology: The Hallmarks of Cancer 
Cancer and even tissue-specific cancer is not a single disease, but a collection of diseas-
es. At the beginning of the century, Hanahan and Weinberg suggested that six principles 
(hallmarks) were inherent to all cancer types and would help to understand how loss or 
gain of function of certain genes may support disease formation [15]. Over the years, 
additional hallmark were proposed and incorporated into the theoretical framework (see 
Figure 1.2). According to theory, cancer development as a multistep process and the 
hallmarks can be viewed as steps that may take place in various orders. The first steps 
towards malignancy are probably almost always changes that lead to increased prolifer-
ation such as the obtainment of “self-sustained proliferative capacity” and the “capa-
bility to evade growth inhibitory signals”. In normal tissues, proliferation and cell 
survival is tightly regulated by growth factors whose release and regulation is poorly 
understood. Cancer cells overcome their dependence on these external signals in various 
ways, e.g. through autocrine secretion of the necessary growth factors, by increasing the 
expression of the corresponding receptors or by activating mutations in the downstream 
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signaling pathways. Homeostasis of cellular proliferation in normal cells is secured by 
intracellular feedback loops that negatively regulate cell proliferation. However, in the 
evolving cancer cell the activity of e.g. PTEN, one of the proteins involved in safe-
guarding, is often quiesced by suppression of expression or by loss-of-function 
mutations [16]. Furthermore, in pre-malignant cells, the increased activation of proto-
oncogenes that leads to aberrant proliferative behavior, normally induces senescence or 
leads to programmed cell death (apoptosis) of the cell. Thus, the “evasion of 
programmed cell death” is yet another hallmark of cancer and is achieved by loss-of-
function mutations of critical regulatory proteins such as the tumor suppressor p53 or by 
the upregulation of anti-apoptotic proteins like Bcl-2.  
A B 
    
Figure 1.2 Hallmarks of cancer by Hanahan and Weinberg. (A) Six traits were found to be 
common to all types of cancer, and are thought to be indispensable for the development of 
neoplasms [15]. (B) Additional hallmarks have been suggested over the years and were assigned 
to the category of tumor “Enabling Characteristics” or to the category of characteristics that 
are thought to evolve in order to meet the cancers demands and to ensure its survival (“Emerg-
ing Hallmarks”) [6]. 
In human cells, telomeres shorten at each round of replication. At a critical length, the 
structure formed by telomeres becomes disrupted, the unprotected DNA ends are recog-
nized by the DNA damage repair machinery, and the cell undergoes senescence. Thus to 
achieve the trait of “unlimited replicative potential” a majority of cancer cells reexpress 
telomerase, the expression of which is normally only detected in stem cells [17].  
Increased proliferation is also connected with replicative stress and increased demands 
for energy and metabolic resources in order to support cell doubling. Both, replication 
stress and reactive oxygen species (ROS) from the increased metabolism contribute to 
mutagenesis and thus promote tumorigenesis. Paradoxically, cancer cells cover their 
energy need by upregulating the conversion of glucose to lactate even at the presence of 
oxygen, which is a much less efficient production of ATP than the oxidative phosphory-
lation taking place in the mitochondria. Increased glycolysis in cancer cells and their 
dependence on glucose, has been demonstrated by Otto Warburg in 1942, and thus was 
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named the “Warburg effect” [18]. Aerobic glycolysis as well as other atypical metabolic 
changes such as increased fatty acid synthesis and increased rates of glutamine metabo-
lism meet the high demand of building blocks for DNA synthesis and cell growth [19].  
However, the demand for nutrients and oxygen in continuously growing tumor cell 
population eventually exceeds the capacity of the existing blood vessels. Thus, the 
“induction of angiogenesis” is considered to be another hallmark of cancer. Though 
induction of angiogenesis is a physiological process that is triggered in organs that are 
in the process of growing, upon tissue injury, or in female reproductive organs, angio-
genesis in tumors differs and the tightly regulated balance of pro-angiogenic and anti-
angiogenic stimuli seems to be tipped towards induction of angiogenesis [20]. Inflam-
matory responses seem to play a crucial role in tumor angiogenesis [21]. As described 
above, tumors have been found to arise in sites of chronic inflammation, but inflamma-
tory responses are also induced in tumors that do not originate in such areas. Certain 
oncogenes, such as RAS and MYC family members induce a transcriptional program that 
leads to the secretion of cytokines and chemokines attracting and modulating inflamma-
tory cells involved in tumor progression and angiogenesis [22, 23]. However, the chron-
ic stimulation of angiogenesis results in the formation of unorganized, irregularly 
shaped and tortuous blood vessels of low functional value. Even though endothelial 
cells, pericytes and vascular base membrane are present, tumor vasculature seems to be 
less well organized and the components are loosely associated, leading to increased 
permeability of the vessels. The leakage of vessels and the absence of functional lymph 
drainage leads to an increased interstitial pressure in the interior of tumors that may 
compromise efficient supply of oxygen and nutrients and the removal of waste [24].  
It is plausible that the continuous constraint of nutrients and oxygen and the increased 
mutagenic rate associated with hypoxia might lead to in a more aggressive phenotype 
capable of forming metastasis [25]. However, several studies indicate that acute hypoxia 
followed by reoxygenation is a more important determinant of cancer progression and 
the establishment of distant metastases than chronically reduced perfusion [26–28]. 
Nevertheless, for a cancer cell to acquire the capacity of “tissue invasion and metas-
tasis”, multiple adaptations are required and therefore it is thought to be a late step in 
malignant transformation. For the achievement of invasive growth, cells need to detach 
from the basal lamina and neighboring cells and they must be able to degrade and 
migrate through the extracellular matrix. Depending on the tumor type, spreading of 
cancer cells may follow different routes. Some cancers only invade neighboring tissues 
and some form colonies at distant sites in tissue microenvironments that greatly differ 
from their origin. To achieve the later, cells need to gain the capacity to intravasate into 
blood or lymphatic vessels, to survive the journey to a distant site, to extravasate, to 
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adapt to the new microenvironment, and to form a new colony. Obviously, cells may 
not obtain the capacity to form metastasis at once. Patients can have a numerous 
circulating cancer cells (CTCs) and not develop metastases; or cells that extravasate 
may remain dormant for several years.  
There is evidence that disseminating carcinoma cells undergo epithelial-mesenchymal 
transition (EMT) obtaining a more mesenchymal phenotype with even stem-cell-like 
expression profiles [29]. EMT and the reverse process mesenchymal-epithelial transi-
tion (MET) play an important role during embryogenesis in the formation of different 
types of tissues and organs, and cancer cells may follow this path in their metastatic 
process. The activation of the TGF-β pathway, which is involved in EMT during 
embryogenesis, also has been shown to induce EMT in cancer cells in vitro. Though 
TGF-β strongly inhibits growth of epithelial cells, obtained insensitivity to TGF-β-
induced growth inhibition may turn the tumor suppressor function of TGF-β into a pro-
metastatic function [30]. Some genes, that are induced by TGF-β signaling and have 
been shown to be involved in EMT, also have been demonstrated to be induced by other 
factors such as hypoxia and may provide a link between hypoxia and tumor progression 
[31–33]. However, epithelial-mesenchymal transition has mainly been studied in cell 
culture. Whether EMT takes place in human neoplasms has been challenged, as cells 
that have undergone EMT are difficult to distinguish from other stromal cells [34, 35]. 
Indeed, many breast cancer specimen analyzed in mice and human patients lacked 
evidence of EMT, but were able to form metastases in the lungs [36]. Thus, although 
EMT does not seem to be a prerequisite for metastasis, as a naturally occurring cellular 
migrational process, it is plausible that cancer cells may take this route to disperse.  
Certainly, a process as complex as metastasis cannot be fully understood from studies of 
cell cultures alone, because interaction with the tumor microenvironment most certainly 
plays a crucial role in this process. The tumor microenvironment consists of fibroblasts 
and adipocytes as well as infiltrating cells of hematopoietic origin, such as macrophag-
es, neutrophils and mast cells. All of these cell types have been associated with tumor 
progression, though tumor-associated macrophages (TAMs) have received the greatest 
attention. The presence of TAMs in the tumor has been correlated with poor patient 
outcome, but some studies claim the opposite (Reviewed in [37]). Strikingly, poor 
prognosis related to TAMs also correlates with macrophage growth factors or chemo-
kines expressed and secreted by the tumor cells. Thus, tumor cells may orchestrate 
TAMs for their use. TAMs have been suggested to facilitate intravasation and primary 
tumor-stimulated macrophages may be involved in the formation of distant metastases 
by the induction of matrix metalloproteinase 9 (Mmp-9) and the release of vascular 
endothelial growth factor (VEGF) [38, 39]. Besides the production of several factors 
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involved in angiogenesis, macrophages also secrete various growth factors including 
ligands of the epidermal growth factor receptor family that stimulate tumor growth 
directly. Although in the early phase of carcinogenesis macrophages of the type M1 are 
involved in the elimination of tumor cells, in established malignancies M2-polarized 
macrophages act as suppressors of the adaptive immune system [40]. Tumors infil-
trating dendritic cells are kept in an immature state, and as in chronic infections, these 
dendritic cells are capable of suppressing T-cell activity. Thus, macrophages also play a 
role in the “evasion of the immune system”, described as an emerging hallmark of 
cancer by Hanahan and Weinberg [6].  
Although the big efforts towards a broader understanding of the tumor biology of solid 
cancers have widened our knowledge, a multitude of questions concerning tumor biolo-
gy remains unanswered. For example, the composition of tumor tissue provides ample 
grounds for discussion. There are indications for the existence of cancer stem cells 
(CSCs), which imply a hierarchical tumor model and on the other side, there is the 
model of clonal evolution. However, there may not be a clear-cut boundary between the 
two theories; clonally evolving cancer cells may obtain stem cell like traits, or stem cell 
derived cancer cells may give rise to progeny that independently expands. So far, most-
ly immunosuppressed animals served as model system to assess the CSC theory by 
testing the tumor initiating capacity by engrafting tumor subpopulations. The results of 
these studies indicate that often only a small subpopulation is capable of tumor 
formation, which is interpreted as indicative for a stem cell population. However, such 
studies may underestimate the actual tumorigenicity of the original cell population, as 
some xenogeneic immune responses cannot be excluded [41]. The finding of valid 
cancer stem cell markers in solid tumors may be indispensable for shedding light on the 
heterogeneity and the composition of tumors. 
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1.4 Cancer Treatment with Focus on Radiotherapy 
Treatment of cancer has greatly changed over the last decades. For a long time surgery 
and radiotherapy were the only effective cancer therapies with the auxiliary support of 
chemotherapy such as the treatment with cytostatics, or endocrine therapy, which was 
used for hormone-responsive cancers such as certain breast cancers. The better under-
standing of tumor biology and the advancement in diagnostics opened the door for 
therapies aiming at cancer type specific moieties or signaling pathways. Even though 
for resectable tumors surgery may be the first choice, about 50 % of all cancer patients 
receive radiotherapy in the course of their illness [42]. Lastly, in combination with 
molecular targeting, radiotherapy may set new standards.  
1.4.1 Ionizing Radiation: Physical Properties and Biological Effects 
Photon-based radiotherapy is applied by an external beam or internally by brachy-
therapy, which involves the introduction of a sealed radioactive source. For irradiation 
with external beams, X-rays produced by the collision of accelerated electrons with a 
metal anode, are widely used, as well as γ-rays emitted by a cobalt unit. The latter is 
increasingly replaced by linear accelerators (X-ray devices). Both, X-rays and γ-rays are 
electromagnetic waves that differ primarily in their origin. Besides photon therapy, 
proton beam therapy is applied, which shows a different dose distribution across the 
                                    
Figure 1.3 Dose distribution profiles of photons, protons and electrons entering biological 
matter, for 22 MeV X-rays, 200 keV X-rays, 60Cobalt-γ rays, 22 MeV electrons, an unmodu-
lated proton-beam plateau with the Bragg ionization peak, and a spread-out proton Bragg peak 
used for proton therapy [43]. 
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tissue than the one produced by photons. Protons are particles that enter the tissue and 
release most of their energy all at once at the so-called “Bragg Peak” (see Figure 1.3, 
above). The penetration depth of a proton depends on its energy. Electromagnetic 
waves, on the other hand, propagate through tissue while exponentially losing energy 
through the interaction with matter. There are different ways of how photons interact 
with matter, three of which are of interest with regard to radiation therapy: the photo-
electric effect, Compton scattering, and pair production (see Figure 1.4). Which effect 
occurs depends on the energy of the photon and the atomic number of the absorbing 
material the photon interacts with. Compton scattering is the most frequent incident 
produced by therapeutic beams. All three events lead to the production of electrons that 
propagate through the tissue leading to multiple interactions. Photons can directly inter-
act with DNA and damage the genetic material; however, it is thought that their main 
targets are water molecules due to prevalence of the latter. Ionized water molecules 
(H2O+) are reactive, annex H-atoms or electrons from other molecules and thus intro-
duce damage to chromosomes, proteins and membrane structures of the cell.  
 
Figure 1.4 The three types of interaction of photons with biological matter, important for radia-
tion therapy. Photoelectric effect: photons (10-25 keV) collide with an electron of the inner 
shell of an atom, whereupon the electron is ejected. The open space is filled by an electron of 
the outer shell leading to the emission of X-rays. Compton scattering: photons interact with 
loosely bound electrons of the outer shell of an atom. The photon transmits energy to the 
electron, itself is scattered and undergoes interactions with other atoms. Pair production: high-
energy photons (>1.02 MeV) that collide with a nucleus lead to the emission of a positron that 
annihilates with an electron producing two photons, that propagate in opposite directions.  
However, it is actually the free electrons, which cause the major part of the damage. 
They also can damage DNA either directly or indirectly. Electrons do not propagate 
linearly through the matter as photons do. With a loss of 2 MeV energy per centimeter, 
their range of action is limited and proportional to their initial energy. Released from the 
original atom, they cause further ionizations, interact with and excite valence electrons 
of other atoms, or break chemical bonds. When the energy of an electron has been 
reduced, it eventually gets trapped, e.g. by a water molecule to form a highly reactive 
hydroxyl radical, which is capable of introducing DNA single- or double-strand breaks, 
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or damages DNA bases. In presence of oxygen, different radicals evolve such as oxygen 
radicals and the relatively long-lived peroxide radical [44]. Furthermore, the DNA radi-
cals emerging from the interaction with such radicals, are thought to become “fixed” 
upon the reaction with O2-molecules, which greatly impairs the repair process or even 
leads to irreparable damage and apoptosis (Reviewed in [45] and [46]). The reduced 
survival in normoxic versus hypoxic cells is well known and the difference is described 
as the oxygen enhancement ratio (OER). The rationale behind ionizing radiation as a 
treatment option is believed to depend mainly on the direct or indirect introduction of 
lethal DNA damage. However, the role of oxidative damage of proteins and lipids, 
which may impair the functionality of organelles such as mitochondria, and the oxida-
tive stress induced in general, have received rising interest during the last years [44].  
1.4.2 Ionizing Radiation and Cancer Cells vs. Normal Tissue Response 
A favorable cancer therapy would only induce damage at the site of the tumor and spare 
normal tissue, which in the case of photon beams cannot be achieved due to the physical 
properties of the photons as described above. Even though technical advances now 
allow a more precise dose application, surrounding healthy tissue still receives a sub-
stantial dose. Like cancer therapeutics that interfere with cell division, radiotherapy 
takes advantage of the fact that cancer cells are fast proliferating cells. Proliferating 
cells are more radiosensitive than nonproliferating cells, as, for example, radiosensi-
tivity is increased for cells in late G2/M phase [47]. Human cells possess sophisticated 
DNA repair machineries to eliminate various types of DNA damage, however, the 
bigger and more complex the damage is the greater is the chance that the cell cannot 
adequately cope with it. Double-strand breaks (DSBs) are thought to be most toxic to 
cells. If DSBs remain unrepaired, the cell may undergo apoptosis, or if falsely repaired, 
chromosomal aberrations can arise that may lead to mitotic catastrophe.  
Cancer cells often have corrupted cell cycle checkpoints, which allows them to progress 
even though there may be unrepaired damage [48]. The G1/S phase checkpoint, which 
is often deregulated in cancer cells, normally prevents cells from entering the S phase 
and from starting to replicate their genome in the presence of DNA damage. For 
instance, in S phase, unrepaired single-strand breaks (SSBs) lead to a collapse of the 
replication fork and introduce DSBs. Various chemotherapeutics that are combined with 
ionizing radiation aim to potentiate the damage introduced, to inhibit efficient repair or 
to arrest cells in the radiosensitive G2/M phase.  
Adaptation of the radiation treatment schedule also has been found to contribute to a 
successful treatment outcome. Standard radiotherapy follows the rule of dose fraction-
ation introduced by Henry Coutard in 1922, who reported impressive results in the 
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treatment of advanced laryngeal cancers with less side effects on the normal tissue [49]. 
The success of fractionated treatment relies on the 4 R’s of radiotherapy: Repair of sub-
lethal damage, Reassortment of cells within the cell cycle, Repopulation and Reoxy-
genation. Fractionated treatment provides normal tissue with sufficient time to repair 
sublethal damage and to replace the cells that have undergone cell death. However, dif-
ferent tissues have very different capacities to repair DNA damage and to repopulate 
damaged tissue. Skin, mucosa and intestinal epithelium are early responding cells and 
accelerated repopulation is triggered within few weeks after the start of treatment. It is 
mainly those tissues that are spared by fractionated treatment.  
On the level of tumor cell kill, fractionation of the radiation dose offers the possibility 
to reach cells that were in a more resistant cell cycle phase during the application of a 
previous dose fraction, which increases the potential to kill all cells. Similarly, hypoxic 
areas, which are more radioresistant, may become reoxygenated and thus more sensitive 
to treatment with radiation. However, there is evidence that accelerated treatment, 
involving higher doses per fraction, but fewer sessions, is actually more efficient than 
the traditional schedule [50]. In the extreme, a high dose of radiation is delivered in only 
one or few fractions [51]. This schedule has been shown to be superior to the standard 
fractionated radiation therapy with respect to the overall survival and local tumor con-
trol for inoperable non-small-cell lung cancers [52, 53]. At higher dose fractions, the 
intrinsic radioresistance of all cancer cells present in the tumor might be overcome.  
The aspect of a highly resistant subpopulation has not been considered in the 4 R’s of 
radiotherapy. However, there is in vivo and in vitro evidence that radiation treatment 
leads to the selection of more resistant cancer cells, which may result in failure of local 
tumor control in patients treated with radiotherapy [54–57]. The development of radio-
resistance may be explained by the heterogeneity of the tumor cell population, leading 
to the survival and thus to the selection of more resistant phenotypes upon radiation 
treatment. Pearse et al. obtained several clones with increased radioresistance after irra-
diation of the parental MDA.MB231 breast cancer cell line with 3-5 fractions of 2-6 Gy 
per fraction. At doses higher than 6 Gy, even the most resistant cell types appeared to be 
affected by the damage induced; on the other hand, at doses lower than 2 Gy, most cells 
were able to cope with the damage introduced. The selected subclones showed a lower 
apoptotic rate, which may account for at least a part of the increased radioresistance. 
Moreover, radioresistance did not arise in cell populations from a single clone [54] and 
not all parental cell lines showed evidence of radioresistant subpopulations [58, 59], 
indicating that existing heterogeneity may allow for the selection of a resistant subpopu-
lation and rather not lead to the origination of new mutations.  
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Reduced apoptosis, the capability of activating DNA repair checkpoints or increased 
capacity to efficiently repair DNA damage, especially lethal double-strand breaks, may 
contribute to radioresistance of a cell population. This are features common to stem 
cells, and thus has motivated researchers to focus on determining cancer stem cells 
(CSCs) or tumor-initiating cells (TICs) [60–62]. In general, regardless whether CSCs, 
TICs, or just resistant cancer cell subpopulations are present, curative radiation therapy 
aims to destroy all cells with clonogenic potential. Thus, the combination with com-
pounds that specifically target the intrinsic radioresistance or the inherent weaknesses in 
such cells has been regarded as having a great potential for increasing the efficacy of 
radiation therapy.  
1.4.3 Conventional Combined Radiotherapy and Chemotherapy 
Classical drugs applied in combination with radiotherapy are cytotoxic drugs that target 
fast replicating cells. 5-fluorouracil (5-FU) acts as antimetabolite and inhibits thymi-
dylate synthase (TS) leading to the depletion of deoxythymidine triphosphate (dTTP), 
which severely interrupts DNA synthesis and repair. 5-FU metabolites can also be mis-
incorporated directly into DNA, whose repair may lead to a replication fork collapse 
and lethal DSBs [63]. Similarly, gemcitabine, a cytidine analogue leads to a redistri-
bution of the cells to the S phase due to replication stress [64] and deregulates dNTP 
pools by depleting dATP [65]. As for the treatment with 5-Fu, this may lead to mis-
incorporation and misrepair of incorrect bases after radiation. Cisplatinum (CDDP) or 
other platinum derivatives act as DNA crosslinking agents, forming interstrand and 
intrastrand adducts, which interfere with DNA-replication and mitosis, and also hinder 
transcriptional activities [66, 67]. Etoposide also interferes with DNA synthesis by 
forming a complex with topoisomerase II and DNA [68]. Etoposide stabilizes the 
cleaved DNA intermediate and inhibits further processing, leading to the generation of 
permanent DNA strand breaks. Paclitaxel and docetaxel on the other hand act on micro-
tubules; they bind and stabilize the microtubule structures and thus interfere with crucial 
mitotic processes, which leads to an accumulation of proliferating cells in the radio-
sensitive M phase. A single compound as wells as combinations of the drugs described 
above can accompany radiotherapy. For example, the combination of docetaxel with 
cisplatin / 5-FU, followed by chemo-radiotherapy has been investigated in clinical 
phase II and phase III trials and was found to significantly improve overall survival of 
patients with locally advanced squamous cell carcinoma of the head and neck [69, 70]. 
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1.4.4 Radiotherapy in Combination with Molecular Targeting 
A better understanding of the underlying molecular mechanisms involved in the patho-
genesis of cancer revealed the potential of specifically targeting molecular moieties, on 
which the cancer cell may depend on. Most promising are approaches that make use of 
cancer specific deficiencies to particularly restrict the recovery of malignant cells after 
conventional radio- and chemotherapies. Furthermore, various aberrantly activated 
signaling pathways, necessary for the tumor cell survival, may be inhibited. Even meta-
bolic or microenvironmental differences between tumor cells and normal cells were 
considered for molecular targeting [71]. However, depending on the type of cancer, 
different targets might be appropriate. Thus, the use of reliable diagnostic markers is 
required. Though research on personalized cancer therapy is still at an early stage, some 
molecular targeting drugs have been already approved for clinical application. Inhibi-
tion of the epidermal growth factor receptor (EGFR) by the antibody cetuximab is one 
example that shows that the determination of the status of the entire pathway and even 
other connected pathways may be critical for the treatment outcome and must be con-
sidered [72].  
Up to now, various strategically different molecular targets were investigated for their 
synergistic effects with ionizing radiation. Bevacizumab a humanized murine mono-
clonal antibody directed against the vascular endothelial growth factor (VEGF) inhibits 
the interaction of VEGF-A with the VEGF receptor [73]. Bevacizumab had initially 
been approved as a single treatment agent to inhibit tumor angiogenesis, but is now 
considered for the use in combination with radiotherapy in order to counteract IR-
induced VEGF expression that was observed to take place in malignant cells. Inhibition 
of VEGF-A by bevacizumab specifically increased the cytotoxic effects of radiation on 
endothelial cells [74, 75]. However, even though endothelial cells in tumors may be 
more instable and fragile, endothelial cells of normal tissue seems to be considerably 
affected too, which may prove to be an insurmountable obstacle for a combinatorial 
treatment [76].  
On the other hand, VEGF inhibition may actually lead to a normalization of tumor vas-
culature, which is otherwise destabilized by the excessive VEGF secreted by tumor 
cells. Normalization of tumor vasculature may improve oxygenation of the tumor tissue, 
and, thus lead to radiosensitization if given ahead of radiotherapy. NVP-BEZ235, a dual 
PI3K/mTOR kinase inhibitor, leads indirectly to reduced VEGF secretion and vascular 
normalization [77]. The PI3K-Akt-mTORC1 pathway is often aberrantly activated in 
cancer cells and promotes cell growth, proliferation and survival (reviewed in [78]). The 
administration of NVP-BEZ235, which is already in phase I/II clinical trials, although 
not in combination with radiotherapy, has been shown to lead to strong radiosensi-
General Introduction 
14 
 
tization of cancer cells and human umbilical vein endothelial cells (HUVECs) in vitro 
[79]. Radiosensitization by NVP-BEZ235 was much stronger than for other PI3K inhib-
itors, and data obtained by Mukherjee et al. suggest that NVP-BEZ235 also inhibits 
PI3K-like kinases (PI3KK) other than mTOR, namely ATM and DNA-PKcs, which all 
have highly homologous catalytic domains [80]. Targeting the DNA repair machinery 
by the inhibition of ATM or DNA-dependent protein kinase (DNA-PK) to delay or in-
hibit repair has been shown to successfully sensitize cancer cells or human tumor xeno-
grafts before [81–83]. However, DNA-PK is crucial for DSB-repair by non-homologous 
end joining, which is the repair prominent pathway in the resting G0/G1 phase of the 
cell cycle and, therefore, is crucial to normal cells. Susceptibility of persons with inher-
ited loss of ATM functionality to DNA damage indicates that normal tissue may be 
severely affected by ATM inhibition. Thus, NVP-BEZ235 as well as ATM or DNA-PK 
inhibitors may lead to a sensitization not only of cancer cells, but also of normal tissue 
and thus may not be feasible for the combination with genotoxic drugs. As for local 
irradiation, toxicity in the surrounding healthy tissue will have to be carefully analyzed.  
The concept of “synthetic lethality”, which originates from studies on Drosophila 
melanogaster, has been adapted for molecular targeting of cancer cells with the expec-
tation of reduced normal tissue toxicity and increased treatment efficacy. Synthetic 
lethality describes the circumstances when two or more mutations in genes lead to cell 
death, whereas the mutation in each gene alone does not. Cancer cells often show defi-
ciencies in the DNA repair machineries or in cell cycle checkpoints, which contributes 
to genomic instability and thus cancer progression. On the other hand, such deficiencies 
can be exploited to generate synthetic lethality. A classical approach is the inhibition of 
poly(ADP-ribose) polymerase 1 (PARP1), which facilitates base excision repair (BER) 
and SSB repair. PARP1 inhibition is less toxic to normal than to cancer cells for the 
following reasons. In cancer cells, unrepaired SSBs may lead to the formation of toxic 
DSBs if the cell progresses from G1 into S phase due to a defect G1/S checkpoint, 
which often occurs in cancer cells. The formation of DSBs, renders especially BRCA1- 
or BRCA2-deficient cancers cells with impaired HR susceptible to PARP1 inhibitors 
[84, 85]. The initial treatment success of the PFS of the PARP inhibitor olaparib 
observed in a phase II trial on serous ovarian carcinoma unfortunately did not manifest 
itself in an increased overall survival. Nevertheless, a phase III trial has been launched 
this year with olaparib for the treatment of BRCA mutated ovarian cancer1. It has been 
also suggested that PARP inhibitors sensitize cells to treatment with ionizing radiation, 
by increasing the number of toxic DSBs derived from SSBs [86]. PARP inhibitors 
specifically sensitize rapidly proliferating cells or cells harboring DNA damage repair 
                                                 
1
 http://clinicaltrials.gov/show/NCT01844986 (downloaded on October 30, 2013) 
General Introduction  
15 
 
deficiencies [87] and the radiosensitizing effect has been demonstrated in multiple in 
vitro and in preclinical studies (reviewed in [88]). 
The compromised G1/S checkpoint not only renders cancer cells sensitive PARP inhibi-
tion, but also to abrogation of the S and the G2/M checkpoint. DNA damage introduced 
by irradiation may not be repaired before these cells enter premature lethal mitosis. 
Inhibition of S and G2/M checkpoints can be achieved by Chk1-inhibitors or the com-
bination of Chk1/ATR inhibitors [89, 90]. Interestingly, cancer cell lines with wild type 
p53 were less prone to undergo mitotic catastrophe than their p53-negative counterparts, 
even though the G2 checkpoint was equally abrogated [91, 92]. For cancer cells that 
possess wild type p53, the G1 checkpoint may become sufficiently activated upon the 
introduction of DNA damage to prevent them from rushing through the entire cell cycle 
without brake. However, many advanced cancers display aberrant p53 signaling and in 
those cases, Chk1 inhibitors may provide an option for targeting cell death resistant 
cancer types, e.g. the aggressive triple negative breast cancer cells as has been demon-
strated in preclinical settings [93]. Several Chk1 inhibitors have entered clinical trials 
and are administered in combination with radiation therapy or DNA damaging agents 
[94]. Also, the combination of Chk1-inhibitors plus IR with molecular targeting drugs, 
e.g. with PARP1-inhibitors or with conventional therapeutics such as gemcitabine are 
under investigation and both show promising results [95–97]. 
The inhibition of growth factor receptors also has received a great deal of attention with 
regard to molecular targeting in combination with IR. The first part of the thesis will be 
dedicated to EGFR inhibition by means of designed ankyrin repeat proteins (DARPins) 
in vitro and in vivo. Thus, the rationale and consequences of EGFR inhibition will be 
described in the following sections.  
The topic of the second part of the thesis is also dedicated to molecular targeting in 
combination with ionizing radiation and will be about the major vault protein (MVP) as 
target for radiosensitization, as well as the analysis of the underlying mechanisms. 
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2.1 Introduction: Targeting the EGF Receptor 
2.1.1 The Epidermal Growth Factor Receptor as Target for Cancer Therapy 
The epidermal growth factor receptor (EGFR/ErbB1) is one of the four members of the 
cell surface receptor tyrosine kinase family ErbB and is expressed in all epidermal, 
mesenchymal and neuronal tissues. The ErbB receptor tyrosine kinases play an im-
portant role in developmental processes and tissue homeostasis [98]. Extracellular 
signals transmitted by the ErbB receptors are involved in the regulation of cell survival, 
proliferation and differentiation as well as in angiogenesis, migration and invasion. 
Deregulation of these important pathways contributes to carcinogenesis. Overexpression 
of EGFR or deregulation of EGFR signaling is found in many solid tumors. Moreover, 
increased EGFR signaling correlates to poor patient prognosis, rendering EGFR a prom-
ising target for cancer therapy. 
2.1.1.1 Activation and Regulation of the EGF Receptor Family 
Like the other members of the ErbB family (except for ErbB2), EGFR consists of an 
extracellular domain for ligand binding, a hydrophilic transmembrane domain and an 
intracellular domain involved in signal transmission through interaction with other tyro-
sine kinases and adaptor proteins. No ligand is known to bind to the extracellular 
domain of ErbB2 (Her2) but it readily dimerizes with other ErbB family members. 
Dimerization is a crucial step in activation of all ErbB receptor tyrosine kinases. The 
binding of a ligand to the extracellular domain and the subsequent conformational 
change allow for the formation of homodimers or the formation of heterodimers with 
other members of the ErbB family. Pairing of the receptors results in activation of the 
kinase domain and the phosphorylation of various tyrosine residues in the cytoplasmic 
receptor domain (for a schematic view of this mechanism, see Figure 2.1). The phos-
phorylated residues provide docking sites for interaction with the activated EGF recep-
tor. Olayioye et al. suggests that depending on the stimulatory ligand, the composition 
of the receptor dimer and the signal duration and intensity, the consequential phos-
phorylation pattern may vary, which leads to a differential recruitment of interaction 
partners and thus to a diversification of the signaling responses. For example, the adap-
tor protein Grb2 only interacts with the homodimer of EGFR after stimulation with 
epidermal growth factor (EGF) but not with the EGFR/ErbB4 dimer activated by 
neuregulin, whereas Shc, another adaptor protein, interacts with both [99].  
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So far, more than 13 structurally and functionally closely related ligands of the epider-
mal growth factor family have been identified [100]. All members of the EGF family 
are type I transmembrane proteins. With few exceptions, they all localize to the plasma 
membrane where the extracellular domain, the actual receptor ligand, is shed upon 
cleavage. This so-called ectodomain shedding is facilitated mostly by metalloproteases 
belonging to the ADAMs family. The ADAMs are transmembrane proteins with mul-
tiple domains, the functions of which are not well known yet, except for the protease 
function. 
 
Figure 2.1 Activation of EGFR, image adopted from Jura et al. [101]. Ligand binding leads to a 
conformational change of the four extracellular protein domains [102], which allows for the 
formation of asymmetric EGFR dimers. The formation of the helical JM-A dimer and the orien-
tation of the juxtamembrane latches stabilize the dimer and position the kinase domain of one of 
the EGFR partners (designated as activator) to phosphorylate the receiver. Recent findings 
imply that electrostatic interactions of the intracellular domains with the membrane are also 
important for stabilization of the dimer [103]. 
Activation of the EGF receptor and downstream signaling eventually leads to its endo-
cytosis, which takes place in a clathrin-dependent as well as in a clathrin-independent 
way. In response to ligand-induced activation, endocytosis of EGFR follows predomi-
nantly the clathrin-dependent way [104]. However, at least four redundant pathways 
through clathrin-coated pits have been reported, involving ubiquitination, interaction 
with AP-2, C-terminal Lys residues, and Grp2 [105]. Originally, it was assumed that 
endocytosis primarily stood for the downregulation of EGFR and its downstream signal-
ing. Indeed, aberrantly increased rates of EGFR endocytosis hampers MAPK signaling, 
which suggests that endocytosis contributes to the regulation of EGFR signaling [106]. 
However, EGFR activity is not limited to the cytoplasmic membrane, stimulation of 
certain pathways, such as the Akt/PI3K pathway, may occur to a significant extent from 
within the cell [107]. Endocytic trafficking is also essential for other functions of 
EGFR, such as the induction of apoptosis in late endosomes [108], or its proposed func-
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tion as co-activator for the transcription of cyclin D1 [109, 110], iNOS [111] and other 
genes (reviewed in [112]) in the cell nucleus. In the nuclear compartment, EFGR is also 
thought to be involved in DNA repair through interaction with DNA-PK [113]. Finally, 
endocytosed EGFR can be recycled to the plasma membrane, which is dependent on 
which ligand is bound to EGFR [114]. Transforming growth factor alpha (TGFα) 
preferentially leads to recycling of EGFR, while EGF targets the receptor for degra-
dation [115]. 
           
Figure 2.2 The receptor tyrosine kinase family ErbB signaling network adopted from [116]. 
The complex interplay of the four ErbB family members allows for the regulation of a plethora 
of signaling pathways, including cell survival, proliferation, migration and differentiation. 
2.1.1.2 Signaling of the EGFR Family in Cancer  
As mentioned before, EGFR was found to be overexpressed or hyper-activated in many 
solid cancer types, including cancer of the head and neck, colon, lung, breast, ovary, 
pancreas, and brain [117–123]. Additionally, other ErbB family members were found to 
be deregulated in cancer tissue. ErbB3, similarly to EGFR, seems to be overexpressed 
across various human carcinomas. Although ErbB2 expression has been mainly studied 
in breast carcinoma, it is expressed in other carcinomas as well. ErB-4 was found to be 
overexpressed in breast, ovarian and colon cancer albeit with lower frequency than the 
other ErbB family members are [124–126]. 
Increased signaling through EGFR was found to be caused by changes on different 
levels of EGFR regulation. Increased receptor abundance through gene amplification or 
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decreased degradation, overexpression of receptor ligands, increased shedding of 
ligands by ADAMs, activating mutations in the tyrosine kinase domain, or truncated, 
and constitutively active EGFR (EGFRvIII) have all been shown to lead to increased 
EGFR signaling in cancer. 
It is still a matter of debate, however, whether deregulation of the EGFR signaling 
contributes to malignant cell transformation or whether it is a consequence of the trans-
formation. Different studies demonstrated that overexpression of EGFR in the presence 
of a sufficient number of growth factors, such as EGF or TGF-α, had the capacity of in 
vitro cell transformation (reviewed in [127]). Moreover, an overexpression of two 
receptors of the ErbB family has stronger transforming capacity than overexpressing 
either receptor alone, as demonstrated by ectopic expression of various ErbB receptor 
pairs in NIH 3T3 cells, which are devoid of ErbB proteins [128]. Except for cells with 
Her2 expression, stimulatory growth factors were necessary for full transformation. 
That Her2 can readily dimerize may contribute to its increased potency in cell 
transformation compared to the other family members.  
Further evidence for the role of EGFR in cell transformation was provided by the 
growth inhibition induced by the downregulation of EGFR in carcinoma cells 
overexpressing the receptor as well as by inhibition of the stimulating growth factors 
[129–131]. However, the necessity of the inhibition of several growth factors or both 
growth receptors, EGFR and ErbB2, at the same time in order to obtain a significant 
reduction in proliferation, indicates that there is at least a partial redundancy in ErbB 
signaling. Similarly, in transgenic mouse models, it has been shown that EGFR 
overexpression alone merely leads to increased proliferation, but not to cellular 
transformation [132]. Further steps are necessary for a cell to turn into a cancerous cell. 
2.1.1.3 EGFR and other ErbB Family Members as Prognostic Marker for Patient 
Outcome 
The prognostic value of EGFR expression and with regard to overall survival and 
progression free survival has been demonstrated for different cancer types, such as lung, 
squamous cell carcinoma of the head and neck (SCCHN), breast, and colon [117, 121, 
120, 122]. In addition, the expression of ErbB2 has been proposed as independent 
prognostic factor [133]. However, this is controversial (Reviewed in [134]). 
Although heterodimerization of ErbB receptors may play an important role in tumor-
igenesis, only few studies addressed the prognostic significance of the combined recep-
tor expression. Xia et al. showed that overexpression of all four ErbB family members 
correlated with decreased overall survival of patients with oral squamous cell carcinoma 
[135]. Even more predictive significance was obtained by including only the three ErbB 
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family members EGFR, Her2 and ErbB3, but not ErbB4 [135]. The inclusion of EGFR 
did not significantly increased the prognostic performance. Abd El-Reim et al. came to 
a similar conclusion in a study on invasive breast carcinoma, namely that the combina-
torial overexpression of Her2/ErbB3 was a strong indication for poor treatment 
outcome. Furthermore, they observed that even though EGFR and Her2, as independent 
markers, showed a negative correlation with patient outcome, the combined expression 
did not. However, triple positive tumors that strongly expressed ErbB4 on top of EGFR 
and Her2 led to significantly worse overall survival and disease-free survival [136]. 
Studies on the ErbB family members as prognostic marker for treatment outcome in 
colorectal cancer were even more contradictory. The investigation of all four family 
members performed by Lee et al. confirmed earlier findings that EGFR and Her2 alone 
were not prognostic factors for colorectal cancer patients. Interestingly, they found a 
strongly biased expression of Her2/ErbB3 in early stage cancers, while in late stages 
Her2/ErbB4 expression was more prominent. The strong correlation with cancer stages 
indicates that different ErbB family members may have differential roles in cancer 
progression [126].  
2.1.2 EGFR Targeted Therapy: Current Approaches  
The association of EGFR with a more aggressive cancer phenotype and its role in cell 
proliferation and survival turned EGFR into a target of interest for cancer therapy. 
Various approaches to counteract EGFR signaling have been developed, whereof inhibi-
tion by monoclonal antibodies and tyrosine kinase-specific inhibitors have found their 
way into clinics. 
2.1.2.1 Monoclonal Antibodies 
Cetuximab, a chimeric human murine monoclonal anti-EGFR antibody has been 
approved by the U.S. Food and Drug Administration (FDA) as adjuvant or single thera-
py in recurrent colorectal cancer and in regionally advanced squamous cell carcinoma of 
the head and neck (SCCHN)2. In a clinical trial (phase III) on SCCHN, cetuximab has 
been shown to have a survival benefit and an increased 5-year survival in combination 
with radiation therapy over radiotherapy alone [137, 138]. In colorectal cancer, how-
ever, retrospective studies lead to the conclusion that patients with KRAS activating 
mutations as opposed to patients with wild type KRAS did not profit from EGFR inhibi-
tion and that disease progression might even be adversely affected (Reviewed in [139, 
140]). In SCCHN, the prevalence of KRAS activating mutations is very low and testing 
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is not routinely performed. In 2006, panitumumab another monoclonal antibody target-
ing EGFR was approved by the FDA as second line treatment of EGFR-expressing 
metastatic colorectal cancer with disease progression.3 Panitumumab is a fully human 
antibody and is considered safer with regard to infusion reactions that arise in response 
to the murine sequence of cetuximab [141, 142]. 
Both antibodies bind to the extracellular portion of the epidermal growth factor, inhibit 
ligand binding and eventually lead to degradation of the receptor. However, since cetux-
imab is an antibody of the isotype IgG1 and panitumumab of the isotype IgG2 their 
mechanism of action in complement activation or in induction of antibody dependent 
cytotoxic reactions differ [143]. Antibodies of the IgG1 isotype lead to a stronger 
complement activation than IgG antibodies of the subtype 2 [144, 145]. Both IgG1 and 
IgG2 antibodies mediate antibody-dependent cell-mediated cytotoxicity (ADCC). 
Schneider-Merck et al. showed that both panitumumab and zalutumumab (an IgG1 
antibody) mediated ADCC with myeloid effector cells in vitro, but that only 
zalutumumab was able to induce ADCC through natural killer cells [146]. Nonetheless, 
with regard to treatment efficacy, it is too early to draw a conclusion; an ongoing  
phase III trial compares the efficacy of cetuximab and panitumumab in metastatic 
colorectal cancer and preliminary results will be published toward the end of the year 
20134. Interestingly, tumors that had acquired resistance to treatment with cetuximab 
through point mutations in the extracellular domain of the EGF receptor showed 
sensitivity towards panitumumab [147].  
However, as mentioned above, not all cancer cells are sensitive to EGFR inhibition in 
the first place. In metastatic colorectal cancer (mCRC), only 10 to 20 % of the patients 
respond to therapy with monoclonal antibodies (mAbs) targeting the EGF receptor 
[148]. For example activation of oncogenic effector proteins downstream of EGFR 
contribute to treatment resistance. In patients with mCRC, activating mutations in 
KRAS account for about 35 - 45 % of treatment failure, with additional 10 - 20 % due 
to activating mutations in BRAF [149]. KRAS mutations and mutations in its down-
stream target BRAF are mutually exclusive, but are not found in all treatment resistant 
tumors. EGFR gene amplification is an indicator for treatment response, but on its own 
is not such a strong predictor as KRAS or BRAF. Likewise, PTEN and PI3K mutational 
status only have a predictive power in KRAS wild type tumors, whereas wild type 
PTEN and PI3K status correlates with increased PFS/OS and PFS, respectively. The 
analysis of ligand expression in correlation with the treatment response to anti-EGFR 
mAbs was hampered by technical difficulties, though ligand overexpression may be of 
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predictive value (reviewed in [150]). Furthermore, the status of other growth factor 
receptors may critically influence the success of EGFR-inhibition therapy. The insulin 
growth factor receptor IGFR and c-Met are two such receptors known to confer resis-
tance to EGFR inhibition. However, increased IGFR and c-Met signaling often becomes 
apparent after or during treatment with EGFR inhibitors and contributes to the evolution 
of treatment resistance to initially sensitive tumor cells [151, 152]. Secondary treatment 
resistance will be described in more detail in the discussion (see section 2.5.6). 
2.1.2.2 Small Molecular Tyrosine Kinase Inhibitors 
The second family of effectors targeting the EGF receptor that is in clinical use 
comprises the tyrosine kinase inhibitors (TKIs). These small molecular compounds 
block the ATP binding pocket of the kinase domain, thereby inhibiting 
autophosphorylation and activation of the receptor, and the induction of downstream 
signaling cascades. Since the tyrosine domain is the most conserved region among 
tyrosine kinases, the specificity of a TKI is an issue, but this also offers the chance to 
target multiple kinases at the same time.  
As an advantage over an antibody treatment, TKIs also inhibit EGF receptors harboring 
activating mutations, which occur predominantly in lung cancers. These mutations are 
located in proximity of the ATP-binding pocket of the tyrosine kinase domain and 
consist of small in-frame deletions or point mutations that lead to increased kinase 
activity [153]. In fact, non-small cell lung cancers (NSCLC) that harbor such mutations 
and may depend on activated EGFR signaling, and thus show a superior response rate to 
treatment with TKIs of 70 % as opposed to 10 % for NSCLCs with wild type EGFR 
(reviewed in [154]).  
However, wild type EGFR is by far more common than mutated EGFR. Thus, clinical 
trials with the EGFR-targeting TKIs gefitinib and erlotinib as first-line or second-line 
treatment in unselected patients rarely showed superiority in PFS and OS compared to 
classical chemotherapy; some trials even reported adverse results (reviewed in [155]). 
The BR.21 study, which led to the approval of erlotinib as a second-line treatment for 
patients with NSCLC, demonstrated an increased response rate, a PFS of 7.9 months vs. 
3.7 months and an OS of 6.7 month vs. 4.7 month as compared to platinum-based 
therapy [156]. A retrospective study on the BR.21 trial with regard to the mutational 
status of EGFR and other downstream effectors pointed out that although EGFR 
activating mutations with KRAS wild type status were strong indicators for treatment 
response, patients with EGFR gene amplifications may also profit from erlotinib [157]. 
Nonetheless, recent studies on erlotinib and gefitinib have been mainly performed in an 
EGFR mutant background and the benefit for patients with wild type EGFR is highly 
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controversial (reviewed in [158]). Moreover, the mutational status of EGFR alone does 
not predict the treatment response, as for mAbs therapy the status of the downstream 
effector kinases or the presence of other members of the tyrosine kinase receptor class 
also plays a role. Thus, the development of TKIs, inhibiting several tyrosine kinase 
targets at the same time, aims at a broader range of action to increase tumor control. 
Lapatinib, a TKI binding to the intracellular domain of both EGFR and Her2, was 
shown to improve progression free survival for patients with ErbB2-positive, locally 
advanced or metastatic breast cancer in combination with chemotherapy as compared to 
chemotherapy alone [159, 160].  
However, as for other TKIs, also for multiple tyrosine kinase inhibitors such as lapatinib 
and sorafenib treatment resistance eventually evolves. Sorafenib binds to and inhibits 
RAF, VEGFR, PDGFR, stem cell factor receptor (KIT), and fms-like tyrosine kinase 3 
(FLT-3) and is approved for advanced hepatocellular carcinoma (HCC). Two independ-
ent studies identified EGFR and ErbB3 as possible mediators of treatment resistance 
[161, 162]. An ongoing phase III trial compares the combination of sorafenib with 
EGFR-TKI gefitinib to sorafenib alone.5 However, no additional benefit of the combina-
torial treatment has been determined so far.  
Development of resistance to TKIs, similarly as for antibodies, may also occur through 
mutations that reduce interaction with the inhibitor or through activation of downstream 
effector proteins. As opposed to antibodies, TKIs exert their activity on the intracellular 
domains of receptors or on cytoplasmic kinases. Due to their hydrophobic characteris-
tics, TKIs depend on cellular uptake mechanisms and are extruded from the cell by 
efflux transporters. Thus, overexpression of multi drug resistance (MDR) proteins may 
also confer resistance to TKIs, a conclusion that is not as predictable as it may seem. In 
the case of lapatinib, exclusion form the cell is facilitated by P-glycoprotein (P-gp) and 
the breast cancer resistance protein (BCRP). Transport by both transmembrane proteins 
involves the binding and hydrolysis of ATP. Interestingly, lapatinib does not only bind 
to the ATP binding pockets of EGFR and Her2 but is also able to inhibit both P-gp and 
BCRP, albeit with lower efficacy [163]. Likewise, TKIs might also inhibit transporters 
involved in cellular uptake. Galetti et al. were not able to pin down the transporters of 
gefitinib and did not observe a difference in intracellular gefitinib concentrations in 
TKI-resistant or sensitive cell lines. But interestingly enough, gefitinib reduced uptake 
of 1-methyl-4-phenylpyridinium (MPP), an artificial substrate for organic cation trans-
porters (hOCTs) [164]. hOCTs are involved in the transport of various anticancer drugs 
such as cisplatin, oxaliplatin, doxorubicin and the TKI imatinib. Therefore, the pharma-
codynamics of the combination of TKIs with other drugs has to be carefully evaluated. 
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2.1.3 Alternative Non-Antibody Scaffolds for Molecular Targeting: Designed 
Ankyrin Repeat Proteins (DARPins) 
2.1.3.1 From Antibodies to Alternatives Scaffolds 
In the past years, numerous drugs based on monoclonal antibodies have been success-
fully introduced for a wide range of diseases, including cancer as well as autoimmune 
and inflammatory diseases. The introduction of the hybridoma technology in 1975 
opened up the possibility for the stable production of a selected monoclonal antibody on 
a large scale [165]. Furthermore, selection methods, such as the still used phage display 
allow, for efficient selection of suitable antibody candidates [166, 167].  
Humanization of rodent antibodies decreases immunogenicity, increases half-life, and 
allows for possible effector functions. However, antibodies still hold major disad-
vantages. The application of antibodies is primarily limited to extracellular targets due 
to their size and properties, which also limit effective tissue penetration. Moreover, 
antibody production is associated with extremely high costs. Expression of functional 
antibodies is restricted to eukaryotic expression systems due to their structure, which 
contains several disulfide bonds and posttranslational modifications such as specific 
glycosylation not suitable for expression in prokaryotic systems. Often, high amounts of 
molecules are necessary for treatment and thus stability of antibodies at high concentra-
tions becomes an issue [168]. With regard to the limited tissue permeability of whole 
antibodies, different steps have been undertaken to reduce their molecular size.  
Three general groups of antibody related proteins have successively evolved: antigen-
binding fragments (Fabs), single chain variable fragments (scFvs) and “third genera-
tion” (3G) molecules comprising a single antigen-binding domain only (see Figure 2.3).  
       
Figure 2.3 Whole IgG antibody molecule consisting of two heavy chains (HC) and two light 
chains (LC) connected by disulfide bridges (left). Antibody fragments (Fab) single-chain varia-
ble fragment (scFv) and single-domain antibodies VHH / VH (heavy chain domain of camelid / 
of IgG antibody) [169] 
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However, although these molecules have been shown to penetrate tumor tissue more 
rapidly, they are also cleared much faster from the blood circulation due to their small 
size and the absence of Fc-mediated recycling [170]. Yakota et al. investigated the 
relationship between the molecular size of antibody fragments and tumor uptake of the 
molecules [171]. With 27.2 % of the injected dose per gram of tissue (ID/g) at 24 hours, 
IgG showed the highest accumulation in the tumor, followed by F(ab′)2, with 19.2 %, 
Fab′ ,with 3.7 % and scFv, with 1.7 % ID/g. For certain applications, a fast clearance of 
a drug is favorable: for example, in the field of diagnostics such as tumor imaging, a 
high tumor to blood ratio is of advantage; or if coupled to a toxic compound or 
radionuclides, healthy tissue toxicity can be reduced.  
Not only immunoglobulin related proteins were taken into consideration for targeting 
cancer specific proteins. Several non-immunoglobulin-based scaffolds have been stud-
ied for suitability, with the aim to develop moieties with improved stability and tissue 
permeability (Reviewed in [172, 173]. Adequate protein motifs have been adopted from 
small, soluble and relatively stable proteins as in the case of the Kunitz inhibitors or the 
lipocalins, or from stably folded extramembrane domains of cell surface receptors in the 
case of Affibodies, Adnectins or the designed ankyrin repeat proteins.  
These protein domains can be divided roughly into two groups, based on the structure of 
their binding sites. In one category, binding is facilitated by surface-exposed loops, as 
for the antibody paratope. In the second category, binding is mediated by accessible side 
chains of secondary structure elements such as α-helices and β-sheets, which assemble 
into a relatively rigid interface. An overview of several scaffold proteins that are under 
investigation for therapeutic use is presented in Table 2.1 (see page 28). Designed 
ankyrin repeat proteins (DARPins) will be described in more detail in the following 
section. 
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Table 2.1 Overview on alternative scaffold proteins at various stages of development for 
targeted therapy [174, 173, 172, 175]. 
References: [176–179, 175, 180–188]  
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2.1.3.2 Designed Ankyrin Repeat Proteins and Their Properties 
The idea behind the study of ankyrin repeat proteins was to develop a scaffold with 
superior properties than attributed to antibodies. A prospective scaffold protein should 
be soluble in body liquids, structurally stable and such that it can be efficiently ex-
pressed in a prokaryotic system. Thus, a scaffold protein preferably does not contain 
disulfide bridges. Moreover, large and rigid interaction interfaces support tighter bind-
ing but should also provide for sufficient side-chain variability at positions that do not 
interfere with the structure and stability of the scaffold protein.  
Ankyrin repeat domains fulfill all these requirements; they are built from stacked 
tandem repeats with a length of approximately 33 amino acid residues each, which 
assemble into a β-turn followed by two antiparallel α-helices (see Figure 2.4). Repeat 
motifs, such as the ankyrin repeat, leucine rich repeat, armadillo repeat, and tetratrico-
peptide repeat are very common in protein-protein interaction interfaces [189].  
                        
Figure 2.4 Designed ankyrin repeat proteins are composed of two caps (N- and C-) and a vary-
ing number of ankyrin repeats composed of a β-turn and two antiparallel α-helices. Seven 
exposed residues per repeat, displayed as red side chains, make up the variable part and provide 
for the diversity of the artificial binders. The figure has been adopted from [190]. 
The ankyrin repeat motif was first discovered in the Notch protein of Drosophila mela-
nogaster [191]. The ankyrin repeat domain in the cytoplasmic domain of Notch 
comprises seven repeats and was shown to be important for Notch signaling [192]. 
Zweifel et al. determined the structural position of known mutations within the ankyrin 
domain: Two of the four mutations were located in buried positions and led to the 
destabilization of the configuration of the domain, whereas the two other were located 
at the surface and had no substantial effect on protein stability. Nonetheless, both types 
of mutation similarly impaired Notch signaling, indicating that the surface residues 
might be involved in the interaction with signaling partners. Similar to the ankyrin 
repeat domain in Notch, artificial ankyrin repeat proteins are assembled from usually 2 
to 4 tandem repeats enclosed by an N-terminal and a C-terminal cap, which both were 
adapted from mouse GABPβ1. The charged and polar surfaces of the caps enable 
solubility under neutral pH conditions by hiding the hydrophobic core [193]. 
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Importantly, the capping also supports efficient folding of the designed ankyrin repeat 
proteins into their native state in bacterial expression systems. Without caps, the 
proteins have to be refolded from inclusion bodies that form in Escheria coli, and 
additionally, solubility at pH 7 has to be secured by the introduction of positive charges 
at the C-terminal end [194].  
Further improvement in stability of the artificial ankyrin repeat domains was obtained 
by the introduction of an optimized consensus sequence that is self-compatible and 
readily assembles into stable repeat stacks if sequentially expressed. Stability of the 
DARPins increases with the number of repeats. Proteins comprising at least three 
consensus internal repeats withstand boiling and guanidine hydrochloride degradation 
[195]. To obtain a reasonably sized collection of different DARPins useful for a target 
specific selection, amino acid residues suitable for variation and not important for 
internal stability were determined. The seven eligible residues are located in the β-turns 
and in the first α-helices of the ankyrin repeats and can be substituted by any amino acid 
except for proline and glycine, which negatively influence stability. Additionally, 
cysteine was omitted from the list of possible residues to prevent the formation of 
unwanted disulfide bonds [193]. The absence of cysteines turned out to be of advantage 
for the conjugation of functional or structural moieties to the DARPins. After protein 
expression and purification, a singly introduced cysteine allows for the site-specific 
crosslinking with a suitable moiety [196].  
DARPins with high affinities for a specific target are selected from libraries that consist 
of ~1012 DARPins for ribosome display [197] or ~1010 DARPins for phage display 
[198]. With only few selection cycles, affinities in the nano- and picomolar range can be 
achieved.  
2.1.3.3 Therapeutic Application of DARPins 
Designed ankyrin repeat proteins are stable, small proteins and similarly to antibodies 
they can be selected to bind to a target with high specificity and affinity. Whereas tissue 
penetration turned out to be a major issue for antibody therapeutics, DARPins have 
been shown to have superior properties in this regard. For example, DARPin MP0112, 
developed by the company Molecular Partners6, binds and inhibits vascular endothelial 
growth factor (VEGF) for the treatment of wet macular degeneration and diabetic macu-
lar edema. Currently two drugs have been approved for treatment of these diseases: 
ranibizumab, an Fab antibody fragment, and pegaptanib, a pegylated aptamer. Both 
drugs are applied by intravitreal injections that have to be repeated on a monthly or bi-
                                                 
6
 http://www.molecularpartners.com/public/index.php?id=105&lang=en (downloaded on Sept. 18th 2013) 
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monthly basis. DARPin MP0112 successfully passed two clinical phase II trials and 
seem to be well tolerated after single intravitreal injections with an indication of high 
efficacy and possibly longer duration of action compared to the present drugs [199]. 
Importantly, in preclinical studies, DARPin MP0112 was demonstrated to effectively 
inhibit VEGF and reduce vascular leakage and suture-induced corneal angiogenesis not 
when administered through intravitreal injections, but also by topical application in the 
form of eye drops [200]. Topical application would be more convenient for patients and 
significantly reduce the costs for the treatment.  
DARPins also have been considered for tumor targeting and were selected for various 
tumor cell markers, such as the tyrosine kinase receptors Her2 and EGFR, and the epi-
thelial cell adhesion molecule EpCAM [201–203]. Zahnd et al. determined in a preclin-
ical study in mouse tumor xenografts that for the anti-Her2 DARPin 8 % ID/g localized 
to the tumor tissue within 24 hours after intravenous injection [204]. This good result 
and that proteins of the size of a single DARPin domain (14 kDa) were rapidly cleared 
by glomerular filtration, indicate that DARPins freely extravasate and reach the tumor 
after systemic application, even though the serum half-life is very short. Accordingly, 
the affinity of the DARPins toward their target significantly influenced the degree of 
tumor accumulation.  
Several approaches to target tumor cells with DARPins are currently under preclinical 
investigation: DARPins linked to effector moieties have been used to deliver toxic 
agents or pro-apoptotic siRNA molecules to tumor cells [205, 206]. Martin-Killias et al. 
demonstrated a significant growth delay in tumor xenografts in nude mice, which had 
been treated with the fusion product of a truncated form of Pseudomonas aeruginosa 
exotoxin A and an anti-EpCAM DARPin. Receptor-mediated endocytosis of the 
DARPin, induced by EpCAM itself, eventually leads to the cellular uptake of the toxin. 
Other DARPins were selected against the growth factor receptors ErbB2 and EGFR. 
Recently, a paper about a divalent DARPin targeting ErbB2 and its specific mechanism 
of action has been published [207]. Whereas the DARPins against the ErbB2 receptor 
does not induce internalization of the receptor, the tetravalent anti-EGFR DARPin binds 
the EGF receptor and leads to its degradation [202]. The anti-EGFR DARPin also inhib-
its ligand-stimulated activation of the receptor, possibly by blocking the ligand binding 
site.  
Though DARPins have a promising potential as drug targeting carriers or can be select-
ed to functionally interfere with their targets, the rapid clearance of the DARPins may 
be a major issue to be tackled with regard to clinical application. 
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2.2 Aims of the Study  
This study addresses the systemic application of the dimeric tetravalent DARPin 
E69_LZ3_E01 with inhibitory function on the epidermal growth factor receptor 
(EGFR). Boersma et al. showed that in vitro DARPin E69_LZ3_E01 inhibited EGFR 
more potently than the clinically approved anti-EGFR antibody cetuximab [202]. Upon 
stimulation with epidermal growth factor, phosphorylation of Erk, a downstream target 
of EGFR, was prevented to a higher degree than with the monoclonal antibody cetuxi-
mab. Adjuvant treatment with cetuximab on the other hand, has been shown to have a 
beneficial effect on the overall survival (OS) and the progression free survival (PFS) of 
patients with solid tumors, especially in combination with radiation therapy [137, 138]. 
Our main goal is to test the efficacy of the anti-EGFR DARPin in cell culture and 
against A431 tumor xenografts in nude mice, particularly in combination with radio-
therapy and then to compare the results with those of the combined treatment with the 
monoclonal antibody cetuximab. Furthermore, we will investigate pharmacokinetic 
properties of the pegylated tetravalent DARPin E69_LZ_E01 after intravenous and 
intraperitoneal injection. Importantly, the pharmacokinetics and tumor accumulation of 
a tetravalent DARPin with two 20 kDa PEG extensions has not yet been investigated. 
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2.3 Material and Methods: Targeting EGFR  
2.3.1 Cell Culture and Maintenance 
The human vulvar squamous cell carcinoma cell line A431 was purchased at the 
Leibnitz Institute DMSZ (German Collection of Microorganisms and Cells Cultures, 
No: ACC-91). The human non-small cell lung cancer cell line A549 was a gift of the 
laboratory of Dr. Susan Band Horwitz. Both cell lines were maintained in RPMI 
medium supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) L-glutamine 
and 1% (v/v) Penicillin-Streptomycin, at 37°C in 5% carbon dioxide in a humidified 
incubator. 
2.3.2 Irradiation 
Irradiation was performed with a Gulmay 200 keV X-ray unit at a dose rate of  
~1 Gy/min at room temperature. Dose performance was assessed with help of a Vigilant 
dosimeter. Determination of the settings and evaluation of the corresponding dose 
profiles were performed by a radiation physicist. 
2.3.3 Reagents and Antibodies 
2.3.3.1 DARPins and Application of DARPins in Cell Culture In Vitro 
All DARPins were kindly provided by Prof. Dr. Andreas Plückthun of the Biochemical 
Institute of University of Zürich. The DARPins were obtained as aqueous solutions and 
were stored at -80 °C for long-term storage or at 4 °C for up to four weeks.  
DARPins are expressed in E. coli and are purified via specific tags. Further information 
concerning the cloning of the EGFR-specific DARPin E69_LZ3_E01, or the expression 
and the purification of DARPins in general, can be found in Boersma et al. and in there 
indicated references [202].  
For in vitro administration, the DARPin solutions were diluted in cell culture medium 
and added in droplets to the medium of the cells, to receive the final concentration.  
Table 2.2 List of the DARPins used; both DARPins were also received in the pegylated form. 
DARPin Target  
E69_LZ3_E01 Extracellular domain of the EGF receptor 
Off7_LZ3_Off7 No known target 
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2.3.3.2 Antibodies and other Reagents 
Table 2.3 List of Reagents 
Reagents Manufacturer 
Agarose A9539 Sigma 
Alamar Blue Biosource Int. 
BD Matrigel 354248 BD 
Cell culture medium and supplements Gibco, Invitrogen 
Cetuximab (Erbitux) Merk Serono 
EDTA solution 115K8901 Sigma 
Dapi Fluoromount-G #0100-20 SouthernBiotech 
RNAse A Qiagen 
TMB Substrate Kit #34021 Thermo Scientific 
TRITON X-100 Sigma 
Table 2.4 List of Antibodies 
Antibodies  Manufacturer Ref. number 
Anti β-Actin Ab from mouse Sigma A5441 
Anti Akt Ab, from mouse Cell Signaling #2920 
Anti pAkt Ab (Ser473), from rabbit Cell Signaling #4058 
Anti EGFR Ab, from rabbit Cell Signaling #4267 
Anti pEGFR (Tyr1173), from mouse Millipore #05-1004 
Anti α-GAPDH Sigma #9545 
Anti p44/42 MAP kinase Ab, from mouse Cell Signaling #4696 
Anti pErk1/2 (Thr202/Thr204) Ab, from rabbit Cell Signaling #4370 
Anti RGS-His Ab Qiagen 34610 
Anti-PEG-Biotin (methoxy group) Ab, from rabbit Epitomics #2137-1 
Anti-Rad51 Ab, from mouse Santa Cruz sc-8349 
Secondary anti-mouse Ab, from goat,  
Fluor®488-linked 
Mol. Probes®,  
Invitrogen 
A-11001 
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Secondary anti-mouse Ab, from goat,  
Fluor®546-linked 
Mol. Probes®, 
Invitrogen 
A-11018
Secondary anti-mouse Ab, from sheep,  
HRP-linked 
GE Health Care NA931V
Secondary anti-rabbit Ab, from donkey,  
HRP-linked 
GE Health Care NA9340V
Secondary anti-rabbit, from goat, 
HRP-linked 
Sigma-Aldrich A6154
Secondary anti-rabbit Ab, from goat,  
Fluor®488-linked 
Mol. Probes®, 
Invitrogen 
A-11070
Secondary anti-rabbit Ab, from goat,  
Fluor®546-linked 
Mol. Probes®, 
Invitrogen 
A-11071
2.3.4 Western Immunoblot Analysis  
For the assessment of the inhibition of EGFR phosphorylation and signaling, cells were 
usually plated in medium containing 1 % Serum instead of 10 %. Cells were stimulated 
with 10-100 ng/ml EGF as indicated for 15 minutes before harvesting. 
Cells were washed with cold PBS and lysed immediately with Laemmli buffer (63 nM 
Trizma base, 2 % SDS, 10 % glycerol and 10 mM DTT freshly added) on ice. The cells 
were scraped immediately, cooked for 7 min at 96 ºC and stored and -20 °C. Protein 
concentrations were determined by NanoDrop (Thermo Scientific). Before loading, 1 µl 
of 2 % Bromophenol blue was added to 100 µl of the thawed protein samples. 50 µg of 
protein was loaded per lane, separated on 10 % acryl-amid gels by electrophoresis, and 
transferred to PVDF membranes (Amersham Hybond™-P, GE Healthcare, Cat. No. 
RPN2106) by a standard wet/tank blotting system from BioRad (100 V for 60 min). The 
membranes were then blocked in 5 % non-fat milk in TBS buffer for 40 min at room 
temperature. All primary antibody incubations were performed overnight at 4 ºC, 
followed by washing and incubation with the secondary antibody coupled to HRP for 60 
min at room temperature. The membranes were then washed and incubated with ECL 
Prime according to the manufacturer. The Western blot signal was detected by a 
FluorChem Q System (Bucher Biotec), equipped with a CCD camera. For 
quantification, the software belonging to the FluorChem Q System was used.   
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2.3.5 Cell Cycle Analysis by BrdU Incorporation and DNA Staining 
Before harvesting the cells for analyses, BrdU to a final concentration of 10 µM was 
added to the cell culture medium. After incubation of 30 min, the cells (ca. 1 million) 
were trypsinized, washed with PBS and fixed in ice-cold 70 % ethanol overnight at 4 
°C. If not stained and analyzed the following day, the cells were stored at -20 °C for up 
to one week. The cells were washed with 14 ml ice cold PBS once. The following steps 
were all performed in the 15 ml falcon tube and at room temperature. 0.5 ml 4 M HCl 
were added to the cells for 10-15 min, for the denaturation of DNA required for the 
BrdU recognition by the Ab. To neutralize the pH, 14 ml PBS were added and the cells 
were washed with 14 ml PBS twice more. Neutralization of the pH was verified by a pH 
test strip. Blocking of nonspecific binding sites was performed by incubation in 2 % 
BSA in PBS for at least 15 min. For the BrdU detection and DNA staining, the cells 
were then incubated with 0.5 µg BrdU Ab/100µl/10 6 cells in PBS containing 2.5 mg/ml 
Propidium Iodide, 10 µl/ml RNAse, 0.2 % BSA and 0.1 % Tween. Depending on the 
cell number, 50-100 µl staining solution was added and the samples were placed in the 
dark for 1-1.5 hours. The flasks were tapped from time to time, to disperse the cells. 14 
ml PBS was added for washing; and after spinning, cells were resuspended in 250 µl 
PBS, transferred to a FACS tube and placed on ice until FACS analysis. The FACS 
analysis was performed with a BD FACSCanto system; and for the evaluation of the 
data, the software FlowJo version 7.6 was used. 
2.3.6 Alamar Blue Assay for Assessment of Cell Proliferation  
Cells were seeded in 96-well plates. Alamar Blue was added according to the manu-
facturer’s specification 4 hours prior to measurement of the absorption at 570/670 nm 
by means of a Tecan GENios plate reader. Alamar Blue contains the weekly fluorescent 
dye resazurin that becomes irreversibly reduced to the red fluorescent resorufin by 
mitochondrial metabolic activity. DARPins and cetuximab were added together with the 
administration of Alamar Blue for the first time line measurement. Cell viability was 
determined up to 72 or 96 hours after drug treatment at 24-hour intervals. All conditions 
were measured in triplicates. 
2.3.7 Clonogenic Survival Assay 
Clonogenicity of cells, which is the ability to form colonies from single cells, was 
determined by seeding low cell numbers in 10 cm Petri dishes to obtain 50 to 150 colo-
nies. 24 hours after seeding, the cells were submitted to radiation and control cells were 
sham irradiated. Cells were left to form colonies for 10-14 days, depending on their 
doubling times. Colonies were fixed with a 3:1 mixture of methanol and acetic acid or 
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in 70 % ethanol, and DNA was stained with a 0.5 % crystal violet solution. Colonies 
with more than 50 cells/colony were counted manually with a GALLENKAMP colony 
counter or automatically by a GelCountTM device (Oxford Optronix). Survival fraction 
(SF) was determined by calculating the ratio between the number of obtained clones and 
the initially seeded cells. For normalization, the obtained SF was divided by the plating 
efficiency PE, which is the ratio of colonies counted for untreated cells to seeded cells. 
For a single experiment, all conditions were assayed in triplicates.  
ܵܨ ൌ #Colonies	counted#Cells	seeded ∗
1
ܲܧ 
2.3.8 3D Cell Culture and 3D Clonogenic Assay 
For 3D cell culture, cells were seeded in medium containing 0.5-0.1 mg matrigel per ml. 
3D clonogenic assays were performed in 96-well plates. Before seeding, wells were 
coated with 50 µl 1 % agarose (sterile). 200 µl of cell suspension already containing the 
matrigel were added to each well (150 cells per well). Plates were placed into the incu-
bator until the matrigel had solidified (3-4 hours) and 100 µl culture medium was 
carefully added on top to prevent the matrigel from drying. DARPins and cetuximab 
were added the following morning and irradiation followed 6 hours after the drug treat-
ment. Colonies were counted by eye with help of a microscope. Survival Fraction was 
determined as for the classical clonogenic assay (see section 2.3.7). 
2.3.9 Immunofluorescence Microscopy of Adherent and 3D Cells 
For indirect immunofluorescence detection of EGFR, phospho-EGFR and of DARPins, 
~10-20’000 cells/well were plated in 24-well plates on cover slips. The cells were fixed 
with 4 % Formalin solution in PBS. Cells were permeabilized in 0.2 % Triton X-100 
(25 mM HEPES [pH7.4], 50 mM NaCl2, 3 mM MgCl2, 300 mM sucrose, just before 
use Triton X-100 and 0.1 M EDTA in solution was added) for 5 min on ice, washed 
with PBS and incubated with 0.3 M Glycine to quench autofluorescence of formalde-
hyde. Cells were blocked with 3 % BSA in PBS for 20 minutes. Then, the cover slips 
were incubated with the primary antibodies (dilution indicated on the data sheets) in 3 
% BSA in a humid chamber for 1 hour. Cover slips were washed 3x with PBS contain-
ing 0.3 % BSA, incubated with the appropriate fluorescently labeled secondary antibody 
for 30-60 minutes in the dark and washed repeatedly with PBS. For the mounting of the 
cover slips onto Microscopy slides, mounting medium containing DAPI for counter-
staining the DNA was used. Slides were stored at 4 °C. 
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For the staining of cells grown in matrigel, 100’000 cells/well were seeded in 24-well 
plates in 1 ml medium containing 0.5 mg matrigel. Before harvesting, the upper part of 
the matrigel that did not contain cells was removed and discarded; the remaining mat-
rigel with cells was pipetted into a 15 ml falcon tube containing ice-cold PBS and left 
on ice for 5 minutes. After spinning, cells were incubated with 3x trypsin for 3 min, and 
then formalin solution was added directly, without spinning, at a final concentration of 4 
% for a period of 10 minutes, followed by washing with PBS. Permeabilization was 
performed using the same buffer as for the adherent cells. Cells were carefully resus-
pended in permeabilization buffer and incubated for 5 minutes on ice. Before spinning, 
the permeabilization buffer was diluted with PBS. All further steps were performed as 
for the adherent cells, but in 15 ml falcon tubes and liquids were exchanged by spinning 
and removing the supernatant. After the final spinning, the entire supernatant was care-
fully removed and cells were collected in 8 µl mounting medium containing Dapi, the 
mounting medium was transferred to onto a microscopy slide and covered by a cover 
slip.  
Fluorescence images were obtained by a LEICA DM6000B fluorescence microscope 
equipped with a DFC350FX camera or a confocal microscope CLSM Leica SP5. 
2.3.10 Mouse Strain and Animal Care 
Procedures concerning animals were in accordance with the regulations of the veteri-
nary authority of Zurich and with the ARVO Statement for care and use of animals in 
research. The protocols were approved by the Swiss Cantonal Veterinary Authorities 
(Permit number 154/2011). Animals used in the studies were 4 weeks old female nu/nu 
mice obtained from CharlesRiver Laboratories, Germany.  
2.3.11 Preparation and Injection of Tumor Cells 
A431 cells of low passage were thawed and cultured for 10 days. For injection into 
mice, cells of 80 % confluency were harvested by trypsinization. The cells were centri-
fuged (for 3 min at 500 rpm) and washed with cold, sterile PBS three times. Thereafter 
the pellet was resuspended in cold PBS to a final concentration of 33 Mio cells/ml and 
kept on ice. The time from harvesting the cells until injection did not exceed two hours. 
For the injection of the tumor cells, the mice were anaesthetized with isoflurane. 150 µl 
cell suspension (5 million cells) were injected subcutaneously on the middle hind back 
of the nude mice by means of a 26G needle. 
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2.3.12 Assessment of Tumor Size 
Tumor size was assessed by caliper measurement of the two longest perpendicular axes 
of the tumor and was calculated according to the formula below, whereas length (l) is 
the longer and width (w) is the shorter axis. Smallest measuring unit was 0.1 mm.  
ܶݑ݉݋ݎ	ݏ݅ݖ݁ ൌ 12 ∗ ݈ ∗ ݓ
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2.3.13 Application of DARPins and Cetuximab, and Tumor Irradiation  
For in vivo application, pegylated DARPins were used. 20 kDa PEG-chains were 
attached to the c-terminal DARPin domain at a single cysteine present in the DARPin 
E69_LZ3_E01. The pegylated DARPins were prepared by the Biochemical Institute 
according to the procedure published by Seely and Richey [208].  
The administration of DARPins was performed by intravenous via tail vein or intraperi-
toneal injection according to the schedule on page 62. The treatment lasted 13 days, at a 
daily dose of 30 mg/kg of body weight. 
The three injections of cetuximab were administered intraperitonealy at an interval of 
five days at a dose of 50 mg/kg of body weight.  
For the application of the intravenous injections, the animals were strained in an appro-
priate device and the tail was warmed to dilate the veins. All injections were performed 
with standard insulin syringes. 
For irradiation, the mice were strained in lead cages with openings on the hind back for 
the tumor to be displayed. The lead cages were placed in a plexiglass “hotel” with filter-
covered air holes and a capacity of six mice. For the treatment of the mice, the same 
irradiation device was used as for the irradiation of cultured cells. Dosimetry was per-
formed by a radiation physicist. 
2.3.14 Histology 
Subcutaneous tumors were harvested and fixed immediately in 4 % PBS buffered 
formalin solution, protected from the light at room temperature. Within one week, the 
tumors embedded in the paraffin. The stainings were performed in collaboration with 
Prof. Dr. med. Holger Moch by the Institute of Medical Pathology USZ.  
Images were obtained by bright-field microscopy using a LEICA DM6000B micro-
scope equipped with a DFC290 camera. 
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2.3.15 Collection and Preparation of Serum Samples 
For the collection of the blood samples, the animals were strained in a shortened and 
perforated falcon tube. The saphenous vein was punctured and a few drops of blood  
(50 µl) were collected in Bd Microtainers (#365950). After coagulation of the blood, the 
serum was separated by spinning (at 6000 rpm for 5min) and stored at -80 °C. 
2.3.16 Sandwich ELISA of the DARPin E69_LZ3_E01 in Serum  
All washing steps were performed with 0.2 % BSA, 0.1 % Tween in 1xPBS unless 
stated otherwise. After each step, the plate was tapped on paper towels to get rid of 
remaining fluid. For the ELISA Maxisorp NUNC-Immunoplates were coated with 
RGS-His antibody (1:5000 stock dilution) overnight at 4 °C, washed twice and incubat-
ed in wash buffer for 1 hour at room temperature to block nonspecific binding. The 
plates were washed with 0.1 % Tween in 1x PBS 2 times and the plate was incubated 
with the diluted serum samples for 1 hour on the shaker, followed by three washing 
steps. Anti-DARPin antibody (Rabbit Serum, 1:1000 stock dilution in wash buffer) was 
added for DARPin detection. The secondary anti-Rabbit HRP conjugated antibody 
(1:1000 stock dilution) was added after 4 washing steps and incubated for 1 hour, 
followed by another four washing steps. Detection with TMP substrate was performed 
according to the manufacturer and absorbance at 450 nm was determined by an Ultra 
Microplate Recorder (Bio-Tech Instruments Inc.).  
2.3.17 Statistical Analyses of the In Vivo Data 
Statistical analyses were performed with Graphpad Prism Software Version 5 and R. 
The tumor growth curves were approximated with a Locally Weighted Error Sum of 
Squares regression (LOESS, span 0.5) in R. For the Kaplan Meier curve, the time point 
were the tumor reached 3x initial tumor size was also determined in R and statistical 
tests were performed in both R and Graphpad 
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2.4 Results 
The nonimmunoglobulin scaffold protein DARPin E69_LZ3_E01 binds and inhibits the 
epidermal growth factor receptor (EGFR) even stronger than the clinically approved 
antibody cetuximab. The mechanism of EGFR inhibition by DARPin E69_LZ3_E01 
(see section 2.4.1) is similar to the manner by which cetuximab inhibits the receptor. 
However, differences exist on the level of EGFR downregulation and inhibition of the 
downstream signaling, which already were described by Boersma et al [202]. We inves-
tigated DARPin E69_LZ3_E01 with regard to in vivo application, such as the dynamics 
of EGFR inhibition, and finally, we tested the in vivo efficacy in a xenograft tumor 
model in nude mice. 
2.4.1 Structure of DARPin E69_LZ3_E01 and Proposed Mechanism of EGFR 
Inhibition 
The structure of DARPin E69_LZ3_E01 includes two DARPin domains connected by a 
leucine zipper motif, which facilitates dimerization of the bivalent DARPin proteins 
(see Figure 2.5A). Both DARPin domains contain three internal ankyrin repeats and 
were selected by phage display against the extracellular part of the epidermal growth 
factor receptor [197]. Each of the two domains recognizes a different epitope [202]. 
Domain E01 recognizes the EGF binding site in the domain III of EGFR. This binding 
motif partially overlaps with the binding site of the mAb cetuximab. The binding site of 
E69 could be located to EGFR domain I. 
A B 
         
Figure 2.5 Structure of the DARPin E69_LZ3_E01 used in this study. (A) Dimerized structure 
of the DARPin E69_LZ3_E01 represented as stick model: domain E69 (red) and domain E01 
(blue), leucine zipper (green) and linkers (yellow). (B) Suggested mechanism of action: Binding 
of the EGF receptor by DARPin E69_LZ3_E01 leads to endocytosis of the receptor/DARPin 
complex. Original images were adopted from [202]. 
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DARPin E69_LZ3_E01 labeled with the fluorescence label Alexa was shown to inter-
nalize upon binding. Moreover, as opposed to EGFR bound by monovalent DARPin 
domains E01 or E69, EGFR bound by the tetravalent DARPins does not recycle to the 
plasma membrane, but instead is degraded (Figure 2.5B). 
Throughout the section results, the denomination “DARPins” will refer to the specific 
DARPin E69_LZ3_E01. The control DARPin used for the in vivo study resembles the 
DARPin E69_LZ3_E01 in structure but the domains E69 and E01 were replaced by an 
non-binding domain called Off7. 
2.4.2 DARPins Downregulate EGFR and Inhibit Downstream Signaling  
To test the potency of DARPin E69_LZ3_E01 to inhibit EGFR in our A431 cell system 
in comparison to the potency reported by Boersma et al. [202], we applied DARPins as 
well as the mAb cetuximab in cell culture and investigated EGFR phosphorylation at 
Tyr1173 and EGFR signaling upon receptor stimulation. Our results were in good 
agreement with the previously published data. Inhibition of phosphorylation of EGFR 
was achieved by both, DARPins and cetuximab, but only DARPins led to a decrease in 
the expression level of the receptor (see Figure 2.6). Moreover, DARPins led to a 
stronger decrease of EGF-induced phosphorylation of the downstream target Erk at 
Thr202/Tyr204 and to a lower extent also to a decrease of the phosphorylation of Akt at 
Ser473. This indicates that the degradation of EGFR is important for the reduction of 
the downstream signaling.  
A B 
 
Figure 2.6 Application of cetuximab or DARPin E69_LZ3_E01 inhibited EGF-dependent acti-
vation of the EGF receptor. A431 cells were incubated for 24 hours with DARPins (at a final 
concentration of 100 nM) or with cetuximab at equimolar concentration in medium containing 
(A) 1 % Serum or (B) 10 % Serum. EGF was added for 15 min prior to harvesting at the indi-
cated concentration. 
The experiment was performed by culturing the cells in medium containing 1 % serum 
to exclude the possible influence of serum-derived growth factors. The same experiment 
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was also repeated with cells growing in medium containing 10 % serum, which, in re-
gard to the in vivo experiments, may better reflect physiological conditions. However, 
both setups gave almost the same results. Overall, the results from the Western blot 
analyses suggest that, in vitro, DARPins are the more potent inhibitors of EGFR down-
stream signaling than cetuximab.  
2.4.3 DARPins Induced Phosphorylation of the EGF Receptor and Activation of 
Downstream Signaling. 
Unexpectedly, we observed phosphorylation of the EGF receptor at Tyr1173 in A431 
cells 24 hours after treatment with DARPins. The phosphorylated EGFR, which we 
discovered by indirect immunofluorescence staining of EGFR and phospho-EGFR, was 
mainly located at the cell-cell interfaces (see Figure 2.7A). We suspected that the clus-
tering of EGFR by the tetravalent DARPin might induce autophosphorylation of EGFR 
by juxtapositioned kinase domains. Cetuximab also led to an accumulation of EGFR at 
the contacting plasma membrane between cells, but phosphorylation of the receptor at 
Tyr1173 was not observed at this time point. 
 
Figure 2.7 The application of DARPins lead to phosphorylation of the EGF receptor. For indi-
rect immunofluorescence A431, cells were fixed 24 hours after treatment with DARPins or 
cetuximab. Cells were assayed for EGFR expression (green) and the presence of phospho-
EGFR (red). Counterstaining for the DNA was performed with Dapi (blue). In the panels on the 
right side, the cells were additionally stimulated with 100 ng/ml EGF for 10 minutes before 
fixation. 
In the previous Western blot analysis of A431 cells under DARPin-treatment, we were 
not aware of such a DARPin-induced phosphorylation. We anticipated that the DAR-
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Pin-induced phospho-EGFR levels might be higher at early time points, due to the 
initial high level of EGFR. The results in Figure 2.8A revealed that DARPin-induced 
phosphorylation of EGFR is detectable by Western blot as well, although the level of 
phospho-EGFR was significantly lower in the DARPin-treated cells, than in the cells 
stimulated with EGF. Importantly, DARPin-induced phosphorylation of EGFR also 
activated the downstream signaling, indicated by phosphorylation of Erk at early time 
points. At the 24-hour time point, however, Erk phosphorylation was decreased even 
below the levels observed in untreated control cells. In the non-small cell lung cancer 
cell line A549 (see Figure 2.8B), we could not detect phosphorylation of the EGF recep-
tor at Tyr1173 in general, not even in EGF-stimulated cells. Nevertheless, we detected 
increased phosphorylation of Erk upon treatment with DARPins, which indicated that 
also in A549 cells EGFR is activated by the DARPin-treatment. Whether A549 cells 
have a mutation in Tyr1173 is not known and remains to be elucidated.  
We also noticed that in A431 cells the EGF-stimulated EGFR was not degraded. The 
strong binding of EGF normally targets the receptor for degradation [114]. In A549 
cells, EGFR was strongly downregulated in presence of abundant EGF (100 ng/ml). 
Probably, in A431 cells, the continuous EGFR signaling in response to EGF stimulation 
is linked to the growth arrest we observed in EGF-treated A431 cells (see Figure 2.11). 
EGF-induced growth arrest was described by others before [209]. On the other hand, in 
EGF-stimulated A549 cells, no difference in proliferation compared to untreated cells 
was observed (see Figure 2.20).  
A B 
    
Figure 2.8 The application of DARPins lead to stimulation of the EGF receptor and induced 
downstream signaling. A431 cells (A) and A549 cells (B) were treated with EGF or DARPins at 
the indicated concentrations and were harvested at early time points of 20 and 40 minutes after 
administration and after 24 hours. Untreated cell were used as control. Lysates were assayed by 
Western blot analysis for phosphor-EGFR and for phosphorylated downstream targets.  
Detection of phospho-EGFR appeared unequally stronger by immunofluorescence 
microscopy than by Western blotting, which obviously is due to technical reasons. 
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Clustered objects emit a stronger immunofluorescence signal than individual objects 
with regard to the background signal. Most importantly, immunofluorescence micros-
copy provides information about the localization of the phosphorylated EGFR. Thus, in 
A431 cells, induction of EGFR phosphorylation after DARPin-treatment was followed 
at 10-minute intervals by immunocytochemistry. Phospho-EGFR was determined as 
early as 10 minutes and the highest levels were observed at 30 minutes after DARPin-
treatment (see Figure 2.9A). Phospho-EGFR was mainly localized at the plasma mem-
brane. Only at the 30-minute time point, there were indications that phospho-EGFR 
might enter endosomes. Moreover, like at the 24-hour time point the plasma membrane 
staining was confined to cell-cell interfaces, which indicated that endocytosis in this 
region might be slower or impaired. 
A 
 
B 
 
Figure 2.9 DARPin and cetuximab induced phosphorylation of the EGF receptor at early time 
points. (A) A431 cells were treated with 100 nM DARPin, fixed at the indicated time points and 
stained for EGFR (green) and phospho-EGFR (red) by indirect immunofluorescence. (B) Time 
line of EGFR phosphorylation in A431 cells treated with 100nM DARPin or cetuximab, or EGF 
at concentrations indicated above. The analysis was performed by Western blotting. 
In comparison to the EGF-induced phosphorylation, stimulation by DARPins was lower 
and of shorter duration (see Figure 2.9B, above). However, the concentration of 100 
ng/ml EGF, we had adopted from literature, might even exceed EGF levels in tumors 
with high EGF expression. Additionally, we observed that also cetuximab was capable 
of inducing EGFR phosphorylation, but to an extent that was significantly lower than 
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the phosphorylation induced by DARPins. This difference might reflect the difference 
in their potency to cluster and downregulate EGFR. 
2.4.4 DARPin-Induced Endocytosis of the EGF Receptor is Independent of Its 
Phosphorylation Status at Tyr1173. 
Our results demonstrated that downregulation of the EGF receptor in A431 cells was 
more pronounced in response to DARPin-treatment than to cetuximab. To test whether 
treatment-induced phosphorylation of the EGF receptor plays a role in the endocytosis 
and subsequent degradation of EGFR, phosphorylation was prevented by the dual 
EGFR/Her2 tyrosine kinase inhibitors AEE778 or PKI-166 prior to the treatment with 
DARPins. Both inhibitors act on the intracellular kinase EGFR domain and thus should 
not interfere with the binding of DARPins to the extracellular domain. A431 cells were 
pretreated with the tyrosine kinase inhibitors, and along with untreated cells, they were 
incubated for 24 hours with or without DARPins. The kinase inhibitors alone did not 
lead to a significant change in the EGFR level as determined by Western blot analysis 
(see Figure 2.10A). More importantly, inhibition of EGFR phosphorylation did not pre-
vent its downregulation upon the treatment with DARPins. Thus, we concluded that 
phosphorylation or at least phosphorylation at Tyr1173 was not essential in the process 
of EGFR endocytosis.  
A B 
          
Figure 2.10 Phosphorylation of the EGFR was not necessary for endocytosis of the receptor.  
(A) A431 cells were treated with 1 µMol AEE778 or 4 µMol PKI-166 1 h prior to treatment 
with 100 nM DARPins. Cells were harvested 24 h after treatment and assayed for the EGFR 
level and its phosphorylation status, as well as for the downstream targets. (B) A431 cells were 
treated with AEE778 and PKI-166 as above. Persistence of EGFR inhibition by the tyrosine 
kinase inhibitors for the duration of 24 hours was assayed by EGF stimulation added 15 minutes 
prior to harvesting. 
Curiously, in the Western blot analyses that was performed to validate that the tyrosine 
kinase inhibitors displayed their inhibitory activity for the entire duration of the 24-hour 
DARPin-treatment (see Figure 2.10B, above), we observed that EGF stimulation of 
AEE778-treated cells lead to Erk phosphorylation. Phosphorylation of Erk was of equal 
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degree as in the control cells, even though EGFR-phosphorylation at Tyr1173 was 
inhibited. In the PKI-166-treated cells, the downstream signaling was inhibited at the 
24-hour time point. Thus, PKI-166 might be better suited for this experiment. 
2.4.5 The Antiproliferative Effect of DARPins Is Stronger than that Observed for 
the Antibody Cetuximab 
In vitro, administration of cetuximab or DARPins led to a decrease in cell proliferation 
in A431 cells (see Figure 2.11A). Even though DARPins always showed a stronger 
reduction on the level of cell proliferation than cetuximab, the effect of EGFR inhibition 
on proliferation in adherent A431 cells was not significant and an increase in concentra-
tion of the inhibitors did not further decrease cell viability.  
Surprisingly, the antiproliferative effect was more pronounced in 3D cell culture, 
wherein cells were grown embedded in matrigel (see Figure 2.11B). However, 
quantification of proliferation in 3D, i.e. the determination of the clone size, is not 
straightforward and was performed only at a qualitative level. Nonetheless, the numbers 
of clones formed after DARPin-treatment were significantly reduced, compared to the 
colony numbers of cetuximab-treated or control cells (see also Figure 2.19C, page 55).  
A B  
           
Figure 2.11 EGFR inhibition by DARPins and cetuximab lead to reduced proliferative activity 
in A431 cells. (A) In adherent cell culture, DARPins were only insignificantly more potent than 
cetuximab. Continuous stimulation by EGF lead to the strongest inhibition of proliferation. Data 
depicts the mean of three independent experiments; error bars represent the SEM. (B) The effect 
of cetuximab or DARPins on cell proliferation was more pronounced in 3D-cell culture than in 
2D cell culture. The arrow indicates a putative senescent cell.  
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The reduction in cell number was not a result of programmed cell death (apoptosis) in 
A431 cells. The amount of PARP cleavage upon administration of DARPins or cetuxi-
mab was assessed by Western blot analysis, but no cleavage of PARP was observed 
(data not shown). On the other hand, inhibition of the EGF receptor lead to inhibition of 
cell cycle progression as was indicated by the shift in cell cycle distribution from the S 
phase towards G0/G1 phase (see Figure 2.12).  
However, reduced cell cycle progression does not explain reduced colony formation of 
DARPin-treated cells in 3D cell culture. PARP cleavage was only determined in adher-
ent A431 cells and might display a different result in 3D cell culture. Otherwise, the 
strong inhibition of EGFR by DARPin-treatment also may induce senescence. In the 3D 
culture of DARPin-treated cells, we observed the occurrence of big, bubble-like cells 
(see yellow arrow in Figure 2.11B, above), that might resemble senescent cells.  
 
Figure 2.12 A431 cells treated with either EGFR inhibitor displayed an increased G1 phase 
population and reduced S phase population. Relative reduction of S phase population was 
stronger in 3D-cell culture (single experiment) than in 2D-cell culture (three combined experi-
ments; error bars represents standard deviation). 
Interestingly, proliferation of A431 cells was most strongly reduced by continuous by 
EGF stimulation (see Figure 2.11A). Konger et al. suggested that EGF at nanomolar 
concentrations lead to a terminal differentiation in A431 cells [210], even though it was 
not clear whether differentiation per se is a consequence of growth arrest or vice versa 
[211, 212]. Only at picomolar concentration, EGF was shown to stimulate proliferation 
in A431 cells [210]. However, in our study, we investigated whether inhibition of the 
EGF receptor by cetuximab or DARPins counteracted EGF-induced growth arrest. Pre-
treatment with cetuximab or DARPins, as well as application of the EGFR inhibitors 
after EGF stimulation (10 ng/ml), led to a rescue of the EGF-induced growth arrest (see 
Figure 2.13). This effect was also observed at a higher EGF concentration (50 ng/ml ~ 
80 nM), which is almost equimolar to the concentration of the EGFR inhibitors applied 
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(data not shown). Interestingly, the difference between the application of EGFR inhibi-
tors before or after EGF stimulation was small, indicating that EGFR is very efficiently 
inhibited by both DARPins and cetuximab. 
 
Figure 2.13 EGF-induced growth arrest was rescued by inhibition of EGFR through the binding 
of cetuximab or DARPins. A431 cells were treated with EGF 4 h before or after treatment with 
cetuximab or DARPins (100 nM final concentration each). Proliferation was determined 72 h 
after treatment start by Alamar Blue assay. Data shows mean of two independent experiments; 
error bars represent standard deviation. 
2.4.6 EGFR Expression in 3D Cell Culture upon Treatment with DARPins or 
Cetuximab 
To evaluate the obvious differences in the EGFR pattern of 3D versus 2D cell culture 
upon DARPin- or cetuximab treatment, we attempted to stain cells derived from 3D cell 
culture for EGFR and phospho-EGFR. For the immunocytochemical staining, cells have 
to be partially liberated from the matrigel, which could be achieved by incubation in ice 
cold PBS for 10 minutes, prior to trypsinization and fixation. This procedure greatly 
impaired the detection of phospho-EGFR. However, the EGFR staining pattern in 3D 
control cells was similar to that of adherent control cells. DARPins led to a reduction of 
EGFR, whereas cetuximab did not, which was easily detectable despite the fact that 
EGFR expression levels varied greatly among different cells (see Figure 2.9A for 2D 
and Figure 2.14 for 3D cell culture). Cetuximab-treated cells strongly clustered and re-
mained attached to each other even after trypsinization and thus revealed that all cells 
within a single clone showed the similar EGFR staining intensity. Cetuximab generally 
did not lead to a downregulation of EGFR and thus we conclude that the EGFR expres-
sion level is inherited by daughter cells. However, we did not investigate whether in 
control cells EGFR expression also passed to daughter cells and whether cells were ca-
pable of switching from low- to high-level EGFR expression over time and vice versa. 
Also in 2D cell culture, FACS analyses of cetuximab-treated cells revealed a substantial 
number of cell duplets, but the cell clustering was more pronounced in 3D cell culture. 
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The cell clusters could not be resolved by trypsinization. However, it was possible to 
separate the cells by incubation in EDTA-Glycine buffer (pH 2), which indicates that 
the antibody cetuximab might be directly responsible for the clustering of the cells. 
Immunofluorescence microscopy of EGFR 24 hours after application of cetuximab 
appeared to be strongest at cell-cell interfaces (see Figure 2.9), but was absent at free 
edges. Possibly, intercellular crosslinking of EGFR by cetuximab inhibited endocytosis 
and degradation of the receptor. Cells treated with the tetravalent DARPin displayed a 
similar cell-cell interface staining as well, but to a lower extent. DARPins, however, are 
supposedly digested by trypsin, and the clustering of cells could not anymore be ob-
served after cell trypsinization. Furthermore, structural properties, such as the size of the 
antibody may account for the stronger intercellular crosslinking and consequently 
reduced downregulation of EGFR. 
 
Figure 2.14 EGFR expression in 3D cell culture after treatment with DARPins or cetuximab. 
A431 cells were seeded as single cells in matrigel. 24 hours after seeding, DARPins or cetuxi-
mab was administered at a final concentration of 100 nM. Cells were harvested 48 hours there-
after and stained for the EGF-receptor (green). Nuclei were counter stained with DAPI. 
2.4.7 Continuous EGFR Inhibition Does Induce Permanent Changes 
With regard to in vivo experiments, we investigated whether the continuous treatment 
with DARPins induced permanent changes in proliferation, EGFR expression and 
downstream signaling. A431 cells were kept under the influence of DARPins for a peri-
od of three weeks, which corresponded to the planned in vivo treatment time. There-
after, the cells were released into fresh medium and their recovery and response to 
EGFR inhibition by DARPins and cetuximab was assessed. In the control cells that 
were merely released into fresh medium, the EGFR protein level and its signaling ca-
pacity was fully restored at the time point of harvesting (Figure 2.15A).  
Moreover, the proliferative activity that was reduced under the prolonged treatment 
with DARPins recovered within hours (see control cells in Figure 2.15B). There was no 
significant growth delay observed in comparison to the proliferation of untreated A431 
cells in Figure 2.11A. Equally, the anti-proliferative effect of EGF was restored at the 
time point of EGF-administration, approximately 20 h after the release into fresh medi-
Results 
51 
 
um. Thus, we conclude that during a period of three weeks, DARPins did not lead to the 
selection of a DARPin-resistant phenotype. However, for the manifestation of newly 
originated mutations a longer treatment period would be necessary.  
A B 
 
Figure 2.15 Continuous treatment with DARPins for three weeks does not induce a selective 
process in A431 cells. After the three weeks incubation, the cells were then released into fresh 
DARPin-free medium. The following day DARPins or cetuximab were administered and (A) 
EGFR expression and signaling with and without EGF stimulation was assayed 24 hours there-
after by Western blot analysis. (B) Proliferation was assessed with Alamar Blue at the indicated 
time points. Ctrl refers to cells released into fresh medium with no drugs added later. Data 
depicts the mean of two independent experiments; error bars represent the SEM. 
2.4.8 The Dynamics of EGFR Inhibition by DARPins and Cetuximab In Vitro 
To optimize a combined treatment modality of ionizing radiation with a radiosensitizing 
agent, it is important to investigate the dynamics of the effect introduced by the agent. 
Thus, we followed the dynamics of EGFR inhibition by DARPins or cetuximab in A431 
cells. We examined the EGF receptor abundance and its Tyr1173-phosphorylation sta-
tus upon EGF stimulation, as well as the downstream signaling by Western blot (see 
Figure 2.16). Already one hour after treatment with DARPins and cetuximab, respec-
tively, phosphorylation of the EGFR-receptor was inhibited and could not be induced by 
EGF stimulation. For the DARPin-treated cells, a minimal band of DARPin-induced 
EGFR phosphorylation was visible. The EGFR receptor itself was gradually reduced in 
the DARPin-treated cells. Intriguingly, also in the cells treated with cetuximab, EGFR 
was reduced over time. In the previous experiments, EGFR levels had remained un-
changed for cetuximab-treated A431 cells. A possible explanation may be that in this 
experiment, cells were seeded at a lower density, which lead to a reduced intercellular 
cross-linking by cetuximab, and thus allowed for increased endocytosis of the receptor-
antibody complex. 
In contrast to the EGFR-phosphorylation, phosphorylation of Erk was only significantly 
reduced 4 hours after administration of DARPins and 8 hours after the application of 
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cetuximab. Hence, phosphorylation of Tyr1173 may not be a precise indicator for the 
EGF receptor status. The gradual decrease of phospho-Erk correlated better with the 
dynamics of the downregulation of the EGFR level. In addition, also in cetuximab-
treated cells phospho-Erk levels were strongly reduced, which we could not observe in 
the previous experiments. This indicates that in order to reduce downstream signaling, 
inhibitors binding to the extracellular domain of EGFR might need to induce endocyto-
sis and degradation of the receptor. Likewise, for Akt, we cannot explain why in the 
DARPin-treated cells, we did not observe a similar reduction in phospho-Akt as above 
(see Figure 2.6); a repetition of the experiment may show the reliability of the results 
concerning phospho-Akt. Furthermore, additional investigations are required to assess 
the correlation of cellular density and endocytosis of EGFR in response to cetuximab. 
 
Figure 2.16 Time line of EGFR Inhibition by DARPins or cetuximab. Inhibition of phosphory-
lation of the EGF receptor by DARPins or cetuximab takes place already at an early time point. 
A431 cells were treated DARPin or cetuximab, both at a final concentration of 100 nM. Sam-
ples for Western blot analysis were harvested at the indicated time points after treatment start. 
Cells stimulated with EGF were incubated with 100 ng/ml EGF for 15 min before harvesting. 
Lysates were analyzed for the expression level and the phosphorylation status of EGFR, and 
phosphorylation of the downstream targets Akt and Erk. 
Equally, if not more important than downregulation of the receptor, is the process of the 
recovery of the EGFR status after withdrawal of the drug, which indicates the duration 
of the treatment effect. On the other hand, the treatment effect is also dependent on the 
half-life of the drug. In contrast to cetuximab, the half-lives of DARPins are much 
shorter and may reach from 10 minutes to 12 hours as published in Zahnd et al. and in 
reference to information received from the Biochemical Institute, University Zurich 
[204]. With regard to the shorter half-life, the recovery time of the receptor might be 
crucial with regard to treatment efficacy.  
To assess EGFR recovery, A431 cells that had been treated for 24 hours with DARPins 
or cetuximab were washed with PBS and released into fresh medium. As early as two 
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hours after the release, phosphorylation of EGFR at Tyr1173 could be observed by 
Western blot analysis (see Figure 2.17A, B).  
A 
 
B 
 
Figure 2.17 Recovery of EGF receptor levels and signaling after withdrawal of DARPins or 
cetuximab. A431 cells were treated with (A) 100 nM DARPins or (B) 100 nM cetuximab for  
24 h and then released into fresh medium. Recovery of EGFR signaling was assayed by EGF 
stimulation for 15 min at the indicated time points after drug withdrawal. Samples were collect-
ed and subjected to Western blot analysis of the phosphorylation status of the receptor itself and 
the phosphorylation of the downstream targets STAT1, Erk and Akt.  
As a downstream signaling moiety, we included signal transducer and activator of tran-
scription 1 (Stat1) that is involved in growth factor dependent signaling [213]. EGF-
stimulated phosphorylation of Stat1 at Tyr701 was strongly suppressed by EGFR inhibi-
tion. Phosphorylation returned by 4 hours and reached control or even elevated levels 
by 6 hours after drug release. As in the previous experiment (see Figure 2.16), 
phosphorylation of Akt was not substantially suppressed by EGFR inhibition and thus 
did not contribute to the readout of the experiment. Consistently, EGF-stimulated 
phospho-Erk was reduced upon application of DARPins or cetuximab and returned to 
basal level within 6 hours of drug withdrawal. The fast recovery of STAT1 and Erk 
phosphorylation upon EGFR stimulation indicate a fast reconstitution of the EGFR 
status after elimination of the EGFR inhibitors from the cell culture medium.  
2.4.9 EGFR Inhibition by DARPins or Cetuximab Does Not Lead to Radio-
sensitization in A431 cells In Vitro 
The combination of cetuximab with radiotherapy in comparison to radiotherapy alone 
results in improved locoregional tumor control and overall survival in patients with 
squamous cell carcinoma of the head and neck (SCCHN) [137, 138]. The proposed 
mechanism of action by which cetuximab supports radiotherapy, and the degree of 
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radiosensitization are controversial. An overview of proposed mechanisms is presented 
in the discussion (see section 2.5.7). Some of the mechanisms of radiosensitization rely 
on the cell’s own repair capacity and on EGFR signaling, which contributes to cell 
survival signaling. These aspects may be assessed in vitro, whereas indirect effects on 
the level of the tumor microenvironment, such as stabilization of the endothelial cells 
upon IR-treatment by increased VEGF section, are more complicated to investigate in 
cell culture. Thus, we mainly inspected direct effects on the level of the cancer cell. We 
investigated cell proliferation and the clonogenic capacity of A431 cells with regard to 
the combined treatment of EGFR-inhibition with IR and compared it to the effects of 
radiation treatment alone.  
On the level of the proliferation in response to the treatment with DARPins or cetuxi-
mab in combination with IR, we were not able to detect a synergistic effect (see Figure 
2.18). However, the results indicate, that there might be an additive effect of EGFR 
inhibition to radiotherapy. Like in unirradiated cells, the difference in proliferative 
activity between cetuximab- and DARPin-treated cells was preserved in irradiated cells, 
but did not increase, as might be the case for a synergistic effect.  
 
Figure 2.18 Inhibition of EGFR does not sensitize A431 cells to IR. Cells were seeded in 96-
well plates; the following day, cells were treated with DARPin or cetuximab at a final concen-
tration of 100 nM each, or with 10 ng/ml EGF. 4 hours thereafter, the cells were irradiated with 
5 Gy or sham irradiated and proliferation was followed by Alamar Blue assay at the indicated 
time points after drug treatment. 
A classical experiment to investigate radiosensitization by a drug on the level of the 
cancer cell is the comparison of the clonogenicity of cells with and without treatment in 
combination with IR. The clonogenic potential of a cell in vivo contributes to tumor 
growth, thus, a reduction of clonogenicity in vitro is an indication of a possibly greater 
treatment effect in vivo. However, by means of the classical clonogenic assay we were 
not able to determine a direct effect of the inhibition of EGFR by DARPins or cetuxi-
mab on radiosensitivity (see Figure 2.19A). The clonogenicity of A431 cells by EGFR 
inhibition with DARPins or cetuximab alone was reduced by about 40 – 50 %, but as 
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mentioned, no synergistic effect in combination with IR was observed. In accordance 
with the results from the proliferation assays, the colonies that formed under treatment 
with DARPins or cetuximab were of smaller diameter. 
Interestingly, in a study that was performed with cells growing in spheres in matrigel, it 
was shown that EGFR inhibition by cetuximab had a radiosensitizing effect [214]. Eke 
et al. performed the classical clonogenic assay with adherent cells as well, but could 
barely determine radiosensitization by cetuximab. The reason behind this observation 
was proposed to be due to differential protein expression and differential signaling in 
cells grown in spheres and in contact with matrigel. Eke et al. compared the expression 
and signaling pattern from cells grown in 2D and in 3D to homogenates from tumor 
xenografts of the same cells and found that the results from 3D conditions better resem-
ble the in vivo pattern. However, this was least applicable for A431 cells, out of the 
three SCC cell lines that were tested by Eke et al. In the 3D clonogenic experiments 
performed by us, we did not observe significant radiosensitization, but the number of 
spheres formed under the treatment with DARPins was by far more reduced than under 
cetuximab treatment (see Figure 2.19B).  
A B 
 
Figure 2.19 Application of anti-EGFR DARPins does not lead to radiosensitization in vitro. (A) 
For the classical clonogenic assay, A431 cells were plated in cell culture dishes and treated with 
DARPins or cetuximab the following day as for the proliferation assay; irradiation at different 
dose points were performed 6 hours after EGFR inhibition. Data depicts two independent exper-
iments combined, with the error bars representing the SEM. (B) For the 3D-clonogenic assay, 
A431 cells were treated with DARPin or cetuximab as above, but grown in matrigel in 96-well 
plates. Data represents a single experiment, error bars show standard deviation of five wells 
counted per condition.  
Nevertheless, as mentioned before, both, DARPins and cetuximab strongly inhibited 
proliferation in 3D (see Figure 2.11B for microscopy image). Moreover, in 3D cell cul-
ture the clonogenicity of A431 cells treated with DARPins alone was markedly reduced. 
This strong reduction in clonogenicity, though not synergistic in our hands, nonetheless 
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may contribute to the success of radiation therapy by additionally reducing the clono-
genic potential of cancer cells. 
2.4.10 A549 Are Not Sensitive to EGFR Inhibition or EGF Stimulation In Vitro  
The non-small cell lung cancer cell line A549 expresses EGFR, but at the same time 
harbors an activating RAS-mutation, which may render them insensitive to EGFR inhi-
bition. A549 cells have been investigated in the past with regard to EGFR inhibition in 
combination with IR. Radiosensitization upon EGFR inhibition was observed by 
Dittmann et al. [215], yet others claimed that the Ras-mutant cell line was insensitive to 
EGFR inhibitors such as cetuximab [216, 217].  
In our hands, A549 proofed to be insensitive to cetuximab. We did not observe inhibi-
tion on the level of proliferation, nor did we observe radiosensitization at a concentra-
tion of 100 nM cetuximab (see Figure 2.20A, B). Equally insensitive was their response 
to DARPins, even though, Western blot analysis had previously revealed, that down-
regulation of EGFR takes place upon treatment with DARPins (see Figure 2.7B).  
In A549 cells, EGFR inhibition does not lead to an accumulation of the cells in the G1/S 
phase as observed for the A431 cells. This may be due to the activating mutation in Ras 
downstream of EGFR. The activated Ras in A549 cells stimulates the Ras-Raf-Mek-Erk 
pathway regardless of the EGFR status, which we confirmed by Western blot analysis 
(data not shown).  
Thus, we concluded that EGFR inhibitors might not be an option for cancer cells that 
harbor activating mutations in Ras. 
A B 
 
Figure 2.20 A549 cells are insensitive to EGFR inhibition by DARPins or cetuximab (A) Pro-
liferation assay: A549 cells were seeded in a 96-well plate. Proliferation was measured by 
Alamar Blue measurement every 24 hours up to 72 hours after the indicated treatment.  
(B) Clonogenicity of A549 cells was determined in control cells or under treatment with 100 
nM DARPins or cetuximab at the indicated in dose points.  
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2.4.11 Characterization of Pegylated DARPins with Prolonged Half-Life for In 
Vivo Application 
For the in vivo application, we decided to use pegylated DARPins, which have a 
prolonged half-life. DARPins on their own are relatively small proteins that may be 
eliminated rapidly from blood circulation. DARPin monomers administered to mice by 
intravenous injection were eliminated within minutes, proposedly via the kidneys [204]. 
On the other hand, whole IgG antibodies, such as cetuximab, have a long serum half-
life, which makes them favorable for therapeutic purposes.  
DARPin E69_LZ3_E01 is a tetravalent binder consisting of two DARPin constructs 
dimerized by means of a leucine zipper, and thus has a markedly increased size com-
pared to the single DARPin domains. Yet, the half-life of DARPin E69_LZ3_E01 was 
surmised not to be sufficiently long, because proteins of the size of 84 kDa may still be 
eliminated through glomerular filtration. Therefore, for the in vivo application, we 
decided to use a pegylated version of DARPin E69_LZ3_E01 that carried a PEG20 
chain on each DARPin monomer.  
Pegylation increases the molecular weight, but on the other hand, it may negatively 
influence the binding affinity of the DARPin domains, which we wanted to investigate. 
We previously observed that the DARPin E69_LZ3_E01 was capable of rescuing EGF-
induced growth arrest in A431 cells (see Figure 2.13, page 49). However, the same 
experimental set-up performed with the pegylated version of the DARPin 
E69_LZ3_E01 only led to a partial rescue of proliferation (see Figure 2.21A). This indi-
cates that the binding affinity probably was reduced by the pegylation, which may affect 
in vivo efficacy of the anti-EGFR DARPin. As expected, the nonspecific pegylated 
Off7_LZ3_ Off7 DARPin used as control in the in vivo setting showed no effect with 
regard to the rescue. A431 cells treated with the control DARPin proliferated at a rate 
comparable to cells treated with EGF only.  
Whereas the affinity may affect tumor localization of the DARPin E69_LZ3_E01, it 
may also alter the efficacy of DARPins to inhibit EGFR. Thus, we compared the effect 
of the original and the pegylated DARPin E69_LZ3_E01 on cell cycle distribution. The 
cell cycle distribution determined 24 hours after treatment with the pegylated version of 
DARPin E69_LZ3_E01 showed a slightly reduced accumulation of cells in the  
G1/S phase compared to the original DARPin E69_LZ3_E01 (see Figure 2.21B). 
However, the accumulation of A431 cells in the S/G1 phase, as well as growth 
inhibition are effects of low magnitude and, thus, differences are difficult to discern.  
Differences in the binding properties of the pegylated DARPin could be assessed by 
quantification of the DARPins bound to the cell surface of A431 cells. Unfortunately, 
this is not as straight forward as it may appear at first sight and need to be performed 
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with radiolabelled DARPins. Labeling of DARPins by indirect immunofluorescence 
cannot be quantitatively compared, because the binding of the primary antibody to the 
DARPins may be influenced by pegylation as well. Figure 2.22A depicts A431 cells 
treated for 30 minutes with pegylated control DARPin Off7_LZ3_ Off7, or pegylated or 
unpegylated DARPin E69_LZ3_E01. Samples were stained with anti-PEG antibodies 
and anti-RGS-His antibodies to visualize the bound DARPins. Even though the RGS-
His staining for the cells treated with the unpegylated DARPin was much stronger, we 
could not relate staining intensity to binding efficacy due to the reason mentioned 
above. 
A 
                   
B 
                    
Figure 2.21 Characterization of pegylated DARPins. (A) A431 cells were treated with EGF  
(10 ng/ml) or medium only, followed by administration of the DARPins at a final concentration 
of 100 nM 4 hours thereafter. Proliferation was determined by Alamar Blue assay. The data 
shows the mean proliferative activity 72 hours after treatment (triplicates, error bars depict 
standard deviation). (B) A431 cells were treated for 24 hours with the respective DARPins. 
Cells were fixed and cell cycle was determined by FACS analysis, by means of BrdU incorpora-
tion and DNA content (single experiment). 
Nonetheless, immunofluorescence labeling of the DARPins in a time line experiment, 
may be useful to compare the kinetics of EGFR endocytosis and degradation. Since the 
staining for the pegylated DARPin was stronger with the anti-PEG antibody, this anti-
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body was used for visualization of the pegylated DARPin. For detection of the 
unpegylated DARPin, the RGS-His antibody was used. Endocytosis was readily 
induced by the unpegylated as well as the pegylated DARPin E69_LZ3_E01, as shown 
at the 30-minute time point (see Figure 2.22B). At the 18-hour time point, there were 
less stained intracellular vesicles in the cells treated with the pegylated DARPins. 
However, a counterstaining for the EGFR levels would have been essentially informa-
tive about the EGFR downregulation at the 24-hour time point. Indirectly the reduced 
levels of DARPins bound in both cases at this time point indicate an efficient down-
regulation by the original as well as the pegylated DARPin. 
A 
  
B 
  
Figure 2.22 Immunofluorescent labeling of DARPins bound to the EGFR receptor in vitro.  
(A) A431 cells were treated with the respective DARPins for 30 minutes and stained with anti-
PEG antibody and anti-RGS-His antibody. Images were taken with the same microscopy 
settings. (B) Time line of the binding of the EGF-receptor and its endocytosis facilitated  
by DARPins: E69_LZ3_E01 (top, stained with anti-RGS-His antibody) and pegylated 
E69_LZ3_E01 (bottom, detected by anti-PEG antibody). 
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2.4.12 Combined Treatment of A431 Tumor Xenografts with the Pegylated 
DARPin E69_LZ3_E01 and IR 
For characterization of the anti-EGFR DARPin E69_LZ3_E01 in vivo, we planned to 
determine pharmacokinetics of the pegylated DARPin and to analyze histological 
sections stained for EGFR abundance and its phosphorylation status, for the phosphor-
ylation of the downstream targets Erk1/2 and Akt and for the PEG-DARPins itself. 
Finally, the efficacy of the treatment with anti-EGFR DARPin E69_LZ3_E01 was 
determined in A431 tumor xenografts in nude mice. 
2.4.12.1 Pharmacokinetics of the anti-EGFR DARPin E69_LZ3_E01 
As previously described, the DARPin E69_LZ3_E01 consists of two separate DARPin 
domains linked by a leucine zipper, which facilitates dimerization of two E69_LZ3_E01 
molecules. The tetravalent binder comprises a mass of 84 kDa, to which two 20 kDa 
linear PEG-chains are attached to. Pegylated DARPins at a dose of 30 mg/kg of body 
weight were administered intravenously (IV) or intraperitonealy (IP) and blood samples 
were drawn at the saphenous veins at the indicated time points. The serum half-life of 
the pegylated DARPin was determined by means of enzyme-linked immunoassay 
(ELISA) and comprised approximately 20 minutes (see Figure 2.23A, B).  
A  B 
  
Figure 2.23 Elimination of pegylated DARPin E69_LZ3_E01 from blood serum after IV or IP 
injection. Both graphs depict the mean DARPin levels at the indicated time points after injection 
(n=5, error bars depict standard deviation). (A) The serum half-life of 20 min was determined 
by nonlinear regression (R square = 0.8346). (B) Data shown with linear scale. 
In comparison, a bivalent unpegylated DARPin of 30 kDa exhibited a plasma half-life 
time of less than 3 minutes [204]. Nonetheless, the half-life of the pegylated DARPins 
was still much shorter than the half-life of cetuximab, which amounted to 40 hours in 
nude mice [218]. This implies the necessity for repeated applications of the DARPins. 
Since the number of injections that can be given intravenously is limited, we tested 
blood serum levels of pegylated DARPins after intraperitoneal injection as well. The 
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mean serum level of DARPins determined by ELISA one hour after drug administration 
was slightly higher compared to the drug serum level after IV injection, possibly due to 
the delay of the drug in reaching the blood circulation. Nevertheless, variation within 
the five mice treated intraperitonealy was substantially larger, at the 1-hour time point, 
than within the animals treated intravenously. This large variation compromises the 
control over the amount of drug reaching circulation and therefore reaching the tumor.  
2.4.12.2 Immunohistological Analysis Does Not Shed Light onto the Functionality of the 
Pegylated DARPin E69_LZ3_E01 
Even though pegylated DARPins show slower elimination from the blood, their bulki-
ness lead to slower tumor localization [204]. Therefore we harvested tumor xenografts 
treated with pegylated DARPin E69_LZ3_E01 for histological analyses, first to deter-
mine DARPin localization and secondly, to observe if the treatment would lead to 
changes in EGFR expression or phosphorylation. The treatment consisted of two injec-
tions at a 12-hour interval, and tumors were harvested 6 hours and 24 hours after the 
second treatment. Unfortunately, the anti-PEG antibody that we successfully used for 
immunocytochemistry (see Figure 2.22, page59) did not detect any pegylated DARPins 
within the formalin-fixed tumor tissue. From these results, we cannot conclude that the 
pegylated DARPins reached the tumor. We did not know at that time that the duration 
of the half-life of the PEG-DARPins would only be 20 minutes, otherwise a 15-minute 
time point might have served as positive control. 
           
Figure 2.24 Immunohistological analyses of tumor xenografts harvested 6 hours after the sec-
ond treatment with the pegylated DARPin E69_LZ3_E01. 
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Moreover, the staining for the EGFR itself was very strong and did not change remark-
ably in comparison to control tumors. Also in the histological sections derived from 
tumors treated with cetuximab, no changes in receptor expression could be determined 
(data not shown). Interestingly, phosphorylation of Erk, a downstream target of EGFR 
signaling, was strongest in areas were phosphorylation of EGFR was comparably low 
(see Figure 2.24, above). This rendered the evaluation of EGFR inhibition and its effect 
on downstream signaling impossible to be evaluated. Overall, histological analyses did 
not provide clear evidence for the in vivo application of the pegylated DARPin 
E69_LZ3_E01 or the mAb cetuximab. Nevertheless, the latter was shown to have a 
strong inhibitory effect on tumor growth (see section below). 
2.4.12.3 Efficacy of the Pegylated DARPin E69_LZ3_E01 Compared to Cetuximab in 
A431 Tumor Xenografts in Nude Mice 
To assess the efficacy of PEG-DARPins in comparison to cetuximab with regard to tu-
mor growth inhibition and radiosensitization in vivo, A431 tumor xenografts were 
established subcutaneously on the hind back of nude mice. The mice were randomly 
divided into six treatment groups. Two groups were treated with PEG-DARPin 
E69_LZ3_E01, one as monotherapy and the second in combination with ionizing radia-
tion. The two control groups were treated accordingly, but instead of the anti-EGFR 
DARPin, a pegylated nonspecific DARPin (PEG- Off7_LZ3_ Off7) was administered. 
Two additional groups were treated with cetuximab alone and in combination with IR, 
respectively.  
Due to the rather fast pharmacokinetics, DARPins were administered daily, for 13 days, 
at a dose of 30 mg/kg of body weight, which is equal to 230 nmol/kg. Cetuximab injec-
tions were administered every fifth day at a dose of 50 mg/kg of body weight 
corresponding to 330 nmol/kg. Drugs were applied intravenously or intraperitonealy as 
stated in the table (see Table 2.5). Animals treated in combination with IR were given 
three fractions of 8 Gy with a five-day interval in between the irradiation fractions, one 
day after application of cetuximab or approximately 4 hours after DARPin-treatment.  
Table 2.5 Treatment Schedule for A431 tumor xenografts in nude mice. 
 
IV = intravenous injection; IP = intraperitoneal injection; IR = application of ionizing radiation 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13
Control-DARPin IV IV/IR IV IP IP IV IV/IR IV IP IP IV IV/IR IV
Control-DARPin & IR IV IV IV IP IP IV IV IV IP IP IV IV IV
DARPin IV IV IV IP IP IV IV IV IP IP IV IV IV
DARPin & IR IV IV/IR IV IP IP IV IV/IR IV IP IP IV IV/IR IV
Cetuximab IP IP IP
Cetuximab & IR IP IR IP IR IP IR
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Treatment with the pegylated DARPin E69_LZ3_E01 did not reduce tumor growth at 
the dosage and schedule applied in comparison to the control treatment group. The 
mean of the tumor growth curves of both groups were congruent (see Figure 2.25). In 
combination with ionizing radiation, the tumors treated with pegylated DARPin 
E69_LZ3_E01 regrew even slightly faster (see Figure 2.25 and Figure 2.26), which 
might be explained by the variance.  
 
Figure 2.25 DARPin E69_LZ3_E01 does not influence tumor growth as monotherapy 
or in combination with ionizing radiation. (A) Tumor growth curves of A431 tumor 
xenografts. Mean tumor size and standard deviation at the indicated time after treatment 
start (n = 10, for all, except for Control DARPin n=14).  
  
Figure 2.26 Kaplan Meier analysis: Time to reach 3 times the tumor size at treatment initiation. 
Overall survival was not significantly different between the group “Control DARPin & IR” and 
the group “DARPin & IR” (p = 0.63 by log-rank test).Cetuximab in combination with IR 
showed a significant difference from the control or the DARPin-treated group that were 
irradiated (p = 0.14, p = 0.11 by log-rank test) 
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The distribution of the tumor sizes, grouped according to treatment, at day 26 (for all 
treatment groups) and day 51 (for irradiated and cetuximab-treated tumors) confirmed 
that there was no difference between the control and the anti-EGFR DARPin (see 
Figure 2.27). Thus, we assume that the half-life of the PEG-DARPins indeed was too 
short to induce tumor growth delay. For the continuous downregulation of EGFR, a 
longer half-life is necessary to achieve a steady state of the administered DARPins in 
the serum. 
A B 
         
Figure 2.27 Distribution of tumor size on day 26 (A) and day 51 (B) after treatment start.  
Data is represented as scatter blot with the median indicated. On day 51, one animal had been 
sacrificed in the “Control-DARPin & IR” group due to necrosis of the tumor. This animal was 
not considered for calculating the median. The one tumor of the cetuximab group that already 
had reached 1500mm3 was considered.  
Surprisingly, cetuximab monotherapy was more efficient than ionizing radiation alone. 
Moreover, growth suppression in vivo was far more efficient than in classical cell 
culture in vitro and better resembles the antiproliferative effect observed in 3D cell 
culture. Partially, the anti-tumor effect of cetuximab in the preclinical settings might 
also have been due to complement-dependent cytotoxicity or indirect inhibitory effects 
on the endothelial cells and thus tumor angiogenesis.  
Interestingly, one tumor, or one animal (considering a possible immune reaction) did 
not respond to cetuximab at all. Moreover, one tumor treated with cetuximab initially 
responded very well with tumor regression, but then started to regrow at an accelerated 
pace (see Figure 2.28, treatment group cetuximab). This might represent the selection of 
a more aggressive phenotype. Of the mice treated with the combined treatment of 
cetuximab and IR, all tumors regressed to a non-measurable size, and 6 out of 10 
showed a total regression with no signs of tumor or even scars remaining. Two of the 
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four tumors that had not fully regressed after the three cycles of combined treatment, 
started to regrow within the 75 days after termination of the treatment. The two other 
tumors were barely visible and resembled fibrous scar tissue. To sum up the combined 
treatment of cetuximab and IR was very effective, which might have been due to EGFR 
inhibition as well as the antibody properties of cetuximab, contributing to a synergistic 
treatment response. 
 
 
 
Figure 2.28 Tumor growth curves of individual mice shown separated according to the 
treatment groups. All groups contain 10 animals, except for the control DARPin group (n = 14). 
Treatment was initiated at day 1 and was completed at day 13, for treatment schedule see page 
62.  
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2.5 Discussion 
The goal of this study was to determine the efficacy of the DARPin E69_LZ3_E01 on 
epidermal growth factor receptor (EGFR) inhibition in tumor xenografts in nude mice. 
This designed ankyrin repeat protein (DARPin) was previously shown to efficiently 
inhibit EGFR in vitro. It does so with greater potency than the monoclonal antibody 
cetuximab. Cetuximab is in clinical use and displays beneficial effects in combination 
with radiation therapy. We confirmed the inhibitory property of DARPin E69_LZ3_E01 
in vitro, performed additional studies to determine its potential as radiosensitizer and 
finally tested its efficacy in a preclinical setting on tumor xenografts in nude mice, in 
combination with ionizing radiation. All results were compared to those obtained with 
the mAb cetuximab.  
2.5.1 Inhibition of EGFR by DARPins or Cetuximab Does Not Fully Inhibit EGF-
Induced Stimulation of the MAPK- and PI3K/Akt-Pathways 
With regard to in vitro efficacy, inhibition of EGFR by DARPin E69_LZ3_E01 
abrogated EGF-induced autophosphorylation of the receptor at Tyr1173 in the same 
way as cetuximab. DARPins even inhibited EGFR downstream signaling to a higher 
extent than cetuximab. EGF primarily acts through EGFR homodimers or EGFR/ErbB2 
heterodimers, thus we expected a stronger inhibition of Akt and Erk1/2 phosphorylation 
in response to EGF stimulation in cetuximab- or DARPin-treated cells. However, also 
in DARPin-treated A431 cells, we still observed an increase of phosphorylated Erk1/2 
and phosphorylated Akt after stimulation with EGF.  
Notably, the reduction of EGF-stimulated phosphorylation of Erk1/2 correlated with the 
downregulation of EGFR, which both were strongly reduced in DARPin-treated cells. 
On the other hand, EGFR downregulation and reduced Erk phosphorylation were in 
general far less prominent in cetuximab-treated cells. The relationship between EGFR 
level and Erk phosphorylation became even more apparent, when cells were seeded at 
low density. Under these conditions, cetuximab was able to induce receptor endocytosis 
and down-regulation and displayed reduced Erk phosphorylation upon EGF stimulation 
as well. However, if the EGF receptors are not endocytosed and, though inhibited, 
remain at the plasma membrane, stimulation with EGF at a concentration as high as  
100 ng/ml may overcome the inhibitory effect of the cetuximab or DARPins by 
competitive binding of the EGFR [219]. The so activated receptors might have been 
overly few to be detected by Western blot analysis. Moreover, we determined the level 
of activated EGFR by looking at only one single phosphorylation site; therefore, we 
might not have acquired the full picture on the extent of EGFR inhibition and activation, 
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respectively. Interestingly, Berger et al. observed complete inhibition of EGFR 
phosphorylation at Tyr1068 with the same concentration of cetuximab and were also 
puzzled to find phosphorylation of Erk to be induced upon stimulation with EGF [220]. 
They reached the same conclusion that an EGF concentration of 60 ng/ml might 
overcome EGFR inhibition by cetuximab and that the few activated EGF receptors may 
sufficiently induce phosphorylation of Erk. Furthermore, in response to strong 
activation of the EGFR downstream signaling, several feedback loops ensure a 
controlled negative regulation of the EGFR signaling [221, 222]. Such feedback loops 
act on multiple levels of the signaling cascade, including EGFR itself [223]. By means 
of computer-based simulation of the EGFR signaling, it was shown that at very low 
EGF concentration, signal amplification from MEK to Erk was several fold increased in 
comparison to stimulation with higher EGF concentrations [224]. 
For the EGF-stimulated activation of Akt in DARPin and cetuximab treated A431 cells, 
we did not observe a possible link between Akt phosphorylation and EGFR abundance. 
Phosphorylation of Akt, in comparison to phosphorylation of Erk, was less strongly 
reduced in EGF-stimulated cells in response to DARPins, and the results obtained were 
inconsistent across different experiments. However, inhibition of Akt might be even 
more important than inhibition of Erk in the context of radiosensitization (see below, 
section 2.5.7.1). Thus, it would be crucial to understand the mechanism of EGF-
stimulated Akt phosphorylation in presence of inhibited EGFR activation.  
A feedback loop emanating from Erk may provide an explanation for the minor 
reduction of Akt phosphorylation in response to EGFR inhibition. For example, EGF 
stimulation of cells treated with Erk inhibitor resulted in increased activation of the 
PI3K/Akt pathway as determined by phosphorylation of Akt at Ser473 [225, 226]. The 
underlying mechanism of this hyperactivation of the PI3K/Akt pathway is not well 
understood. Turke et al. suggested that inhibition of Erk reduced an inhibitory threonine 
phosphorylation in the conserved juxtamembrane domain of ErbB3, which then resulted 
in increased ErbB3 activity and thus increased downstream Akt phosphorylation [227]. 
Even though the status of Erk-inhibited cells may not exactly represent the status of 
EGFR-inhibited cells, it is conceivable, that inhibition of EGFR signaling and thus 
reducing the connected inhibitory feedback signals may increase signaling through 
other family members of the ErbB family. 
2.5.2 Efficacy of DARPin E69_LZ3_E01 and Cetuximab Is Stronger in Cells 
Grown in Spheres than in Conventional Cell Culture 
Most probably, due to the inability of cetuximab and DARPins to completely inhibit 
EGFR-mediated Erk activation, cetuximab and DARPins per se did not impose major 
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stress on adherent cells in culture. DARPins were more potent in the downregulation of 
the EGFR and in the inhibition of the EGFR downstream signaling and induced a slight-
ly stronger growth inhibition than cetuximab. But overall, both treatment modalities, 
cetuximab and the anti-EGFR DARPin E69_LZ3_E01 induced a minor growth delay in 
vitro. Our results on cetuximab confirmed earlier data published by Kimura et al. [228]. 
Interestingly, growth inhibition was far more pronounced when cells were grown in 3D, 
in matrigel. While in 3D, treatment of A431 cells with either cetuximab or DARPins 
manifested in the formation of much smaller spheres, DARPin-treatment also reduced 
clonogenicity by about 40 percent. For the cetuximab-treated cells, the sphere number 
remained the same and only a size reduction was observed. However, it was difficult to 
discern by microscopy alone whether all spheres counted, met the colony size of  
50 cells, that was defined as evidence for the clonogenic potential of a cell. Further 
analyses, such as staining for cell nuclei would allow for the quantification of cell 
numbers per sphere. Unfortunately, conventional staining methods cannot simply be 
applied to spheres and need to be established first. Another drawback of 3D cell 
culturing is that the drugs applied cannot be easily washed away. Thus, it is difficult to 
differentiate between the influence of the drug on clonogenicity and the influence of the 
drug on the proliferative activity of the cells. We did not remove cetuximab and 
DARPins in the classic clonogenic assay either, but there cell proliferation was not as 
strongly affected that it interfered with the evaluation of the colonies.  
Cell cycle analysis by BrdU incorporation revealed that A431 cells cycle slower in 
matrigel, with 14 % of the cell population being in S phase as opposed to 30% in 
adherent cell culture. The S phase analysis of DARPin- and cetuximab-treated cells also 
corroborated the findings of increased growth inhibition in 3D cell culture: S phase 
population treated with cetuximab or DARPins in 2D was reduced by approximately 
40% and 50%, respectively; in 3D cell culture, reduction comprised 57% and 72%, 
respectively. However, 3D experiments were only performed once and a more in-depth 
analysis will be required to verify these results. 
2.5.3 Intracellular Crosslinking and Induction of Autophosphorylation, 
Unwanted Side Effects? 
As a result of these 3D cell culture experiments, we realized that the application of the 
mAb cetuximab led to a strong intercellular crosslinking. Cetuximab-treated A431 cells 
harvested for FACS analyses or for immunofluorescence staining could not be separated 
merely by trypsinization, which we attributed to the antibody. Brown et al. reported that 
45-60% of the serum IgG withstand digestion with trypsin in Tris-buffer at pH 8 for 8 
hours, at a trypsin to substrate concentration of 1:23 [229]. Moreover, biotechnology 
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and life science companies such as Thermo Scientific list the method of trypsin-digest 
for the fragmentation of IgM antibodies but not for IgG antibodies, which indicates, that 
IgGs are not efficiently fragmented by trypsin. By incubation in glycine-HCl buffer at 
pH 2.5, which is often used for the dissociation of antibody-antigen complexes, we 
achieved the detachment of the cells. Thus, we assumed that aggregation of A431 cells 
treated with cetuximab was facilitated by antibody interaction.  
In 2D cell culture, the effect of intercellular crosslinking by cetuximab was noted during 
FACS analysis. A substantial number of duplets or bigger cell aggregates were 
detectable in FACS samples that were treated with cetuximab, but not in control 
samples or DARPin-treated samples. Moreover, intercellular crosslinking by cetuximab 
seemed to impair endocytosis of the EGF receptor. Cetuximab-treated A431 cells 
displayed a strong EGFR staining at cell-cell interfaces, which was not present at free 
edges of the cell membrane where cells are not in contact with other cells. This may 
also explain the discrepancy in the extent of cetuximab-induced EGFR downregulation 
that we observed between different experiments. We hypothesize that reducing cell 
density and thus reducing intercellular crosslinking, may allow for a stronger 
downregulation of the EGFR. However, in solid tumors cells do not grow separated 
from each other. In vitro results should therefore be carefully revised with regard to 
effects obtained through EGFR downregulation (see below).  
Theoretically, the tetravalent DARPin E69_LZ3_E01 could also bind EGF receptors 
located on two neighboring cells. However, DARPin-treated cells readily separated 
upon harvesting. On the other hand, trypsin may cleave DARPins and disguise the 
effect of intercellular crosslinking. Membranes at cell-cell interfaces of cells treated for 
24 hours with DARPins also displayed an increased EGFR staining, which indicates 
that intercellular crosslinking may take place as well. However, the staining in DARPin-
treated cells was less intense than in cetuximab-treated cells, correlating with the 
stronger downregulation of the EGFR by DARPins. More importantly, the binding of 
the EGFR by DARPin E69_LZ3_E01 resulted in phosphorylation of the receptor at 
Tyr1173. We hypothesize that the clustering of the EGFR by the tetravalent DARPin 
enables autophosphorylation. DARPin-induced phosphorylation reached its peak within 
the first hour of treatment and was then reduced over time, probably due to the 
internalization of the DARPin/EGFR-complexes. At the 24-hour time point after 
treatment with DARPins, phosphorylated EGFR still could be detected, but was 
exclusively localized at cell-cell interfaces. Possibly, phosphorylation was maintained 
through intercellularly linked receptors that could not be turned off by endocytosis. 
Phosphorylation of the EGFR itself did not seem to be necessary for endocytosis and 
degradation, as previously demonstrated by others [230]. However, DARPin-induced 
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phosphorylation of the EGFR led to a short-term activation of the downstream 
signaling, determined by the increase in Erk phosphorylation.  
Treatment with cetuximab also resulted in phosphorylation of the EGFR at Tyr1173, 
however to a much lower extent. Similar observations have been reported before. For 
instance, Mandic et al. observed increased EGFR phosphorylation also at Tyr1173, 
whereas Li et al reported a similar effect on the amino acid residue Tyr845 [231, 232]. 
Both studies were performed on squamous cell carcinoma cells of the head and neck. 
Raben et al. tested phosphorylation at Tyr1068, another important site in several non-
small cell lung cancer cell lines with the same result [233]. Although cetuximab 
prevents internalization of EGFR to a greater extent than DARPins, the positioning of 
the receptor kinase domains of receptors clustered by DARPins must favor kinase 
activation to a higher degree than the clustering by cetuximab.  
At this stage, we are not capable to discern the impact of the treatment-induced 
phosphorylation, which is considerably stronger for DARPins than for cetuximab, on 
cell proliferation or treatment efficacy.  
2.5.4 Pharmacokinetics of DARPins in Comparison to the Pharmacokinetics of 
Therapeutic Antibodies 
Our study demonstrates that DARPin E69_LZ3_E01 is highly efficient in EGFR inhibi-
tion and EGFR downregulation in vitro. However, its rapid clearance hampers systemic 
application. While pegylation of the DARPin monomers prolonged serum half-life to a 
yet insufficient 20 minutes, at the same time pegylation may reduce the binding capaci-
ty of the DARPin domains through steric hindrance. Practically all studies on pegylation 
of antibody fragments (Fab) reported such a loss of antigen binding affinity (reviewed 
in [234]), which may also be the case for DARPins that are of similar or even smaller 
size. We did not assess binding affinity directly, however, the reduced capacity of the 
pegylated DARPin to rescue EGF-induced growth inhibition in A431 cells indicates that 
binding affinity for EGFR and thereby receptor inhibition was altered by the pegylation 
status.  
Further investigations on the pharmacokinetics and biodistribution of the pegylated 
DARPin E69_LZ3_E01 are required to understand how the drug distributes in the body, 
how it reaches its target, and how it is eliminated from the system. In vivo, a drug such 
as DARPin E69_LZ3_E01 that relies on sustained inhibition of the target to be effective 
is useless if eliminated overly rapidly from the system. As described above, the DARPin 
E69_LZ3_E01 forms dimers, resulting in a protein with four DARPin domains. Howev-
er, a previous study on tumor targeting with DARPins demonstrated that the increase in 
size and affinity by additional DARPin domains did not lead to better tumor localization 
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[204]. Data obtained by Zahnd et al. suggests that the size of a divalent DARPin of 
approximately 30 kDa does not prevent the fast elimination of the drug by glomerular 
filtration. Unfortunately, the increase in size by a second DARPin domain probably 
reduced vascular extravasation and diffusion and led to an overall lower tumor uptake 
compared to a DARPin consisting of a single domain. Likewise and probably for the 
same reason, tumor accumulation of DARPins conjugated to polyethylene glycol (PEG) 
chains was slowed down, which was compensated though by an increased serum half-
life. As a consequence, tumor localization of the DARPins was not greatly improved by 
pegylation [204]. Unfortunately, we were not able to detect the pegylated DARPin 
E69_LZ3_E01 in the histological sections of tumor xenografts harvested 6 hours after 
the second of 2 consequential treatments. Our pharmacokinetic analysis revealed that 
the pegylated DARPin was cleared from the blood within 2 hours. Thus, tumor-bound 
DARPins eventually must have been degraded. Experiments with e.g. radioactively 
labelled DARPins, as performed by Zahnd et al., could shed light on the amount of the 
pegylated DARPin E69_LZ3_E01 reaching the tumor.  
As good as DARPin E69_LZ3_E01 performed in cell culture, the biggest obstacle for a 
successful application in vivo is a stable supply of DARPins to the tumor site. This 
would be required for a continuous inhibition of the EGFR. As opposed to DARPins, 
antibodies of the IgG1 isotype such as cetuximab display a long serum half-life, which 
is not only determined by the difference in size. Depending on the dose administered, 
saturation of the elimination pathways for antibodies leads to a serum half-life of more 
than 100 hours [235]. IgG antibodies are mainly eliminated through cellular uptake and 
consequential degradation [236]. Most therapeutic antibodies can be eliminated by non-
specific interaction of the Fc region with Fc-receptors, which are expressed on virtually 
all cells.  
Cellular uptake does not always lead to the degradation of the antibody; IgGs bound by 
FcRn receptors may be recycled and released into extracellular fluids. This process does 
not only significantly increase the serum half-life of IgGs, but also facilitates trans-
membrane transport of the hydrophilic macromolecules [237, 238]. The role of cells 
expressing Fcγ receptors in the clearance of IgG antibodies, such phagocytotic cells or 
other cells of the immune system, is still unknown [239]. Clearance of monoclonal 
therapeutic antibodies often display a nonlinear clearance due to saturation of the target-
mediated clearance pathways, which depend in the case of cetuximab on the abundance, 
distribution, internalization and turnover of the EGFR [239].  
As it is the case for large-sized DARPins, accumulation at the tumor site is much slower 
for the large size 152-kDa mAb cetuximab than for small molecules. Lee and Tannok 
demonstrated in tumor xenografts that cetuximab and trastuzumab distributed in a time 
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and dose dependent manner [240]. After intravenous injection of cetuximab, the anti-
body was mostly found in the surrounding cell layers of the tumor vasculature at the 
early time points. The antibody concentration decreased with increasing distance from 
the blood vessel. 24 hours after application, the staining for cetuximab showed a more 
homogenous distribution. Interestingly, the antibodies did not reach hypoxic tumor 
areas. After injections with low antibody concentrations, the staining remained peri-
vascular even after 24 hours, indicating that cetuximab is captured by target sites and 
only tumor saturating concentrations lead to a relatively uniform pattern with time. 
Again, these findings suggest that a long half-life of a macromolecular drug or its con-
stant supply is essential for the treatment of solid tumors. For the treatment with the 
pegylated DARPin E69_LZ3_E01, our daily administration was clearly insufficient, 
taking the rapid clearance of the drug and the rapid reconstitution of the EGFR signal-
ing into account.  
2.5.5 Effect of Cetuximab Monotherapy on A431 Tumor Xenografts 
The tumor growth delay induced by the cetuximab monotherapy, was equal if not even 
stronger than the delay caused by irradiation with three fractions of 8 Gy. The growth 
inhibitory effect of cetuximab we observed was stronger in 3D than in 2D and interest-
ingly, results from 3D cell culture experiments better predicted the in vivo tumor 
growth response to cetuximab than the effect observed in adherent 2D cell culture. 
However, the mode of action of cetuximab on solid tumor growth is still debated.  
We compared the outcome of our study on A431 tumor xenografts to similar studies, 
which were also performed on tumor xenografts derived from the same cell line, and 
also in nude mice. From these studies, we adopted the treatment schedule for the mono-
treatment with cetuximab. To increase the effect introduced by the combined treatment 
modality, we decided to apply three cycles of irradiation, combined with cetuximab or 
with DARPins. Due to the limited amount of DARPins at our disposal, the initially 
planned 7-day cycles of daily DARPin administration (30 mg/kg body weight) were 
shortened to cycles of five days. Cetuximab was administered once per cycle on the day 
prior to irradiation, or accordingly, 3 times every five days without irradiation, at a dose 
of 50 mg/kg of body weight, which corresponds to about 1.2 mg per mouse. In the earli-
er preclinical studies on combined treatment of A431 tumor xenografts, cetuximab was 
administered once prior to radiotherapy and then every three days or twice per week for 
3, or 8 doses of 1 mg mAb cetuximab per mouse, respectively [241, 242]. Interestingly, 
in the study of Milas et al., A431 tumor xenografts treated with 3 x 1 mg cetuximab, the 
antibody alone did not lead to a significant growth delay. On the other hand, in the 
study we performed and in the study of Saleh et al., a clear growth delay was already 
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induced by the monotherapy with cetuximab. Even though the cetuximab regimen 
administered by Saleh et al. was longer than the treatment applied by Milas et al., the 
duration of the treatment probably does not account for the difference in the tumor 
response between the two studies. In our study, all tumors strongly responded already 
prior to the second injection, except for one specific cetuximab-insensitive tumor (see 
below).  
Tumor size plays an essential role in the responsiveness of A431 tumor xenografts to 
the treatment with cetuximab [243, 244]. Fan et al. showed that tumors of a size of  
150 mm3 at the start of the treatment, responded with complete growth inhibition for the 
period of treatment (1 mg/mouse twice a week for 30 days). In tumors with an initial 
size of 200 mm3, only a growth delay could be induced. Cetuximab treatment in tumors 
of the size above 400 mm3 did not lead to any absolute growth delay in comparison to 
the control group. Clinical significance of a drug that only shows an effect in small 
tumor xenografts and none in well-established tumor xenografts is likely to be question-
able. On the other hand, Saleh et al. reported sensitivity of A431 tumor xenografts as 
big as 400 mm3 at treatment start. Thus, we conclude that additional factors other than 
size determine tumor response to cetuximab.  
The mouse strains used by all three studies were athymic nude mice, but they were 
obtained from different breeders. Unless it is because of the acquisition of genomic or 
epigenetic changes in the A431 cell line over time, tumor-host cell interactions or 
tumor-host immune interactions may be at least partially responsible for the varying 
treatment response of A431 tumor xenografts to cetuximab. Notably, Milas et al. used  
3 to 4 month old nude mice, while in our study as well as in Saleh’s study much 
younger mice (4 and 6-8 weeks old) were used. Moreover, Milas et al. injected tumor 
cells intramuscularly, while in the other studies described above as well as in ours, the 
experiments were performed on subcutaneous tumor xenografts. But then again, tumor 
localization can also not be the only reason of the differential growth response 
observed, as a follow up study by Milas et al. was performed in subcutaneously injected 
tumor cells, affirming the minor growth delay previously observed in intramuscular 
tumor xenografts. 
Reproduction of the various conditions in a single lab would be very laborious, but may 
reveal the factors influencing the efficacy of cetuximab. Eventually though, the potency 
of cetuximab will have to be evaluated in human patients. Nude mice lack mature  
T-cells and thus are used as model for human tumor xenografts, which otherwise would 
be rejected by the animal’s immune system. However, the aspect of T-cell dependent 
ADCC cannot be studied in this host model. Additionally, NK cells are highly activated 
in nude mice [245], which also may yield misleading results. Nonetheless, the tumor 
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xenografts model with tumor growth delay as a readout still represent a good tool to 
study potential tumor responses to new treatment modalities. 
2.5.6 Acquired Resistance to the EGFR-Inhibitor Cetuximab 
Intriguingly, one of the ten A431 tumor xenografts treated with cetuximab was not sen-
sitive to cetuximab. This tumor grew as fast as the control tumors, not even showing an 
initial response. This might be simply related to incorrect application of cetuximab in 
this specific mouse. However, that the intraperitoneal injection failed three times in the 
same mouse is rather unlikely. Nonetheless, we did not monitor blood levels of cetuxi-
mab after injection and therefore, this possibility cannot be completely disregarded. 
Another explanation for the nonresponsiveness of this tumor may be clonal expansion 
of an insensitive cell at an early stage of tumor xenograft formation. A431 tumor xeno-
grafts required up to five weeks to grow to the treatment size of 170 mm3, with a long 
initial phase with no visible growth. During this initial phase, a cell might have gained a 
proliferative advantage by an activating mutation downstream of the EGFR or a muta-
tion in a redundant pathway leading to growth advantage and insensitivity to EGFR-
inhibition.  
Yet a third hypothetical explanation may concern the immune response. Even though 
nude mice do not have a fully functional immune system, they still possess components 
of the innate immune system, capable of interacting with the Fc region of an antibody, 
such as macrophages, natural killer (NK) cells or the complement system. Trastuzumab 
(Herceptin) an antibody specific to Her2 has been shown to work partially if not 
predominantly through antibody-dependent cellular cytotoxicity (ADCC) [246, 247]. 
Rituzimab, the first therapeutic antibody approved by the U.S. Food and Drug Associa-
tion (FDA), targeting the pan-B cell marker CD 20, induces its antitumor effect through 
ADCC as well as through activation of the complement system [248]. Cetuximab, of the 
same isotype (IgG1), was selected for clinical trials because it did not exhibit comple-
ment-dependent cytotoxicity (CDC) or trigger inflammatory responses, in contrast to 
another EGFR-targeting antibody of the IgG2a isotype [249, 250]. Moreover, cetuximab 
was initially thought not to trigger ADCC either. However, more recently published 
studies demonstrate that nevertheless, cetuximab-mediated ADCC contributes to its 
antitumoral mode of action [228, 251]. If ADCC was a major determinant of the in vivo 
effect of cetuximab, the nonresponsiveness of the single mouse might have been associ-
ated to a defective NK activity. However, in our study we did not perform additional  
in-depth studies on the mechanism of action of cetuximab and no experiment were 
performed to assess ADCC. 
Discussion 
75 
 
Interestingly, a second tumor xenograft, which initially responded with strong tumor 
regression, started to regrow after treatment completion at an accelerated pace, its 
growth rate even surpassed that of the control tumors. In this case, clonal selection of a 
more aggressive phenotype under treatment pressure may have occurred. Treatment-
acquired resistance in cancer cells that do not harbor any of the compensatory muta-
tions, such as activating K-Ras or EGFR kinase domain mutations, has been described 
previously [252]. In some cases, treatment resistance to cetuximab may be overcome by 
trastuzumab, an inhibitory anti-ErbB2 antibody, and likewise resistance to trastuzumab 
can be overcome by cetuximab [253]. Supporting the hypothesis that other members of 
the ErbB family may be involved in acquired resistance to cetuximab, Yonesaka et al. 
showed that several of the selected cetuximab-resistant HCC827 and GEO cell clones 
had acquired ErbB2 amplifications. Cetuximab did not substantially reduce Erk1/2 
phosphorylation in these clones, unless the ErbB2 kinase inhibitor lapatinib was addi-
tionally administered, which restored cetuximab sensitivity [254]. Moreover, Yonesaka 
et al. identified a cetuximab-resistant A431 cell clone, which had not acquired increased 
expression of any member of the growth factor receptor family, but overexpressed 
heregulin at a 2.5 fold increased level. Depending on the isotype, heregulin binds to 
ErbB3 and ErbB4, or ErbB4 only. A431 cells express ErbB3, but not ErbB4. ErbB2 in 
turn functions as co-receptor for ErbB3 or ErbB4. These receptor heterodimers are 
activated by the binding of heregulin and may have a partially redundant function to 
EGFR. Furthermore, Yonesaka et al. demonstrated that administration of exogenous 
heregulin to otherwise cetuximab-sensitive cell lines led to a dose dependent increase in 
cetuximab-resistance and Erk1/2 phosphorylation. 
Acquired resistance to the treatment with cetuximab may also occur through the acqui-
sition of new mutations. In an in vitro selection process, such a point mutation occurred 
in the in the EGFR ectodomain (S492R), which then interfered with the binding of 
cetuximab, and thus conferred treatment resistance [147].  
In a similar experimental setup, the expression of members of the Ras family proteins 
was observed to be substantially increased in resistant clones in comparison to the one 
in the parental cell line [255]. Ras proteins are not only members of growth factor 
signaling cascades but their activity also leads to an increased release of various growth 
factors, that stimulate more growth factor receptors than only EGFR (see section 
2.5.7.1). 
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2.5.7 Combined Treatment of EGFR Inhibition with Cetuximab and Ionizing 
Radiation 
Cetuximab in combination with ionizing radiation substantially increases tumor growth 
delay or tumor control in preclinical settings [256, 241, 257, 258]. In a clinical phase III 
trial on squamous carcinoma of the head and neck, the combined treatment modality of 
cetuximab with radiotherapy resulted in an increased 5-year survival in comparison to 
radiotherapy alone [137, 138]. In our preclinical study on A431 derived tumor xeno-
grafts, we also observed that the treatment response to the combined treatment with IR 
and cetuximab was superior to radiotherapy alone. However, we could not determine 
from our data, whether the application of cetuximab elicited a synergistic effect on 
tumor growth in combination with ionizing radiation. As discussed before, cetuximab 
alone already led to a significant tumor growth delay, which had not been observed in 
all of the previously performed preclinical studies (see above). 
The reason for the beneficial treatment response when combining irradiation with cetux-
imab has not yet been fully elucidated. Likewise, no predictive marker for treatment 
indication could be identified so far. Different mechanisms have been proposed on how 
EGFR inhibition may contribute to radiosensitization. These include impaired DNA 
repair, reduced repopulation, and increased apoptosis, enhanced oxygenation in frac-
tioned radiotherapy, and reduced angiogenesis.  
2.5.7.1 Radiosensitization through Inhibition of EGFR Downstream Signaling 
For clinical use, EGFR inhibition by cetuximab has been approved by the U.S. Food 
and Drug Association (FDA) for local combination with radiation therapy for the treat-
ment of locally or regionally advanced squamous cell carcinoma of the head and neck 
(SCCHN). In epithelial-derived solid tumors such as SCCHN, EGFR expression is often 
upregulated, which has been shown to correlate with poor prognosis for the treatment 
with radiation [117, 259]. Liang et al. demonstrated increased radioresistance due to 
ectopically expressed EGF [260]. Moreover, radiation treatment led to ligand-
independent autophosphorylation of the EGFR and activation of downstream signaling, 
which was proposed to lead to accelerated proliferation and enhanced cell survival 
[261–263]. Furthermore, a second, delayed phase of EGFR stimulation has been 
attributed to the release of TGFα or amphiregulin in a dose-dependent manner by 
ionizing radiation [264, 265].  
EGFR signaling through the PI3K/Akt pathway increases cell survival after the expo-
sure of cells to DNA damaging agents or IR. Thus, inhibition of either EGFR or the 
PI3K/Akt pathway leads to radiosensitization [266–268]. The EGFR downstream target 
Ras has also been linked to resistance to IR, although this radioresistance may not be 
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directly mediated by the activation of the Ras/MAPK/Erk signaling, but rather by also 
activating the PI3K/Akt pathway [267]. Cells with activating Ras-mutations show a 
substantially higher secretion of growth factors after irradiation than cells with wild 
type Ras [269, 270]. Activation of Akt in response to IR has been shown to depend on 
these secreted growth factors rather than on a direct stimulation by Ras signaling [271]. 
This implies that in combination with radiation, EGFR inhibition might have a radio-
sensitizing effect by inhibiting EGFR stimulation and subsequent Akt activation upon 
radiation-induced growth factor secretion. 
In clinical trials, activating mutations in KRAS were determined to be an adverse prog-
nostic marker for treatment of colorectal cancer with cetuximab [272–275]. On the other 
hand, the prognostic significance of the KRAS mutation status for the combination of 
cetuximab with radiochemotherapy is controversial. Some clinical studies observed a 
statistical significance for the K-ras status as predictive marker [276, 277]; whereas 
others report that in combination with radiochemotherapy, the prognostic significance 
was lost [278–280].  
Caron et al. also demonstrated that the radioresistance conferred by activating mutations 
in KRAS or HRAS was mediated via the increased secretion of growth factors and the 
consequential stimulation of growth factor receptor signaling [281], which may provide 
a rationale for the use of cetuximab. However, the growth factors they found to be  
of importance, included heregulin, which, as mentioned above, was also suggested  
to mediate cetuximab-resistance via ErbB3/HER2 signaling in cancer cells [254]. 
Furthermore, in the KRAS mutated cell line A549, the siRNA knockdown of EGFR 
alone was also not sufficient to sensitize the cells to radiation. In contrast, the 
elimination of the mutated KRAS significantly reduced clonogenicity of A549 cells 
treated with IR [282]. Moreover, selected, cetuximab-resistant clones, which showed 
increased activity of Ras family proteins, not only displayed reduced sensitivity to 
radiation alone, but also were insensitive to EGFR-inhibition by cetuximab in the 
combined treatment with IR [255]. These findings corroborate that other ErbB family 
members compensate for the inhibited EGFR signaling. 
Accordingly, we did not observe radiosensitization by cetuximab in the KRAS mutant 
cell line A549. In our hands, though, cetuximab did not sensitize the KRAS wild type 
cell line A431 either. Not even DARPins, which led to a much stronger inhibition of the 
EGFR than cetuximab and a strong reduction of clonogenicity in 3D cell culture, sensi-
tized A431 cells with respect to ionizing radiation.  
Former studies on radiosensitization by cetuximab in vitro are controversial, and no 
clear correlation to activating mutations downstream of the EGFR could be identified 
[283]. Mansoor et al. also did not observe any radiosensitization by cetuximab in the 
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squamous carcinoma cell line A431 in vitro, which reflects well our own results [242]. 
On the other hand, Dittmann et al. reported radiosensitization upon EGFR inhibition in 
the non-small cell lung cancer cell line A549 [215], which we could not confirm in our 
experiments. 
Probably, accumulation of cetuximab-sensitive cells in the less radiosensitive G1 phase 
of the cell cycle may compensate for reduced EGFR signaling. Moreover, in A431 cells 
Akt phosphorylation at Ser473 was only moderately reduced. This might be sufficient to 
preserve cell viability after a radiation insult. As mentioned above, the PI3K/Akt path-
way seems to play an important role in radioresistance and in response to other DNA 
damaging agents (reviewed in [284]). 
2.5.7.2 Inhibition of EGFR May Lead to Impaired DNA Damage Repair 
As mentioned above, stimulation of proliferation and survival pathways are only one 
aspect of how EGFR modulates cellular and tumor radiosensitivity. Other studies 
suggest that EGFR is also directly involved in the DNA damage repair process by 
facilitating nuclear import of DNA-dependent protein kinase (DNA-PK). DNA-PK  
is a key player in non-homologous end joining, which is a major DNA double-strand 
break repair pathway in mammalian cells [285, 286]. Huang et al. and Dittmann et al. 
observed that the cellular application of the mAb C225 (cetuximab) reduced the 
baseline levels of nuclear EGFR and nuclear DNA-PK, and inhibited their nuclear 
translocation in response to ionizing radiation [256, 215]. Similar results have been 
obtained by cellular application of the small molecular EGFR inhibitor gefitinib, which 
led to time- and dose-dependent relocalization of DNA-PKcs from the nucleus to the 
cytosol [287]. Interestingly, EGFR inhibition with the mAb C225 or gefitinib induced 
the molecular interaction of EGFR with DNA-PK. The amount of EGFR/DNA-PK 
complex formation that followed EGFR inhibition by cetuximab surpassed the amount 
of complex formation induced by ionizing radiation [215]. Similar results with regard to 
complex formation were observed upon EGFR inhibition by gefitinib that were 
compared to cells treated with DNA damaging agents such as etoposide and cisplatin 
[287]. However, EGFR/DNA-PK complex formation and DNA-PK redistribution is cell 
line dependent, e.g. the breast cancer cell line MDA-453 did not display any change in 
complex assembly upon treatment with gefitinib. It would be interesting to assess 
clonogenic survival of the various cell lines investigated in response to the combined 
treatment of gefitinib or cetuximab with ionizing radiation, along with additional 
mechanistic experiments, in order to determine the relevance of nuclear EGFR for 
radioresistance. 
Discussion 
79 
 
Shin et al. investigated treatment with cetuximab alone or in combination with IR, both 
in vitro and in vivo on tumor xenografts. In accordance with our own results, a stronger 
susceptibility to both treatment modalities was observed in the in vivo models than in 
classic in vitro cell culture [283]. Thus, EGFR inhibition may have additional effects on 
the level of the tumor microenvironment that outweigh the effect of direct cellular 
radiosensitization. 
2.5.7.3 Radiosensitization through the Influence of EGFR Inhibition on VEGF 
Secretion and Tumor Vasculature 
Tumor hypoxia and blood vessel formation (angiogenesis) are at constant interplay in a 
growing, proliferating tumor. In hypoxic cancer cells, the release of pro-angiogenic 
factors is triggered, which in turn stimulates endothelial cell proliferation and thus the 
formation of new blood vessels [288, 289]. There is increasing evidence that EGFR 
signaling in tumor cells plays a prominent role in increased secretion of pro-angiogenic 
factors (reviewed in [290]).  
Already in 1993, it was discovered that blocking the vascular endothelial growth factor 
(VEGF) suppressed tumor growth in vivo [291]. Similarly, Perotte et al. showed that 
inhibition of EGFR by cetuximab down-regulated transcription and translation of 
angiogenic factors such as VEGF in tumor xenografts, along with reduced neovascular-
ization [292]. Downregulation of VEGF and a twofold reduction of micro vessel density 
(MVD) has also been observed in cetuximab-treated A431 tumor xenografts [293].  
Problematically, irradiation increases secretion of VEGF, which correlates with en-
hanced radioresistance [294, 295]. Interestingly, tumor xenografts, established from 
sublethally pre-irradiated A431 cells, showed a markedly higher MVD than control 
tumors. Concurrent treatment with cetuximab partially decreased the MVD of these 
tumors [263]. Cetuximab also decreased VEGF secretion in established SCCHN tumor 
xenografts treated with the anti-EGFR antibody alone or in combination with ionizing 
radiation [256]. Similar to the Pueyo study, a reduction in MVD could only be observed 
in response to the combined treatment modality and not in response to either treatment 
alone. These findings suggest that irradiation increases secretion of pro-angiogenic 
factors, which contribute, as part of the stress response, to the stabilization of tumor 
vasculature damaged by the irradiation insult.  
Garcia-Barros et al. proposed that the tumor response to radiotherapy is mainly regulat-
ed by endothelial cell apoptosis [296]. In this study, tumor xenografts established in 
acid sphingomyelinase (ASMase) knockout mice, with very radioresistant endothelial 
cells, were refractory to single high doses of ionizing radiation. On the other hand, 
tumor xenografts established in ASMase wild type mice were much more sensitive. 
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However, the role of tumor vasculature in tumor radiosensitivity cannot be conclusively 
derived from the comparison of these two mouse models. Tumor development in 
ASMase-deficient mice was significantly slowed down. Additional endpoints such as 
tumor control and not only tumor growth delay will have to be addressed, in particular 
when the treatment response of tumors with different growth rates is compared. 
Paradoxically, in some studies angiogenesis-inhibiting agents not only reduced the for-
mation of new blood vessels but also led to a normalization of the vasculature, which 
resulted in increased tumor oxygenation [297–299]. Tumor vasculature often holds an 
increased number of vessels compared to normal tissue. However, tumor blood vessels 
are often tortuous, physically abnormal and functionally insufficient. The resulting in-
consistent blood flow leads to an insufficient supply of oxygen and to acute or chronic 
hypoxia. It is generally accepted that hypoxic tumors or hypoxic tumor areas are more 
radioresistant. In vitro, it has been shown that clonogenic survival was increased in cells 
irradiated under hypoxic conditions [300–303, 46, 304]. Furthermore, clinical studies on 
tumor oxygenation and treatment response to radiotherapy indicate that hypoxia is an 
adverse prognostic factor for the patient outcome [305, 306]. Based on the current state 
of knowledge, it is proposed that the presence of oxygen leads to “fixation” of the DNA 
damage. Absence of oxygen therefore may protect hypoxic cells from obtaining more 
complex DNA lesions. Lee et al. investigated whether downregulation of VEGF in-
creases radiosensitivity through enhanced oxygenation. He could show that treatment 
with anti-VEGF antibody led to enhanced oxygenation in tumor xenografts. However, 
these tumor cells were still sensitized to ionizing radiation even when the tumor blood 
supply was transiently blocked by clamping for the time of treatment [297]. These 
results suggest that tumor vascular normalization, including enhanced oxygenation, is 
not the only explanation for tumor radiosensitization upon downregulation of VEGF. 
Stabilization of tumor vasculature by VEGF may be equally, if not more important, in 
conferring radioresistance. 
2.5.8 Conclusion 
The role of EGFR signaling in radiation response is not fully understood yet. Results 
derived from independently performed preclinical studies are often contradictory, even 
when the same cell lines were used and experiments were performed under similar con-
ditions. Furthermore, it is important to keep in mind that even tumor xenografts in nude 
mice are simplified models and may not encompass the complex tumor biology as a 
whole. Orthotopic and spontaneous tumor models represent more advanced systems, but 
at the same time, they are laborious in handling and expensive. Likewise, tumor control 
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and not tumor growth delay might represent the better endpoint, especially for these 
more advanced tumor models.  
EGFR is a key player involved in diverse regulatory pathways, such as proliferation, 
cell survival, angiogenesis, and DNA repair. The complexity of the pathways affected 
by the inhibition of the EGFR receptor renders it difficult to assess the consequences of 
blocking the receptor. Moreover, cancer cells often show deregulation in one or several 
pathways downstream of the EGFR or rely on signaling through other family members 
of the ErbB tyrosine receptor family, which further complicates analysis. Eventually, 
examination of treatment responses in human patients, in combination with specific 
molecular testing is indispensable for shedding light on the heterogeneity of treatment 
responses to EGFR inhibitors. 
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3.1 Introduction 
3.1.1 Vaults: An Overview of Structure and Composition 
Vaults are large ribonucleoprotein particles with a hollow barrel-like structure [307] and 
a mass of 13 MD. Vault particles are found in many eukaryotic species from protozoans 
and slime molds to fish, amphibians, avians and mammals [308]. In mammals, they are 
composed of three proteins: the major vault protein (104 kDa), the vault poly 
(adenosine diphosphate-ribose) polymerase also known as VPARP (193 kDa), and 
telomerase-associated protein-1 TEP1 (240 kDa) [309–311]. Besides proteins, several 
small untranslated RNAs (vRNAs) have been found to associate with vaults. The major 
vault protein, as its name implies, constitutes the major part of the vault particle and 
accounts for more than 70% of the total mass of the complex. The molecular 
architecture of the rat liver vault complex was elucidated at high resolution using 
cryoelectron microscopy [312]. A vault consists of two dimers of half-vaults, which 
align at their waists to form together a barrel-like structure with the overall dimensions 
of 40 x 40 x 67 nm3.  
 
Figure 3.1 Side and top view of the vault structure. One of the 78 major vault proteins 
constituting the barrel is shown in maroon. 
Each half-vault comprises 39 identical major vault proteins (MVP), the major self-
assembling structural component (Figure 3.1). Other studies suggest a slightly bigger 
structure including 48 major proteins per half-vault [313]. Interestingly, vaults can 
open, the two halves can dissociate at their waists at acidic pH [314], and half vaults can 
be exchanged to form new vaults in live cells [315–317]. Based on these features and on 
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its large interior volume, which may encapsulate hundreds of proteins, recent interest in 
recombinant vaults derives from nanoparticle research trying to exploit vaults as drug 
delivery system. 
The two minor vault proteins VPARP and TEP1 are not part of the shell-like structure 
and probably reside at the top center of the caps or within the vaults, as determined by 
cryoelectron microscopy difference mapping with recombinant proteins [318]. VPARP 
contains a catalytic site related to PARP1 and presumably ribosylates substrates, to 
which MVP and VPARP itself may belong to [310, 319]. TEP1 has been shown to 
interact with vRNAs, to be important for their stability and their localization in vaults 
[320]. Molecular composition of the vault has been roughly estimated as 78-96 MVPs, 
eight VPARPs, two TEP1s, and at least six copies of vRNA [321].  
3.1.2 MVP the Major Component of Vaults 
The lung resistance protein (LRP), which was later found to be the human homolog of 
MVP [309], originally was discovered in a multidrug resistant lung cancer cell line 
[322]. However, MVP expression is also present in normal tissue and varies among dif-
ferent cell types. Vaults are most numerous in macrophages [323, 324] and epithelial 
cells with secretory and excretory functions, as well as cells chronically exposed to 
xenobiotics such as bronchial cells and cells lining the intestine [322]. Most of the 
vaults are located in the cytoplasm, although a small fraction of these particles apparent-
ly has been found to localize at or near the nuclear membrane and possibly to associate 
with the nuclear pore complex [325]. 
The human gene encoding MVP has been located in chromosome 16 (16p11.2), approx-
imately 27 cM proximal to the gene location of the multidrug resistance protein-1 
(MRP1, also designated as ABCC1) [326]. However, although both ABCC1 and MVP 
map to the short arm of chromosome 16, they are rarely co-amplified and are normally 
not located within the same amplicon and can be switched on separately [326, 327]. 
Analysis of the human MVP gene revealed a TATA-less promoter, which also lacks 
other core-promoter elements. On the other hand, several putative transcription factor 
binding sites were recognized, including an inverted CCAAT box, a p53-binding site, 
and a GC box element [328]. An in silico analysis identified a putative STAT-binding 
site that strongly resembles an interferon-γ-activated site element (GAS), which 
preferentially binds to STAT1 homodimers [329]. Disruption of the STAT-binding site 
reduces basal MVP promoter activity, suggesting a role of JAK/STAT signals in the 
activation of MVP expression [330].  
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Comparison of the human MVP sequence to the murine MVP sequence revealed an 
identity of over 90 % [331]. Both the high degree of evolutionary conservation and the 
complex structure of vault particles, as well as its broad distribution in tissues, suggest 
an important function in cellular processes [308]. Although vaults have been proposed 
to play a role in drug resistance, nucleocytoplasmic transport, and regulation of signal-
ing, a definitive function for MVP or vaults has yet to be assigned. Intriguingly MVP 
knockout mice did not display phenotypes supporting the above-mentioned roles of 
MVP that had been observed in vitro [332]. In fact, MVP-deficient mice develop 
normally without signs of deteriorating health. Even though the major component of the 
vault particle is absent in MVP knockout mice, and vault particles are no longer detect-
ed, the remaining components TEP1, VPARP, and vRNA might still interact and fulfill 
a functional role. 
3.1.3 Interaction Partners and Putative Functions of Vaults 
The detailed knowledge of the structure of MVP and vaults stands in contrast to the 
poor understanding of their endogenous function. Several observations, though, indicate 
that MVP may be directly involved in major cytoplasmic signal transduction cascades.  
Interestingly, MVP contains various phosphorylation sites that are conserved among 
different species [333]. MVP is phosphorylated by protein kinase C (PKC) and casein 
kinase II (CKII) in vitro, but itself has no kinase activity [334]. Stimulation of cells with 
epidermal growth factor (EGF) induces phosphorylation of the tyrosine residues of 
MVP [335]. The phosphorylated MVP complexes with the SH2-domain-containing 
tyrosine phosphatase Shp-2. Shp-2 is important for activation of the downstream Ras-
Raf-Mek-Erk cascade upon EGF stimulation [336]. MVP also interacts with the kinase 
Erk, presumably to fine-tune the activity of the Erk-downstream target Elk-1. Further-
more, the findings of another study indicate that EGF-induced tyrosine-phosphorylation 
also facilitates the interaction of MVP with the SH2-domain of Src-kinase in stomach 
cancer tissue and healthy stomach tissue. In vitro, Src-kinase triggered further phos-
phorylation of MVP and MVP, on the other hand, suppressed Src activity and reduced 
EGF-dependent Erk activation [337]. Likewise, MVP binds to the tumor suppressor 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN); a significant 
quantity of endogenous PTEN associated with vault particles in HeLa cells, which may 
implicate that MVP interferes with the tumor suppressor function of PTEN, mediating 
increased drug resistance [338]. However, MVP-PTEN-interaction might be relevant 
only for the nuclear import of PTEN, thereby regulating the nuclear function of PTEN 
[339], see below). Eventually, identification of the specific growth factor-regulated 
MVP phosphorylation sites and the interaction partners of MVP in response to growth 
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factor stimulation is required to reveal how MVP/vaults are involved in these signal 
transduction cascades. 
Similarly, a co-immunoprecipitation approach revealed the interaction between MVP 
and the photomorphogenic 1 ubiquitin ligase (COP1). Yi et al. suggest that MVP affects 
the capacity of COP1 to interact with the transcription factor Jun in a yet unknown 
manner. In unstressed cells, cytoplasmic MVP/vaults were shown to bind to and modify 
COP1, presumably via the other vault components. Following shuttling into the nucleus, 
COP1 binds to c-Jun with high affinity and suppresses the transcriptional activity of Jun 
by targeting it for degradation. UV-induced phosphorylation of MVP led to a simulta-
neous release of bound COP1 and turned off nuclear shuttling, thus permitting Jun to 
exert activation of the activator protein 1 (AP-1) transcription [340]. Jun, as a member 
of the AP-1 transcription factor dimer, plays a crucial role in regulation of cell prolifera-
tion of various cell types and was linked to neoplastic transformation (reviewed in 
[341]).  
Negative regulation of downstream signaling has been identified also on the level of the 
hypoxia-inducible factor-1α (HIF-1α). Even though expression of both HIF-1α and 
MVP increase under hypoxia, the stability of HIF-1α protein was enhanced to higher 
extents in MVP-depleted cells. Direct complex formation of vaults with HIF-1α, PHDs 
and pVHL was demonstrated and suggests that MVP/vault might act as scaffold protein 
for ubiquitination and degradation of HIF1α [342], thereby affecting hypoxia-regulated 
expression of HIF-1α -dependent genes. 
As mentioned above, the generation of MVP knockout mice did not reveal any indica-
tion for an essential role of MVP and vaults during embryogenesis. Under normal envi-
ronmental conditions, there are also no signs of deregulated cellular processes in tissues 
of adult mice. Furthermore, both embryonic stem cells and bone marrow cells derived 
from MVP knockout mice display a similar sensitivity towards classic cytostatic agents 
as their wild type counterpart cells, and in vivo, normal tissue toxicity towards doxo-
rubicin remains unchanged in the MVP-deficient mice. Interestingly, though unex-
pected, MVP and vaults may play a role in the innate immune response and contribute 
to the uptake and clearance of lung pathogens such as Pseudomonas aeruginosa via 
lipid rafts in lung epithelial cells. Internalization of total bacterial load is 55 % lower in 
MVP knockout mice, leading to an approximately three-fold increase in mortality [343]. 
On the other hand, L. monocytogenes the bacterium causing lysteriosis, seems to make 
use of MVP/vaults in order to evade intracellular autophagy. L. monocytogenes express-
es the surface receptor InlK, a member of the internalin family, which interacts with 
MVP and thus seems to be protected from recognition by the autophagy machinery in 
macrophages and in HeLa cells [344]. However, Dortet et al. did not observe that MVP 
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was involved in the internalization process of L. monocytogenes, as in the case of 
Pseudomonas aeruginosa. On the other hand, recently, it has been shown that MVP is 
involved in cell physiological internalization processes as well. In macrophages, MVP 
is involved in the ligand-stimulated internalization process of class A scavenger recep-
tors (SR-A). Stimulation of SR-A activates TNF-α synthesis and secretion, leading to 
autocrine induction of apoptosis in macrophages, which is reduced in MVP-depleted 
macrophages [345]. The authors suggest that patients with inflammation driven athero-
sclerosis may benefit from a reduced cytokine release by inhibition of the MVP/SR-A 
interaction. TNF-α antagonists have been introduced with great success for the treat-
ment of various inflammatory diseases and are currently also in phase I and II clinical 
trials, in patients with advanced cancer [346]. 
MVP expression is enhanced by interferon γ through the JAK/STAT pathway providing 
further evidence that MVP is involved inflammatory processes [330]. Moreover, vari-
ous other observations indicate that MVP participates in immunological responses as 
well (Reviewed in [347]). In vitro, human dendritic cell maturation was accompanied 
by a strong upregulation of vault expression, and inhibition of MVP by an antibody 
mixture impaired expression of maturation markers in monocyte derived dendritic cells 
[348]. However, despite these findings, no differences in dendritic cell migration and 
antigen presentation and T-cell responses were observed in the MVP knockout mouse 
model [349], which may possibly be due to interspecies differences.  
Other vault components like vRNAs are hypothesized to be play a role in immune 
responses too. In response to infection with the Epstein-Barr virus a strong induction of 
“vault”-RNA expression has been reported [350, 351], which led to the suggestion that 
they might be involved in antiviral defense. 
Finally, the hollow structure, the rapid movements, the distinct subcellular localization 
(as for example at the nuclear membrane), and the in vitro and clinical correlations with 
drug resistance in several types of human cancers led to the hypothesis that vaults might 
represent rather promiscuous transport vehicles [352–354]. 
3.1.4 Drug Resistance: the Best Known Role of MVP 
Several proteins have been linked to multidrug resistance (MDR), such as the ABC-
drug transporter p-Glycoprotein (P-gp, also designated as ABCB1), members of the 
multidrug resistant protein family (ABCC1, ABCC2, and ABCC3), the human breast 
cancer resistance protein (BCRP) and the lung-resistance protein (LRP) [330, 355, 356]. 
The LRP was initially discovered due to its high expression level in a multidrug-
resistant but ABCB1-negative lung cancer cell line [322] and has been identified in 
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1995 to be the human major vault protein [309]. Thereby, a first link between the MDR 
and vaults was established. Since then, MVP/vaults have been investigated in numerous 
studies as predictive marker in various cancer types with regard to treatment response 
and patient outcome (see section 3.1.6). 
MVP has been detected in 78 % of 61 human cancer cell lines, and its expression levels 
correlate with resistance against a variety of MDR-related but also MDR-unrelated 
drugs, indicating that the mechanism by which MVP confers drug resistance is different 
from classical MDR proteins [357, 358]. Moreover, upregulation of MVP was 
determined in multiple human cancer cell lines upon treatment with anticancer agents, 
including anthracyclins, etoposide and cisplatin, further supporting a putative link 
between treatment sensitivity and cellular stress adaptation to cytotoxic agent  
[322, 359–364]. Overexpression of MVP was also frequently observed at the early steps 
of resistance selection [365–368]. Multiple preclinical studies corroborated the link be-
tween MDR and the MVP expression level in cancer cells, despite some contradictory 
studies [369] and the fact that the MVP knockout mouse model did not show enhanced 
hypersensitivity to cytostatics [332]. Even though in MVP-deficient mice an increase of 
P-gp, MRP1 (ABCC1), and BCRP activity was not observed, unknown mechanisms of 
MDR may be responsible for the lack of consequences of MVP knockdown with regard 
to drug sensitivity. In a yet unknown manner, cancer cells may be more sensitive to 
disruption of functional MVP than normal cells. To investigate the role of vaults in 
cancer cells with regard to MDR, changes in drug sensitivity were assessed upon 
ectopic expression of MVP. Siva et al. reported that expression of the major vault 
protein, which was accompanied by a concomitant upregulation of TEP1 and VPARP, 
did not confer drug resistance in the human ovarian carcinoma cell line A2780 [370]. 
On the other hand, Hu et al. found that the ectopic expression of MVP in the gastric cell 
line GC7901 induced resistance to vincristine and adriamycin [371]. In the same study, 
a daughter cell line of GC7901 with a selected MDR phenotype was transfected with 
siRNA against MVP, which led to an increased drug sensitivity. In SW620 colon cancer 
cells, MVP expression along with expression of MRP and P-gp could be induced by 
sodium-butyrate, which resulted in increased resistance to several cytotoxic drugs. 
Interestingly, inhibition of MVP by two MVP-specific ribozymes abolished the sodium-
butyrate-induced MDR phenotype [364, 372]. Mechanistically, Kitazono et al. observed 
a nuclear exclusion and increased accumulation of DNA-damaging agents in the 
cytoplasm of sodium-butyrate-treated cells. Similar observations had been made before 
in multi-drug resistant cell lines and was determined to be P-gp independent [373]. 
However not all drugs to which sodium-butyrate confers resistance to, unfold their 
activity in the cell nucleus, indicating that increased nuclear efflux as observed for 
doxorubicin may not be the only function of vaults in drug resistance. Vaults may also 
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mediate MDR by the transport of drugs away from their subcellular targets, e.g. by the 
sequestration into exocytotic vesicles, a mechanism that was previously shown to 
mediate drug resistance [374]. Hervelsen et al. observed not only reduced sequestration 
of doxorubicin in UMUC-3 bladder tumor cells upon MVP knockdown, but also noted a 
disarrangement of the lysosomal compartments [375].  
Interestingly, human vRNAs produce several small RNAs (svRNAs) by mechanisms 
different from those in the canonical microRNA (miRNA) pathway. One of the svRNAs 
downregulates CYP3A4, a key enzyme in drug metabolism, disclosing a new link 
between vaults and drug resistance [376]. With regard to cancer, the relevance of these 
findings yet needs to be clarified. CYP3A4 is predominantly expressed in liver tissue, 
where MVP expression is low. Moreover, CYP3A4 is also expressed in cancer tissue, 
where in contrast, it was shown to correlate with reduced overall survival [377]. 
3.1.5 A Novel Role for MVP: Implications in Radiotherapy 
In recent years, MVP and vaults have not only been linked to drug-resistance, but also 
to DNA-damage response and DNA-damage-repair. MVP transcription and protein 
level is increased in response to various DNA-damaging agents, including ionizing 
radiation (IR) [378]. Interestingly, VPARP- and to lesser extent TEP-1-deficient mice 
have an increased incidence of carcinogen-induced colon tumors [379]. These findings 
indicate that vaults may be involved in maintaining genomic stability and thus may play 
a role in DNA repair processes. 
As described in the “General introduction”, the high cytotoxicity of IR is mainly based 
on the induction of DNA double-strand breaks (DSB) via the generation of reactive 
oxygen species. DSBs can be repaired by the two major DSB repair pathways: the 
homologous recombination (HR) and the non-homologous end joining (NHEJ). The fact 
that error-free repair by HR depends on the presence of an intact sister chromatid 
restricts this pathway to the S and G2 phase of the cell cycle. This is in contrast to error-
prone repair by NHEJ, which can function throughout the cell cycle and therefore is 
thought to be the predominant DSB repair pathway in mammalian cells. Tumors typi-
cally show an increased S and G2 phase cell population. Thus, HR represents the more 
interesting target to specifically sensitize tumor cells to DNA damaging agents, leading 
to an enhanced therapeutic window.  
MVP and vaults have been linked to both DSB-repair pathways. With regard to NHEJ, 
an inverse correlation between high MVP and low Ku70/80 expression levels as well as 
low pro-apoptotic Bax protein levels was identified in a cohort of 160 patients with 
localized cervix carcinoma [380]. Ku70 and Ku80 are key proteins in NHEJ, and also 
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play a regulatory role in apoptosis through the interaction with Bax/Bcl-2 [381, 382]. 
Newly synthesized Bax is inhibited from inducing apoptosis in two ways: Ubiquitina-
tion labels Bax for proteasomal degradation and secondly, Ku70 has been shown by 
Amsel et al. to sequester Bax away from the mitochondria. Interestingly, Ku70 was 
shown to bind and either directly deubiquitinate Bax or to mediate deubiquitination of 
bound Bax. Thus, the binding of Bax by Ku70 prevents Bax from being degraded, but 
also from promoting cell death. In response to apoptotic stimuli, Ku70 releases Bax, 
which then acts as mediator of apoptosis [381]. Low expression levels of Ku70 might 
therefore result in low expression levels of Bax, which indeed has been observed in the 
study performed by Lloret et al. [380]. In this study, high MVP expression levels were 
associated with low Ku70/80 protein levels (see above), and additionally correlated with 
upregulated Bcl-2, altered p53 expression, and increased proliferation. Despite the lack 
of mechanistic insights, these data suggest that if overexpression of MVP is the cause of 
reduced Ku70 expression, MVP and vaults might promote carcinogenesis by sup-
pression of NHEJ and apoptosis, leading to increased genomic instability. Eventually, 
molecular dissection of the key signal transduction cascades that lead to reduced  
NHEJ-activity in MVP-overexpressing cells will elucidate the association between 
MVP/vaults, NHEJ and a deregulated apoptotic threshold. A relationship between 
decreased apoptosis and upregulated MVP-expression has also been described by 
another study. Ryu et al. observed that cellular MVP levels increased with age, both in 
vitro and in vivo. This age-related upregulation of MVP increased apoptotic resistance 
of senescent human diploid fibroblasts by interfering with c-Jun-mediated repression of 
Bcl-2 [383]. Thus, MVP was suggested to play a role in regulating cellular signaling 
and survival, and might be considered as therapeutic target for modulating apoptosis 
resistance of cancer cells [384]. 
A novel link between the intracellular level of MVP and homologous recombination 
(HR) has been considered based on yet unpublished data from our own laboratory. We 
observed that MVP-depleted tumor cells were more radiosensitive than their wild type 
cognate cells, possibly due to direct interference with homologous recombination. In 
comparison to control cells, Rad51-foci were strongly reduced in irradiated, MVP-
depleted cells and thus vaults might play a role in the coordination of HR complex for-
mation at the site of DSBs, or they might be involved in the maintenance of Rad51 
protein levels. MVP mediates nuclear import of PTEN and regulates its nuclear function 
[338, 385]. Supporting the hypothesis that MVP may interfere with DNA repair via 
regulation of PTEN nuclear transport, Shen at al. showed that PTEN was necessary and 
sufficient for the induction of Rad51 expression levels and DSB-repair [386]. However, 
PTEN is associated with the function as tumor suppressor and is often lost in tumor 
cells. The loss of PTEN may actually contribute to tumor progression through the 
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deregulation of the cell cycle regulator kinase 1 (CHK1) and coherent loss of the G2/M 
cell cycle checkpoint, leading to increased genetic instability [387]. Interestingly, loss 
of PTEN in tumor cells with the concomitant reduction in homologous recombination 
and the deregulated G2/M checkpoint can be exploited by the combination with inhibi-
tion of PARP, creating a situation of synthetic lethality [388, 389]. Since MVP and 
vaults might be involved in nuclear import of PTEN and homologous recombination, it 
will be of interest to determine whether the MVP expression level may also affect 
genomic instability and sensitivity to PARP-inhibition. 
Despite the fact that we have so far only limited insights into the mechanisms how MVP 
and vaults interact with the two DNA double-strand break repair machineries, there are 
indications that MVP and vaults may co-regulate correct DNA repair of spontaneous 
and treatment-induced double-strand breaks. Due to the barrel-like structure, vaults may 
act as carriers, not only for toxic agents, but also for the coordinated intracellular 
transport of DNA repair-related proteins and thereby act as scaffold proteins or shuttling 
vectors. Otherwise, the vault-associated proteins VPARP or TEP-1 may play a so far 
not identified role in DNA repair, they may display as part of intact vaults only.  
As indicated above, in vitro studies revealed that gene expression levels of MDR-related 
proteins such as P-gp and MVP increased after fractionated irradiation [390]. 
Furthermore, it is well known that radiation treatment can induce resistance to various 
cytotoxic drugs [391], although the molecular mechanisms are not fully understood. 
Bottke et al. observed that the radiation-induced upregulation of MDR-related proteins 
correlated with increased resistance to cisplatin, doxorubicin and bendamustine [390]. 
These findings suggest that MVP may not only play a role in radio-resistance by 
supporting HR, but may also confer radiation-induced chemoresistance. 
3.1.6 MVP and Tumor Malignancies: Vaults as a Predictive / Prognostic Marker 
Numerous studies were performed to evaluate the expression status of MVP in human 
malignancies as a predictive and prognostic marker with regard to chemotherapy 
response and patient prognosis. However, these studies mainly focused on hematologi-
cal malignancies and the lack of clear guidelines for analyses of prognostic markers 
hamper the validity of such studies. The results are influenced by factors such as the 
MVP detection assay performed, the number of patients included, or the type of statisti-
cal analysis performed (univariate vs. multivariate analysis). The quality of MVP as a 
prognostic or predictive marker in this type of malignancy is still questionable, and 
standardized detection methods are needed. Nevertheless, a direct association between 
MVP expression and therapy resistance and prognosis in patients suffering from acute 
myeloid leukemia was identified [392–395]. An inverse correlation between MVP 
Introduction 
93 
 
expression and patient prognosis, therapy response, and survival rate has been reported 
in acute lymphoblastic leukemia patients [396–398] and similar results have been de-
scribed for adult T-cell leukemia [399, 400] and multiple myeloma [392, 401, 402].  
On the other hand, relatively few studies have addressed the role of MVP in solid 
tumors, with overall contradictory findings (see Table 3.1). For example, MVP was 
evaluated as prognostic marker in ovarian carcinoma, resulting in positive [403, 404] 
and negative [405, 406] associations reported. Results regarding breast cancer  
[407, 408], non-small cell lung cancer [409, 410], or different types of sarcomas are 
inconclusive [411, 412]. On the other hand, MVP has been established as a reliable 
marker for the response to chemotherapy in bladder cancer patients [413], in melanoma 
[414] and for determining the aggressive phenotype of testicular germ-cell tumors [415] 
and glioblastoma [416]. Most likely, concomitant operation of several drug resistance 
mechanisms may be necessary to cause the phenotype of MDR [362]. Izquierdo et al. 
refer to the frequent occurrence of co-expression of MVP and MRP1, which associates 
with increased drug resistance levels in MDR-selected tumor cells [357].  
Table 3.1 Overview on clinical studies investigating the association between MVP and therapy 
response and survival.  
Author 
Patients 
(n) Tumor Response DFS OS 
Izquierdo et al., 1995 [327] 57 Ovarian cancer Yes Yes Yes 
Schadendorf et al., 1995 [414] 71 Melanoma Yes   
Ramani et al.,1995 [418] 21 Neuroblastoma   No 
Dingemans et al., 1996 [419] 36 NSCLC No  No 
Linn et al., 1997 [420] 70 Breast cancer No   
Uozaki et al., 1997 [421] 60 Osteosarcoma Yes  Yes 
Arts et al., 1999 [405] 115 Ovarian cancer No No No 
Pohl et al., 1999 [422] 99 Breast cancer No No No 
Volm et al., 2000 [423] 87 NSCLC Yes  No 
Goff et al., 2001 [424] 29 Ovarian cancer No   
Pohl et al., 2001 [425] 68 Colorrecto No   
Diestra et al., 2003 [413] 83 Bladder cancer Yes   
Harada et al., 2003 [426] 57 NSCLC Yes   
Silva et al., 2007 [417] 78 SCCHN Yes  Yes 
DFS, disease-free survival; OS, overall survival; NXCLC, non-small cell lung cancer; 
SCCHN, squamous cell carcinoma of the head and neck. 
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With regard to a putative role of MVP in radiation resistance, MVP expression nega-
tively associates with local disease free survival and cancer-specific survival in a series 
of patients suffering from squamous cell carcinoma of the oropharynx, who received 
primary radiotherapy with curative intent (in univariate and multivariate analyses) 
[417]. In this study, elevated MVP expression also seems to be associated with a radio-
resistant subset of patients, proposing MVP as a novel useful predictive marker associ-
ated with Radiation Therapy [417]. The link between MVP and radioresistance and the 
underlying mechanisms are not well defined today, but the above-cited role of MVP in 
DNA repair and in regulation of the apoptotic threshold may be part of it. The complex-
ity of MVP as a predictive and/or prognostic marker is also illustrated by a study on 
cervical cancer patients who received combined radiochemotherapy [427]. In a sub-
cohort of the patients with clinical complete response, increased MVP and IGF-1R 
expression were observed to strongly associated with reduced long-term local control. 
High MVP expression correlates with high IGF-1R expression, and together are associ-
ated with chemo-and radioresistance in localized cervical carcinoma and oral cavity 
squamous cell carcinoma [428, 429]. Probably, both proteins are required to confer 
chemoradioresistance, and cervical carcinoma patients with low levels of MVP and 
IGF-1R expression had excellent survival rates [427]. However, this result may not be 
definitive since the number of patients included in this study was rather low, with 23 
patients in the low MVP/IGF-1R and 27 patient in the high MVP/IGF-1R group. It is 
still unclear how and if MVP and IGF-1R expression is interconnected. In the previous-
ly study mentioned study on cervical carcinomas, a strong correlation suggests an inter-
dependency, whereas in the study on oral cavity squamous cell carcinomas, correlation 
between MVP and IGF-1R was less strong and their predictive power was restricted to 
cancers of stage III and IV. 
As illustrated by these studies and the studies mentioned in the previous sections, we are 
still far away to have identified a mechanistic link between MVP expression level and 
treatment response. It is still a matter of debate to which extent vaults are involved in 
chemo- and radioresistance. It will be important to study the regulatory mechanism for 
high MVP expression in cancer cells and to evaluate in more detail whether and how 
cancer cells depend on MVP expression for treatment resistance.  
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3.2 Background and Aim of the Study 
3.2.1 Background of the Study 
As mentioned in section 3.1.5, previous experiments performed in our group indicated a 
novel link between MVP and radiosensitization by interfering with homologous recom-
bination [430].  
A dose-dependent increase of MVP was observed upon irradiation in the non-small cell 
lung carcinoma cell line A549 and in the human colon cancer cell line HCT116. 
Depletion of MVP lead to radiosensitization in both cell lines. However, this effect was 
lost in HCT116 with a p53-negative or PTEN-negative background.  
Interestingly, formation of Rad51-foci were strongly reduced upon depletion of MVP, 
whereas RPA-foci formation did not seem to be affected. Preliminary data indicated that 
MVP might interact with the BRCA2/Rad51 complex. These findings suggest that MVP 
may be involved in homologous recombination by either direct interaction with HR-
proteins or via PTEN-dependent Rad51 transcription. The link of MVP to the nuclear 
transport of PTEN would explain the absence of radiosensitization in PTEN-negative 
cells.  
3.2.2 Aim of the Study 
In this continuative study, we aimed to corroborate the findings above and to further 
elucidate the precise role of MVP in homologous recombination and Rad51-foci 
formation, respectively. It was planned to extend the investigation of the role of MVP in 
DNA repair and radiosensitization to normal cells, and finally to correlate MVP expres-
sion in tumor biopsies of squamous cell carcinoma of the head and neck with treatment 
outcome concerning radiotherapy. 
To address the role of MVP in HR we planned to determine the HR-capacity in MVP-
depleted cells [431] and to assess the interaction of BRCA2 with MVP by immunopre-
cipitation of BRCA2 and vice versa. Further, we planned to dissect the kinetics of DNA 
repair and specifically of HR in MVP-depleted cells by immunofluorescence staining of 
γH2AX as indicator for DNA damage, and RPA- and Rad51-foci formation as readout 
for homologous recombination. The study was to be extended to various cancer cell 
lines with regard to their genetic background, e.g. PTEN-and p53-status. However, the 
unexpected MVP knockdown phenotype we were confronted with took us by surprise 
and indicated the necessity for validation of the siRNA approach.  
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3.3 Material and Methods 
3.3.1 Index of Methods Described in the First Part of the Thesis 
Irradiation ...................................................................................................................... 33 
Western Immunoblot Analysis ...................................................................................... 35 
Cell Cycle Analysis with BrdU incorporation .............................................................. 18 
3.3.2 Cell Culture and Maintenance 
All cells were kept at 37°C in 5% carbon dioxide in a humidified incubator. 
Cell Line Description Culture Conditions 
A549  
(ATCC No CCL-185) 
Gift from S. B. Horwitz 
Non-small cell lung cancer 
cell 
RPMI medium  
supplemented with  
10% (v/v) fetal bovine 
serum (FBS),  
1% (v/v) L-glutamine and 
1% (v/v) Penicillin-
Streptomycin (P/S) 
SW480 
(ATCC No CCL-228) 
Human colon carcinoma 
cells 
SW620 (from the same  
patient as SW480) 
(ATCC No CCL-227) 
Human colon carcinoma 
cells from lymph node 
metastasis 
CAPAN-1 
Obtained from Cell Line 
Service, Eppenheim, DE 
Human pancreatic ductal 
adenocarcinoma, derived 
from liver metastasis  
BxPC-3 
H. Friess, Munich, DE 
Human pancreatic ductal 
adenocarcinoma 
MDA-MB-231 
Received from P. Rhode-
mann, DE 
Human breast carcinoma 
cell line 
MEF MVP wt 
MEF MVP-/- 
gift of E. Wiemer,  
Rotterdam, NL 
Mouse embryonic fibro-
blasts derived from MVP 
wild type and knockout 
mice  
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Cell Line Description Culture Conditions 
HCT116  
(ATCC No CCL-247) 
Gift from Bert Vogelstein 
Human colon carcinoma 
cells 
McCoy medium  
supplemented with  
10% (v/v) FBS and  
1% (v/v) P/S 
HCT116 V163 PTEN-/- 
 
HCT116 V166 PTEN+/+ 
HCT116 PTEN knock out 
cell line 
mother cell line of V163 
U2OS 
Kindly provided by A. 
Sartori  
Human osteosarcoma cell 
line 
DMEM medium  
supplemented with  
10% (v/v) FBS,  
1% (v/v) L-glutamine,  
1 mM Sodium Pyruvate, 
and 1% (v/v) P/S 
MEF p53+/+ 
MEF p53-/- 
[432] 
E1A/Ras transformed 
mouse embryonic fibro-
blasts 
 
3.3.3 Reagents, Antibodies and siRNA sequences 
Reagents Manufacturer 
Agarose A9539 Sigma 
Alamar Blue Biosource Int. 
Caspase Inhibitor IV #219011 Calbiochem 
Cell culture medium and supplements,  
if not stated otherwise 
Gibco, Invitrogen 
EDTA solution E7889 Sigma 
ECL Prime WB Detection Reagent RPN2232 GE Healthcare 
GelRedTM Nucleic Acid Gel Stain #4100 Biotium 
Lipofectamine 2000 Invitrogen  
Lipofectamine RNAi MAX Invitrogen 
Caspase Inhibitor Z-VAD-FMK #G7231 Promega 
ProLong® Gold Invitrogen 
Triton X-100 Sigma 
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Antibodies  Manufacturer Ref. number 
Anti β-Actin Ab from mouse Sigma A5441 
Anti BRCA2 Ab, from mouse Calbiochem OP05 
Anti BRCA2 Ab, from rabbit,  
Agarose-immobilized 
Novus Biologicals NB600-417 
Anti DYKDDDDK Tag Ab, Fluor®488-
linked, from rabbit 
Cell Signaling #5407 
Anti pH2AX (Ser139) Ab, FITC labeled,  
from mouse 
Millipore #05-636 
Anti MVP, from rabbit Sigma  HPA002321 
Anti MVP, from mouse Labvision MS664PABX 
Anti p53 (Ser15) Ab, from rabbit Cell Signaling #9284 
Anti PARP p85 Fragment Ab, from rabbit Promega G734A 
Anti-Rad51 Ab, from mouse Santa Cruz sc-8349 
For secondary Antibodies, see page 34. 
 
siRNA Sequence  
siMVP#1 GCACCUACAUGCUGACCCA unknown 
siMVP#2 ATCATTCGCACTGCTGTCTT [375] 
siMVP#3 GGGGAAGAAUGGCUGGUCA [433] 
siMVP-586 
siMVPmurine CGUGUGAUUGGAAGCACCUAC siMVP#1 adapted 
siMVP_A CUGACCCAGGACGAAGUCCUG Ambion 
siMVP_B GAGAGAAGCGAGCCCGCGUGG Ambion 
siMVP_C UCGCAAGGAACUUUUGGAGCU Ambion 
siLuc CGTACGCGGAATACTTCGA  Dharmacon  
Scramble_A GAACACCCGACGCGGAGUCUU derived from siMVP_A 
Scramble_B GGCAUGCUGAUACCGAGUUAU derived from siMVP_B 
sip53 siGenome SMART pool Dharmacon 
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3.3.4 Transfection of Cells with siRNA 
All cells were transfected according to the reverse transfection protocol for the Lipofec-
tamine® RNAiMAX Transfection Reagent (Invitrogen). Lipofectamine (30 µl) in  
Optimem to a total of 1 ml was incubated for 5 minutes and siRNA (3.75 µl of 40 µM 
stock solution) was diluted in 1 ml Optimem. Lipofectamine and siRNA mixture were 
combined, incubated for another 15 minutes and then transferred to a 10 cm dish. 
Meanwhile cell suspension of a concentration of 50’000 cells/ml was prepared in anti-
biotics-free cell culture medium. 10 ml cell suspension were added to the cell culture 
dish on top of the transfection mixture. 6 hours after transfection, medium was replaced 
with antibiotics-free cell culture medium.  
Maximum downregulation of MVP was observed around 72 hours after transfection. 
Around 96 hours after siRNA transfection MVP started to increase.  
3.3.5 Proliferation Assay 
For A549 cells treated with siRNA, assessment of the cell number by Alamar Blue 
assay was not feasible, because the treatment with siMVP seemed influenced the mito-
chondrial metabolic activity. Therefore, proliferation was assessed by cell count. The 
cells were seeded in 6-well plates, transfecting the cells with siRNA at the same time 
according to the protocol above (dividing the amount for a 10 cm dish by 5). For each 
condition and time point, a one well was prepared. For the assessment of the cell 
number with the NucleoCounter® NC-100™ (Chemometec), the cells were trypsinized, 
spun and resuspended in an appropriate amount of medium. The measurement was 
performed according to the manufacturer’s specifications.  
3.3.6 Clonogenic Survival Assay of MVP-Depleted Cells 
For the performance of the clonogenic assay, see page 36. With regard to MVP down-
regulation, cells were seeded 48 hours after siRNA transfection. Irradiation was then 
performed at 72 hours after transfection, where MVP expression was shown to be 
lowest.  
3.3.7 Immunofluorescence Analysis of γH2AX- and Rad51-Foci 
Immunofluorescence staining was performed according to the protocol on page 37. 
Cells were labeled simultaneously for γH2AX and Rad51 and the DNA was counter-
stained with Dapi. For analysis by fluorescence microscopy, the nucleus of each cell or 
the nuclei of several cells at a time were captured with z-stack image sequences. Using 
the free LEICA software LAS AF Light, the z-series was viewed in the maximum 
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projection view, which merges the stack into a single image. The number of foci per cell 
was then counted by eye. About 75 cells were evaluated for each condition and time 
point.  
3.3.8 Immunoprecipitation of BRCA2 
1 million cells were seeded in a 10 cm cell culture dish and irradiated the following day 
with a dose of 5 Gy. 5 hours after irradiation, cells were washed with PBS and lysed on 
ice with 600 µl non-denaturing lysis buffer (20 mM Tris pH8, 137 mM NaCl,  
10 % glycerol, 1 % (v/v) Nonidet P-40, 2 mM EDTA, just added before use: 50 µg/ml 
PMSF and aprotinin, leupeptin, pepstatin1 µg/ml each). After 10 min incubation on ice, 
the cells were scraped, transferred to an Eppendorf tube centrifuged in a precooled 
centrifuge (4°C) for 20 minutes at 20’000 g. Then the supernatant was transferred to a 
clean Eppendorf tube and protein concentration was determined by NanoDrop. 50 µl 
lysate were set aside for SDS page. 80 µl slurry of agarose-immobilized BRCA2 Ab 
was added and incubated overnight at 4 °C under constant agitation. Then, the tube was 
centrifuged tube at 2’500 g for 1 min. The supernatant was carefully removed, leaving 
80 µl in the tube, not to disturb the beads. The beads are resuspended in 1000 µl lysis 
buffer, left on a shaker on ice for 3 min. This washing step was repeated four more 
times. After the last centrifugation step, the supernatant was removed as above and the 
remaining liquid was removed with help of a syringe. 50 µl 1x Laemmlibuffer was 
added to the dry beads and after vortexing they were put on a shaker for 12 min at room 
temperature. Then, the samples were centrifuged at 10’000 g for 5 min to pellet the 
beads and the supernatant was collected for Western blot analysis. 
3.3.9 Synchronization of Cells by Double Thymidine Block 
For synchronization of the fast proliferating A549 cells in the late G1 phase, thymidine 
was added to the cell culture medium to a final concentration of 2 mM and incubated 
for 14 h. Then the cells were washed twice with preheated PBS and then released for  
10 h in fresh medium without thymidine. The second block was performed equally to 
the first and as well as the release. 
3.3.10 Statistics 
Statistical analyses were performed with Graphpad Prism Software Version 5. Error 
bars, depicting the standard error of mean, are only displayed for experiments per-
formed at least twice. The number of experiments performed is indicated in the 
description of the graph. 
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3.3.11 Construction of the Expression Plasmid Coding for FLAG-tagged, siMVP-
Resistant MVP  
The MVP sequence was obtained from the plasmid pEW65 coding for GFP-MVP 
(kindly received from E. Wiemer, Rotterdam, NL) by PCR. Primers were designed 
using Primer-BLAST (NCBI). 
Table 3.2 Primer Pairs: 
N-terminal FLAG-tagged MVP:  length of PCR product: 2688 kb 
Forward primer*: 5’-GGAACTGAAGAGTTCATCATCCGCATCC-3’ 
 - ATG sequence omitted 
- alanine was replaced by glycine for favorable cloning 
Reverse primer*: 5’-GGATCCGGCCTACCGCAGTACAGGCACCACGT-3’ 
 - GGATCC (BamHI restriction site) 
- TAGGCC (Stop sequence) 
* Underlined base pairs do not anneal. 
C-terminal FLAG-tagged MVP  length of PCR product: 2694 kb 
Forward primer*: 5’-GGATCCGCCGCCATGGCAACTGAAGAGTTCATCAT-3’ 
- GGATCC (BamHI restriction site) 
- Kozak sequence before ATG (GCCGCC) 
Reverse primer*: 5’- CCACCGCAGTACAGGCACCACG -3’ 
- Stop sequence omitted  
- serine sequence (TCC) added (see manual) 
* Underlined base pairs do not anneal. 
The MVP PCR products were separated by gel electrophoresis and the product of the 
appropriate size was extracted using the QIAquick Gel Extraction Kit (Qiagen #28704). 
The PCR products then were cloned into the StrataClone Expression Vectors (Agilent 
Technologies) according the manufacturers specifications:  
- StrataClone Mammalian Expression N-Terminal FLAG Vector System #240229 
- StrataClone Mammalian Expression C-Terminal FLAG Vector System #240230 
StrataClone SoloPack competent cells were transformed with the ligation reactions 
according to the protocol and spread on LB-Agar plates containing 20 mg/ml kana-
mycin.  
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Single clones were picked and cultured for the preparation of minipreps with the 
QIAprep Spin Miniprep Kit (Qiagen #27104).  
The plasmids were verified by restriction digest (XhoI, NEBIS or EcoRI, Life Technol-
ogies) and sequencing. 
Site directed mutagenesis was performed by the QuikChange II XL Site-Directed Muta-
genesis Kit (Agilent Technologies #200521) according to the manual. The PCR product 
was transformed into JM109 competent Escherichia coli by a standard heat shock pro-
tocol. Several clones were picked and cultured for the preparation of minipreps with the 
QIAprep Spin Miniprep Kit (Qiagen #27104) and the full MVP sequence containing the 
mutations was verified by sequencing. 
Forward Primer for siMVP#2 resistant MVP*: 
CATAAGAACTCAGCCCGCATCATCAGAACCGCGGTGTTTGGCTTTGAGACCTCGGAAGC 
Forward Primer for siMVPmurine resistant MVP*: 
CCGGAAAGGTGCGCGCTGTAATTGGCTCGACGTACATGCTGACCCAGGACG 
* Underlined base pairs correspond to the siRNA sequence; bold bases were exchanged. 
3.3.12 Transfection and Selection of A549 Cell Clones Expressing the Plasmid 
A549 cells were transfected with Lipofectamine® 2000 according to the manufacturer’s 
specifications. 48 h after transfection selective medium containing 800 µg/l G418  
(450 µg/mg potency, Sigma) was added. 2 weeks after selection, cells were seeded in  
96-wells to obtain single clones. Single clones were harvested by trypsinization; half 
was seeded in 12-well plates and half in 24-well plates on cover slips. The cells seeded 
on cover slips were stained with anti-FLAG Ab according to the immunofluorescence 
staining protocol on page 37 to select for clones with ectopic MVP expression.  
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3.4 Results 
This project is a follow-up to the MVP project that has been initiated by Andreas 
Hollenstein during the last two years of his PhD-studies. For a brief overview to the 
background and our aims of the study, see section 3.2.1 and 3.2.2.  
3.4.1 Knockdown of MVP Sensitizes for Ionizing Radiation  
In a first step, radiosensitization in MVP-depleted cells was confirmed by means of 
clonogenic assays, including additional dose points. The same two siRNAs with the 
sequences siMVP#1 and siMVP#2 were used as in the previous experiments. Moreover, 
an additional siRNA targeting a third MVP sequence was tested, we will refer to as 
siMVP#3. This siRNA has been shown to be least toxic among other sequences tested 
and was very efficient in silencing MVP in HeLa cells [433]. As control siRNA, we 
used siLuc targeting the firefly luciferase, which is not expressed in mammalian cells. 
The siRNAs siMVP#1 and siMVP#2 in combination with ionizing radiation reduced 
clonogenic survival in A549 cells to a similar extent, in comparison to cells treated with 
the control siRNA siLuc. Figure 3.2 displays the data for siMVP#1. The siRNA 
siMVP#3 led to an even stronger radiosensitization (data not shown). 
 
Figure 3.2 Clonogenic survival of A549 cells treated with siRNA against MVP or control 
siRNA against luciferase at increasing radiation doses. The diagram shows the mean of three 
independent experiments; the error bars represent the standard error of mean (SEM). Unpaired 
Student t-test, two-tailed, *p < 0.05, **p < 0.01. 
3.4.2 Persistent γH2AX-Foci in MVP-Depleted A549 Cells after Treatment with 
Ionizing Radiation 
The phosphorylated form of the histone variant H2AX, referred to as γH2AX, is used as 
an indirect measure for the DNA damage. At the site of DNA damage H2AX is 
Irradiation in Gy
Su
rv
iv
in
g 
Fr
ac
tio
n
0 2 4 6 8 10
0.001
0.01
0.1
1
siLuc
siMVP#1**
*
Results 
104 
 
phosphorylated and foci of γH2AX can be detected by immunofluorescence staining. 
We assessed the initial DNA damage introduced by the treatment with ionizing radia-
tion (IR) by counting the number of γH2AX-foci at an early time point and followed the 
repair process by the clearance of γH2AX. This analysis was previously performed, but 
we aimed to study the kinetics of the DNA repair process in more detail and included 
further time points in our study. Analysis of γH2AX-foci clearance indicated that the 
kinetics of DNA repair during the first 6 hours after irradiation with 2 Gy was similar 
for both siMVP- and siLuc-treated A549 cells (see Figure 3.3). At a later time point,  
24 hours after irradiation, the level of H2AX-phosphorylation in control cells returned 
to the basal level of non-irradiated cells. However, the number of γH2AX-foci remained 
elevated in cells treated with siMVP. This result suggested that DNA damage might not 
be as efficiently repaired in MVP-depleted cells as in control cells. 
 
Figure 3.3 Clearance of γH2AX-foci in MVP-depleted and A549 control cells after irradiation 
with 2 Gy. Cells were stained with fluorescently labeled antibodies against phosphorylated 
H2AX. At least 75 cells were randomly chosen and analyzed by microscopy and the mean 
number of foci per cell is displayed in the diagram (single experiment). 
3.4.3 Reduced Rad-51 Expression and Rad51-Foci Formation in A549 Cells with 
Knockdown of MVP  
Non-homologous end joining (NHEJ) represents the fast and error prone DNA double-
strand break repair pathway in mammalian systems. The kinetics of the clearance of 
γH2AX-foci during the first hours after IR indicates that NHEJ remained undisturbed 
by MVP silencing. At later time points, the remaining γH2AX-foci were removed more 
slowly in cells treated with siMVP than in control cells. Even though NHEJ takes place 
throughout the entire cell cycle, the complexity of certain DNA damage may require 
repair by homologous recombination (HR), the second DNA double-strand break repair 
mechanism. As previously shown by Andreas Hollenstein, the formation of Rad51-foci, 
a process essential to HR, was strongly suppressed in cells with downregulated MVP 
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(see Figure 3.4). Rad51-foci were assessed in a 24-hour time line, to determine whether 
HR was delayed or reduced for the whole period. The time line analysis revealed a 
general reduction of Rad51-foci formation. The quantification of the numbers of Rad51-
foci per cell for the 6-hour time point, where control cells showed highest foci numbers, 
is depicted in Figure 3.5A. We were also interested to determine the influence of the 
MVP status on replication protein A (RPA) binding to the DNA. RPA covers the resect-
ed DNA strand before it is replaced by Rad51. However, for up to 6 hours, RPA-foci 
formation was as efficient in MVP knockdown cells as in control cells and showed even 
a slight increase at the 6-hour time point (see Figure 3.5B), which might be due to a 
reduced replacement by Rad51. From this, we concluded that HR was initiated in the 
siMVP-treated cells, but Rad51-foci formation was hampered. 
 
Figure 3.4 A549 cells treated with siMVP showed reduced Rad51-foci formation after treat-
ment with IR. Cells were irradiated 72 h after siRNA-treatment with 4 Gy and assayed 6 h 
thereafter for Rad51 and H2AX-phosphorylation by immunofluorescent staining. Nuclear DNA 
was counterstained with Dapi. The scale bar represents 10 µm. 
In cooperation with BRCA2, Rad51 binds to RPA-covered, single-stranded DNA and 
replaces RPA. Rad51 and BRCA2 are also involved in pairing the bound sequence with 
the intact homologous sister chromatid, which serves as template for the repair of the 
damaged strand [434]. The complex formation of Rad51 with BRCA2 is essential for 
Rad51-foci formation in response to exogenous DNA damage, but not for Rad51-foci 
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formation in response endogenous DNA damage, e.g. occurring due to the collapse of 
replication forks [435].  
A B 
 
Figure 3.5 Rad51-foci formation and Rad51 protein expression was reduced in A549 cells after 
treatment with siRNA against MVP. 72h after treatment with the indicated siRNA, cells were 
irradiated with 4 Gy and fixed 6 hours thereafter, followed by immunofluorescence labeling of 
(A) Rad51 and (B) RPA.  
Preliminary data obtained in our laboratory showed that MVP co-immunoprecipitated 
with BRCA2, indicating that MVP may be involved in the nuclear transport of the 
BRCA2/Rad51 complex [430]. Western blot analysis of Rad51-expression was per-
formed for the time course of the MVP knockdown and revealed that Rad51 protein 
levels declined over time and were strongly decreased at the 70-hour time point at 
which irradiation for clonogenic assays and for assessment of foci was performed (see 
Figure 3.6). Thus, the hampered Rad51-foci formation might actually be due the 
reduced Rad51 expression levels. Rad51 protein levels increased when the effect of the 
siRNAs started to wane (data not shown).  
 
Figure 3.6 Western blot analysis of MVP and Rad51 protein levels in A549 cells treated with 
siLuc and siMVP#1-3 and harvested at the indicated time points after treatment. 
Interestingly, the reduction of Rad51 expression level as determined by Western blot 
analysis, inversely correlated with the amount of siRNA applied against MVP. On the 
other hand, MVP-expression was already strongly downregulated at the lowest amounts 
of siRNA applied (see Figure 3.7A). However, we did not monitor the mRNA levels of 
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MVP, which might have better correlated with the Rad51 protein levels for the different 
siRNA conditions. Of notice, Rad51-foci formation in siMVP-treated cells was partially 
restored, by reducing the amount of siRNA, which also correlates with increased Rad51 
protein expression (see Figure 3.7B). This indicates that the reduced Rad51 protein lev-
els at least to some extent may be responsible for the reduced Rad51-foci formation.  
A B 
        
Figure 3.7 Repression of Rad51 protein level and Rad51-foci formation depends on the amount 
of siMVP applied. (A) MVP was efficiently downregulated by very low siMVP concentrations 
as determined by Western blot analysis, 72 h after transfection with siRNA. Concurrent down-
regulation of Rad51 correlated with the amount of siRNA applied. For all three siRNAs target-
ing MVP, the highest amount of siRNA applied led to the strongest Rad51 repression. (B) The 
mean number of Rad51-foci 6 h after radiation treatment with 4 Gy was most strongly reduced 
in cells treated with highest amount of siMVP#2 (single experiment). 
3.4.4 BRCA2 as Interaction Partner of MVP Could Not Be Confirmed 
To corroborate our previous findings that MVP may be a potential interaction partner of 
BRCA2, a co-immunoprecipitation (Co-IP) experiment was performed with an antibody 
against BRCA2. We extended the previous experiment by including CAPAN-1 cells as 
negative control. CAPAN-1 cells express MVP and Rad51, but only a truncated version 
of BRCA2. The mutation of BRCA2 is due to a deletion (6174delT) in one allele, and 
loss of heterozygosity led to elimination of the second wild type allele. The truncated 
BRCA2 is not recognized by the antibody used for IP and thus CAPAN-1 cell lysates 
were used to probe for non-specific binding of proteins to beads or antibody. In the 
previous experiment, a rabbit IgG-coupled agarose was used as an isotype control anti-
body. Within this experimental setup, MVP did not co-immunoprecipitate. In the 
control experiment, performed with CAPAN-1 cell lysates and the same polyclonal 
antibody used for co-immunoprecipitation in A549 cells (by A. Hollenstein [430]), 
MVP was pulled down as well. However, as expected, BRCA2 was not detected in the 
Western blot analyses of the immunoprecipitated proteins (see Figure 3.8). Thus, we 
could not to confirm a direct interaction between MVP and BRCA2. However, to be 
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able completely exclude the existence of a BRCA2/MVP interaction, additional experi-
ments, e.g. a pull down with MVP as bait, are required. 
                     
Figure 3.8 MVP was pulled down regardless of BRCA2 in the co-immunoprecipitation experi-
ment using an antibody against BRCA2. MVP, Rad51 and BRCA2 protein levels were deter-
mined by WB. Different antibodies were used for IP and detection of BRCA2 by WB. The 
antibody used for the WB recognizes the truncated form of BRCA2 in CAPAN-1 cells, but 
BRCA2 is not recognized by the antibody used for the IP.  
3.4.5 Loss of Rad51 Expression: Cause or Consequence of Cell Cycle 
Redistribution in A549 Cells Treated with siMVP?  
As described above, Rad51-expression was strongly reduced in A549 cells 72 hours 
after transfection with siRNA against MVP. Previously, we determined by real-time 
PCR that MVP silencing resulted in a decrease of Rad51 mRNA levels in PTEN wild 
type HCT116 cells, whereas in the PTEN-deficient HCT116 cells, this effect was absent 
(see [430], p.69). A link between nuclear import of PTEN and MVP had been estab-
lished earlier [339, 385]. These findings support the hypothesis that reduced MVP pro-
tein levels, upon silencing of MVP, might hamper the nuclear import of PTEN and thus 
lead to reduced Rad51 transcription [386].  
The strong reduction of Rad51 expression that we observed upon silencing of MVP, 
coincided with cell cycle redistribution (see Figure 3.9A). The loss of Rad51 expression 
could be the cause, as well as the consequence of cell cycle redistribution. Rad51 is 
mainly expressed in S and G2 phase, and its expression is lost during mitosis and 
remains low throughout G1 phase [436]. In an osteosarcoma cell line, suppression of 
Rad51 by shRNA resulted in an accumulation of the cells in the G2 phase of the cell 
cycle [437]. Similarly, we observed a reduced S phase cell population and a G2 arrest in 
A549 cells upon repression of Rad51 by siRNA (see Figure 3.9B). The cell cycle distri-
bution induced by siRad51, resembled the cell cycle distribution we observed for A549 
cells treated with siMVP#1 and siMVP#2 (see Figure 3.9A). The siRNA siMVP#1 
induced a strong and the siRNA siMVP#2 a mediocre G2 arrest. This difference, 
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however, might be due to the differential efficiencies of the two siRNAs. The 
phenotypes for siMVP#1 and siMVP#2 are in concert with the hypothesized 
MVP/PTEN/Rad51 axis. On the other hand, the sequence siMVP#3, which was very 
potent in MVP silencing and non-toxic to HeLa cells, resulted in a strong G1-arrest in 
A549 cells. A G1-arrest may explain the loss of Rad51, as Rad51 levels are low in G1 
phase of the cell cycle, but does not support the hypothesis of a cell cycle redistribution 
following reduced Rad51 expression. If Rad51 expression was lost as a consequence  
of MVP silencing, A549 cells would have arrested in G2 phase (see Figure 3.9B), which 
we did not observed for the siRNA siMVP#3.  
A B 
    
Figure 3.9 Cell cycle distribution of A549 cells 72 h after transfection with siRNA. (A) S phase 
determined by 30 min of BrdU incorporation was reduced after treatment with siMVP#1-3. The 
sequences siMVP#1 and siMVP#2 led to a G2 arrest while siMVP#3 shows a G1 arrest. 
Diagram depicts the mean of three different experiments; the error bars represent the SEM. (B) 
Downregulation of Rad51 leads to a G2 arrest 72 hours after transfection (single experiment). 
As mentioned previously, MVP depletion decreased Rad51 transcription only in 
HCT116 PTEN-proficient cells. However on the protein level, we observed a compara-
ble decrease of Rad51 protein levels in HCT116 PTEN-deficient and PTEN-proficient 
cells (see Figure 3.10A). This observation was reported previously by A. Hollenstein 
[430], but no explanation could be found for this discrepancy. Nonetheless, the reduc-
tion of Rad51 in HCT116 cells of either PTEN status indicates that PTEN might not be 
directly involved in the siMVP-dependent attenuation of Rad51 protein levels. 
Silencing of MVP by siMVP#1-3 was accompanied with pronounced phenotypes of 
growth inhibition. Thus, we also considered the possibility that the MVP knockdown 
may have an effect on cell cycle progression or on the cell integrity per se, which even-
tually leads to reduced Rad51 expression levels. In support of this hypothesis was the 
fact that not all cancer cells showed a deregulated Rad51 expression level upon MVP 
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knockdown, such as BxPC-3 and CAPAN-1 cells. Both did also not show a growth 
inhibition upon treatment with siMVP#2 (see Figure 3.10B). In addition, normal cells 
also do not depend on MVP for Rad51 transcription, as MVP-knockout mice show a 
normal development. This indicates that the deregulation of Rad51 might be an indirect 
effect of the cell cycle arrest, rather than a direct effect of the MVP knockdown.  
A B 
 
Figure 3.10 Relative expression levels of MVP and Rad51 of cells treated with siMVP#2 to 
cells treated with siLuc determined by WB. (A) Both the PTEN-proficient (HCT116 V166) and 
the PTEN-deficient (HCT116 V163) cells showed decreased Rad51 levels upon MVP knock-
down. (B) The knockdown of MVP did not lead to reduced Rad51 protein levels in the pancre-
atic cancer cell lines BcPC-3 and CAPAN-1.  
We observed that the Rad51 levels correlated well with the percentage of population in 
S phase of the cell cycle. For example, at 72 hours after cellular transfection with 
siMVP#1, the S phase cell population and the Rad51 expression level was strongly 
reduced in A549 cells. The same effect was already observed 48 hours after transfec-
tion, but to a less pronounced extent.  
To evaluate a putative link between Rad51 repression and the reduction in S phase cell 
population, A549 cells were submitted to a double thymidine block right after siRNA 
transfection, thereby accumulating the cells in G1 phase. Then cells were released to 
enter S phase at around 48 hours after siRNA transfection and cell cycle distribution 
and protein expression were determined. Accordingly, MVP knockdown cells entering 
S phase under these conditions did not display reduced Rad51 protein levels, and the 
number of cells in S phase correlated well with the Rad51 protein level regardless of the 
MVP expression levels (see Figure 3.11). The extent of MVP downregulation in cells 
treated with the double thymidine block was equal to the knockdown in unsynchronized 
cells, as determined on the level of protein expression (data not shown). The 48-hour 
time point may be too early to determine the full consequence of the MVP knockdown. 
However, due to the reduced proliferation, it was technically not feasible to synchronize 
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the MVP-depleted cells at a later time point. Nevertheless, under the assumption of a 
direct link between MVP expression and Rad51 expression, it would be expected that 
A549 cells that enter S phase show a reduced Rad51 expression and thus eventually 
accumulate in G2 phase due to compromised HR and subsequent unresolved DNA 
damage. First, we did not detect increased γH2AX staining in the MVP knockdown 
cells 72 hours after transfection (see Figure 3.3) and second the correlation of the per-
centage of S phase cells with Rad51 expression indicates that the cells entering S phase 
do not display reduced Rad51 levels, which should already be visible at the 48-hour 
time point.  
             
Figure 3.11 There is a correlation of Rad51 expression with the size of S phase cell cycle popu-
lation. A549 cells were treated with siMVP#1 or siLuc as a control. 6 hours after transfection 
part of the cell dishes was submitted to a double thymidine block. These cells were released for 
3 hours to enter into S phase. Finally, all samples were harvested at the indicated time point,  
S phase cell population (BrdU-incorporation) was determined by FACS analyses and Rad51 
expression levels were determined by Western blot analysis. 
In parallel to the experiments above, we also investigated Rad51 protein levels as a con-
sequence of induction of apoptosis. Plating efficiency of cells treated with siMVP#1-#3 
was significantly reduced, which is an indication for reduced cell viability. We assessed 
induction of apoptosis by determination of cleaved poly(ADP-ribose) polymerase 
(PARP) in response to treatment with siMVP#1-#3. PARP is involved in the recognition 
of single-strand breaks and is inactivated by caspase 3 in the early phase of programed 
cell death. Thus, monitoring cleaved PARP provides a mean to assess apoptosis [438]. 
Rad51 also is known to be a target of caspase 3 and is cleaved upon induction of 
apoptosis [439].  
Indeed, downregulation of MVP by siRNA was accompanied by the activation of 
caspase 3 in a dose dependent manner with an inverse correlation to Rad51 expression 
levels (see Figure 3.12A). However, inhibition of caspase activity by a pan caspase 
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inhibitor did not restore the Rad51 protein level, indicating that induction of apoptosis is 
not the main cause for the reduction of the Rad51 expression level upon MVP-
depletion.  
A B 
     
Figure 3.12 Caspase activity determined by PARP cleavage was induced in A549 cells by 
transfection with siMVP. (A) An increase of cleaved PARP was detected with increasing con-
centration of siMVP#2 used (72h after transfection). (B) The additional reduction of Rad51 
between the 48- and 72-hour time points after transfection was not rescued by inhibition of 
caspase activity. The control was treated with the solvent DMSO only. 
3.4.6 Manifestation of the MVP knockdown Phenotype Depends on p53 and p53 
Is Involved in MVP Regulation 
The severe phenotype we observed in A549 and HCT116 cells upon MVP-depletion 
raised the possibility of a putative link between MVP and resistance to oncogene-
induced senescence of cancer cells (see Figure 3.13 for the phenotypes of A549 cells 
treated with siMVP#1-#3). Yet, MVP silencing does not result in phenotypic changes in 
normal cells and in various cancer cell lines. MVP-knockout mice do not display any 
developmental and growth defects [332]. Hervelsen et al. silenced MVP with siMVP#2 
in human bladder cancer cells and did not report any adverse effect with regard to cell 
viability or proliferative activity [375]. Furthermore, the sequence siMVP#3 was char-
acterized to be nontoxic in HeLa cells [433], whereas in A549 cells the siRNA with this 
sequence strongly impaired cell proliferation. 
 
Figure 3.13 Knockdown of MVP in A549 cells leads to a severe inhibition of cell proliferation. 
A549 cells were transfected with 15 nM siMVP and seeded the following day at subconfluent 
conditions. Cells were allowed to form colonies for 72 h, were then fixed and stained with 
crystal violet, and documented by bright field microscopy. 
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To determine possible reasons for the differential response in our cell systems compared 
to previously documented results, we considered the genetic background of the A549 
and the HCT116 cell line. Remarkably, both cell lines express wild type p53, which 
normally acts as a tumor suppressor and is involved in cell cycle control and apoptosis. 
The gene TP53 coding for p53 is among the most frequently mutated gene in cancer 
[440]. However, both A549 and HCT116 cells express wild type p53 and in both cells 
lines p53 signaling was activated upon treatment with ionizing radiation and induced 
the expression of the cell cycle inhibitor p21. The p53-response in HCT116 cells was 
delayed and p53 reached the peak of activation only 48 hours after irradiation, whereas 
A549 cells showed a regular activation of p53 within the first hours after irradiation 
(determined by Ser17-phosphorylation of p53, data not shown). This indicates that  
p53-signaling is at least partially intact. Furthermore, we observed that transfection with 
the siRNAs targeting MVP alone induced phosphorylation of p53 at Ser17 (data not 
shown). 
Thus, we suspected that the status of the tumor suppressor p53 might play a role in the 
differential response to MVP silencing and decided to extend our MVP knockdown 
studies to additional cells lines. Various human cancer cells lines, as well as mouse 
embryonic fibroblasts (MEFs) were treated with siMVP#2 and siMVP#m, targeting the 
murine MVP sequence, respectively. Evidently, the knockdown of MVP had a stronger 
antiproliferative effect on cells expressing wild type p53 than on p53-deficent or  
p53-mutant cells. A simplified overview is presented in the table below (see Table 3.3).  
Table 3.3 Schematic overview on cell lines treated with siMVP: MVP expression level, p53 
status and effect of MVP-depletion on cell viability and proliferative activity 
 
  
p53 status: wt = wild type, mut = mutated, loss = spontaneous loss of expression, ko = knockout 
MVP expression level: color intensity reflects expression level 
Cell viability: ↓↓↓ = induction of apoptosis, ↓↓ and ↓ = strong and mediocre inhibition of prolif-
eration, → no significant effect on proliferation, (→) no significant effect on proliferation, 
determined only by cell cycle distribution 
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The effect of MVP silencing was most prominent in the p53-positive E1A/Ras-
transformed MEF cells, in which MVP-depletion clearly induced apoptosis. No 
apoptosis, but growth arrest was induced by MVP silencing in their p53-negative 
counterpart cells (see Figure 3.14A). Similarly, in HCT116 p53-positive cells and their 
p53-negative counterparts, proliferation was inhibited to a greater extent in cells 
expressing wild type p53 (Figure 3.14B). The same p53-dependence applied to the 
osteosarcoma cell lines U2OS and Saos-2, wild type and deficient in p53, respectively 
(Figure 3.14C). Of all three cell line pairs, the p53-deficient cell line showed notably 
lower doubling times to start with. Therefore, we also examined the effect of MVP 
silencing in the p53-mutant colon adenocarcinoma cell line SW480, which possess a 
comparable doubling time as observed for the p53-proficient cell lines. However, 
knockdown of MVP did not affect proliferation in this cell line, nor in SW620 cells, a 
cell line established from a metastatic tumor of the same patient (Figure 3.14D).  
A B 
 
C D 
      
Figure 3.14A-D All cell lines, except MEFs, were treated with the siRNA sequences siLuc and 
siMVP#2, respectively, at a final concentration of 15 nM. MEF cells were treated with a siMVP 
sequence targeting the murine MVP sequence at equal concentration. 24 h after transfection, 
cells were reseeded in 6 well plates and the cell number was determined at the indicated time 
points by cell count. Diagrams A and B depict a single experiment and B and C show the result 
for two combined experiments (error bars stand for the SEM).  
Interestingly, the 3T3 MEFs derived from MVP-knockout mice, which we kindly 
received from Prof. Dr. Wiemer (Rotterdam, NL), had undergone complete loss of p53 
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expression. The 3T3 protocol for the acquisition of immortalized fibroblasts implies a 
stochastic event such as loss of p53, or loss of p19ARF upstream of p53 [441, 442]. Thus, 
loss of p53 in the MVP-knockout fibroblast might provide a selective advantage related 
to the status of MVP or may be a mere coincidence as part of immortalization. Intri-
guingly, the MVP-proficient 3T3 MEFs, which express wild type p53 were also not 
affected by MVP-depletion. However, we did not perform further investigations with 
regard to this aspect. A discrepancy with regard to cell proliferation also exists between 
the p53-positive cancer cell lines sensitive to suppression of MVP and the MVP-
knockout mouse model that is not affected by the absence of the MVP. Furthermore, no 
information about the effect of MVP silencing in normal human cells exists.  
p53 wild type cells did not only respond in a more sensitive way to MVP silencing, but 
the p53 status might also correlate with increased MVP expression. For all cell lines 
investigated in this project, an increased MVP expression level was observed in p53 
wild type cells (see Table 3.3, above). Only p53-knockdown E1A/Ras MEFs displayed 
a similar MVP level as their p53 wild type counterpart. Furthermore, MVP expression 
was reduced in p53-depleted A549 cells (see Figure 3.15), corroborating that p53 might 
play a role in the regulation of MVP expression. Previously, Lange et al. suggested a 
link between p53 and MVP based on putative p53-binding elements in the promoter 
region of MVP [328].  
 
Figure 3.15 MVP expression is reduced in A549 cells upon knockdown of p53. A549 cells 
were treated with the indicated siRNA concentration. Cells were irradiated with 4 Gy at 24, 48, 
and 72 h after transfection and were harvested 6 h thereafter for Western blot analysis of MVP, 
p53 and p21 expression. Western blot performed by Tamara Codilupi.  
3.4.7 Validation of the MVP knockdown Phenotype Could Not Be Achieved by 
Rescue Experiments  
The discrepancy between MVP knockdown phenotype observed in the p53-positive 
cancer cell lines versus loss of MVP in normal cells raised unanswered questions. 
Furthermore, the variability of the different MVP knockdown phenotypes induced by 
the three siRNA sequences “remained an enigma”. All three siMVP sequences led to a 
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decrease in proliferation in A549 cells. However, there was a clear difference in the 
extent of growth inhibition and in the final cell cycle distribution. The severity of the 
MVP knockdown phenotype with regard to proliferation could be due to the differential 
efficiencies of the siRNAs, but the difference between the cell cycle distributions 
induced by the three siRNAs is more difficult to explain. As mentioned earlier, A549 
cells arrested in G2/M phase upon application of siMVP#1 or siMVP#2, whereas 
treatment with siMVP#3 resulted in a strong G1 arrest (see section 3.4.5). These 
inconsistencies indicate that one or the other siRNA may display nonspecific effects and 
deregulates additional proteins and pathways. 
Thus, we decided that validation of the RNAi phenotype, observed in MVP silenced 
p53-proficient cells, was indispensable. Validation can be performed by a rescue exper-
iment. The target protein is reintroduced by ectopic expression of an RNAi resistant 
version of the target and thus the RNAi phenotype is expected to be reduced. A549 cells 
were transfected with a plasmid coding for a flag-tagged MVP that was resistant to 
siMVP#2 due to nucleotide substitutions in wobble base pairs within the siRNA-
targeted MVP mRNA sequence (see Material and Methods, page 101 for further infor-
mation on the construction of the expression plasmid).  
For the performance of the rescue experiment, cells stably expressing the flag-tagged 
MVP are required. Interestingly, the expression of the flag-tagged MVP construct was 
suppressed in untreated control A549 cells, and was only detectable in cells treated with 
siMVP#2 (see Figure 3.16A). This substantially complicated the selection of clones 
stably expressing the MVP construct. Possibly, in A549 cells, the cellular turnover of 
MVP was increased by the additionally expressed MVP in presence of already high 
levels of endogenous MVP. Moreover, the flag-tagged MVP along with endogenous 
MVP most probably assembles into common vaults, which results in less pronounced 
staining of individual vaults; especially as the endogenous MVP level generally was 
higher than the ectopically expressed MVP in the selected clones. Thus, after siRNA 
silencing of the endogenous MVP, MVP protein levels were only partially restored by 
flag-tagged MVP, such as for A549 clone C2.7 (see Figure 3.16), which was one of the 
clones with highest expression of flag-tagged MVP.  
Repeated treatment of the MVP-transfected A549 pool with siMVP#2 did not enrich 
cells with high flag-MVP expression (data not shown), nor did the expression of ectopic 
MVP increase in the clone C2.7 as determined by Western blot analysis (see Figure 
3.16B). Moreover, the expression of flag-tagged MVP in clone C2.7 and other addition-
al clones (not shown) did not release growth suppression caused by the siMVP treat-
ment (see Figure 3.16C). Therefore, we could not confirm that the phenotype introduced 
by the siRNA treatment was a direct consequence of the MVP knockdown. On the other 
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hand, these results do not explicitly prove that the MVP knockdown phenotype we 
observed was due to off-target effects. This would require evidence for proper assembly 
and functionality of the ectopically expressed flag-tagged MVP. Immunofluorescence 
staining for the c-terminally flag-tagged MVP displayed the same coarse-grained 
appearance as for the native MVP, indicating proper assembly into vaults. Moreover, 
expression of c-terminally GFP-tagged MVP was performed by others, and vault 
assembly was validated by electron microscopy [443]. 
A 
 
B C 
  
Figure 3.16 Expression of siMVP#2-resistant MVP did not rescue the proliferative activity of 
A549 cells. (A) The A549 cell clone C2.7 expressing c-terminally flag-tagged MVP was treated 
with the indicated siRNAs and was stained for the flag-tag 72 h after transfection. (B) WB of 
clone C2.7 after single transfection with siRNA (left) or after the fifth siRNA transfection 
(right). (C) Proliferation of original A549 cells and clone C2.7 after treatment with siLuc and 
siMVP#2, respectively, at a final siRNA concentration of 5 nM. 
3.4.8 Combined Application of siRNA Sequences Reduced Severity of the MVP 
Knockdown Phenotype 
Taking into consideration that the MVP knockdown phenotype might derive from the 
undesired knockdown of proteins other than MVP, several experiments were performed 
to elucidate this possibility. Off-target effects are nonspecific effects and thus the 
identification of the protein, or proteins affected by the siRNA, other than the target 
protein, is laborious, if not even impossible. Only a limited number of experiments were 
performed that indirectly provide further indications for possible off-target effects.  
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We assumed that each of the siRNA sequences targeting MVP introduces different 
nonspecific effects. The severity of these off-target effects might be reduced by the 
application of a mixture of siRNAs. The cellular response to MVP silencing by 
siMVP#2 alone was compared to the cellular response to a mixture of all three siMVP 
sequences (see Figure 3.17A). The sequence siMVP#2 manifested in the least severe 
MVP knockdown phenotype of all three sequences with regard to proliferation. 
Nonetheless, the mixture of siRNAs alleviated the phenotype, even though the same 
concentration of total siRNA was applied. The siRNA siMVP#2 alone strongly reduced 
Rad51 expression levels and induced phosphorylation of p53 at Ser17. Both effects 
were significantly reduced in the samples treated with the mixture of siRNAs. However, 
proliferative activity recovered only at very low siMVP concentrations (see Figure 
3.17B). The proliferation rate of A549 cells that were treated with the siRNA mixture 
returned to control levels at a concentration of 0.56 nM siRNA, whereas cells treated 
with siMVP#2 resumed normal proliferative activity only at a the threefold lower 
siRNA concentration. Unfortunately, the cell proliferation assay was performed only 
once. 
A B  
  
Figure 3.17 Differences in the siMVP knockdown phenotype between cells treated with 
siMVP#2 and a mixture of all siMVP sequences. (A) Determination of MVP and Rad51 expres-
sion levels, and p53-phoshorylation (Ser17) in A549 cell lysates harvested 48 and 72 h after 
transfection. (B) The fold increase in cell numbers 72 h after transfection with different concen-
trations of siRNA was determined by cell count. 
3.4.9 Testing of Additional siRNA Sequences 
Another approach to shed light on the possibility of nonspecific siRNA effects was to 
test siRNAs targeting different parts of the MVP mRNA than the previous siRNAs. 
Additional siRNA sequences were used to test and to compare their effects to those 
induced by the siRNAs we used so far. For the target MVP, no in vitro validated siRNA 
sequences were available. Thus, we probed three commercially available sequences 
(from Ambion) that had been selected for high specificity and efficiency by means of an 
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algorithm. These sequences will be denominated siMVP_A, siMVP_B and siMVP_C. 
For additional control siRNA sequences two of the obtained MVP sequences were 
scrambled by means of an algorithm dedicated to design non-binding siRNA sequences 
using the same nucleotide composition.  
Astonishingly, only one of the three new siMVP sequences was capable of downregu-
lating MVP in A549 cells; the other two sequences, especially siMVP_A rather induced 
MVP expression levels (see Figure 3.18A). The additional control siRNAs with the 
scrambled sequences_A and B did not change MVP expression levels. Additional con-
trol experiments with siLuc siRNA confirmed our previous results that transfection of 
siLuc induces MVP expression in A549 cells. On the level of proliferation, the 
siMVP_C efficiently downregulated MVP, but did not influence cell proliferation (see 
Figure 3.18B). These results indicate that the MVP knockdown phenotype obtained 
with the previously used siRNAs may indeed be due to nonspecific siRNA interactions. 
Of note, also the scrambled sequence_A strongly reduced proliferation, as well as the 
MVP-stimulating sequence siMVP_A. Our observations emphasize that nonspecific 
effects may be very common to the siRNA technique and that these side effects, 
depending on the genetic background of the cancer cell, e.g. with regard to their p53 
status, may induce cell cycle arrest. 
A B 
 
Figure 3.18 Determination of MVP knockdown by additional siRNA sequences targeting MVP 
and their effect on cell proliferation. (A) A549 cells were transfected with the siRNA sequences 
indicated, at a final concentration of 15 nM. Cells were harvested 72 h after transfection and 
MVP expression was determined by Western blotting. (B) The fold increase in cell number was 
determined at the 72-hour time point for each siRNA condition, by cell count. 
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3.4.10 MVP Is Induced by Ionizing Radiation and other Stress Stimuli 
We could not confirm a direct link of MVP to DNA damage repair, but we observed 
that MVP was induced upon treatment with ionizing radiation (see Figure 3.19A). We 
did not find an increased MVP protein level as an immediate treatment response to 
ionizing radiation, but observed an increase at around 48 hours post irradiation in A549, 
HCT116, and U2OS cells. This indicated that MVP in response to IR might be involved 
in similar resistance mechanisms as in senescent cells. Ryu et al. observed that MVP 
was induced in senescent fibroblasts and in aging tissue and they suggested that vaults 
play a role in the resistance to apoptosis [383, 384]. 72 hours after irradiation with 10 
Gray, we observed a pronounced increase of MVP in A549 cells, as well as reduced 
Rad51 expression (see Figure 3.19A). This indicated reduced proliferative activity, 
which might even be related to IR-induced senescence. Interestingly, upregulation of 
MVP in response to irradiation was partially mediated by secreted factors and could be 
counteracted by changing the medium (see Figure 3.19B).  
Other cellular stress factors also upregulated MVP in the three cell lines A549, HCT116 
and U2OS, like the hypoxia-mimicking agent DMOG (data not shown), supporting a 
putative role of MVP in stress response. Upregulation of MVP after DMOG also coin-
cided with strongly reduced proliferation, similar as in response to high doses of IR.  
A B 
            
Figure 3.19 Increase of MVP upon treatment with ionizing radiation in A549 cells. (A) Cells 
were treated with IR (10 Gy) and harvested at the indicated time point after irradiation for 
Western blot analysis of MVP, phospho(Ser17)-p53 and Rad51 expression levels. Tubulin was 
used as loading control. (B) A549 cells were irradiated with 10 Gy or sham irradiated. Cells 
designated as ctrl cells were supplied with fresh medium every 24 hours. The medium of the 
cells designated with CM (conditioned medium) was not changed. Lysates were taken at 48 and 
72 h after IR and analyzed for MVP expression. Actin was used as a loading control (WB 
performed by Tamara Codilupi). 
For these experiments, the cells were seeded at very low density, as we previously 
realized that the MVP expression level substantially increased in confluent cells (Figure 
3.20A). Clearly, the amount of medium added to the cultured cells, greatly influenced 
the process of MVP induction and confluency itself did not seem to be the major cause 
of MVP upregulation. This again suggested that secreted factors or other changes in the 
medium such as pH, lactate levels or percentage of serum might influence MVP-levels. 
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The increase of MVP induced by the conditioned medium proofed to be reversible. 
MVP expression decreased if confluent cells, with high MVP levels, were plated at 
subconfluent density in fresh medium (see Figure 3.20B). The reduction in MVP 
expression coincided with the increase in proliferative activity, which was determined 
by Rad51 expression levels. 
Further evidence that MVP induction was not facilitated by cell density, but by the con-
ditioned medium, was obtained by culturing subconfluent cells in conditioned medium. 
The MVP expression level was strongly upregulated in cells incubated in conditioned 
medium in comparison to cells incubated with fresh medium (Figure 3.20C). In this 
experiment, cells were seeded at a very low density, to assure that even at the 48-hour 
time point, cell density remained low. Nonetheless, in these cells MVP-expression 
could be induced by conditioned medium derived from plates with confluent cells. This 
effect was even more pronounced when confluent cells were seeded at low density and 
were then incubated in conditioned medium. Under these conditions MVP expression 
further increase, whereas in the same cells, plated in fresh medium, MVP expression 
returned to the basal level (see Figure 3.20D). 
A B 
 
C D 
           
Figure 3.20 Conditioned medium facilitates upregulation of MVP in A549 cells. (A) A549 cells 
were seeded at different cell densities in 6-well plates and were incubated with 2 or 8 ml of me-
dium. Samples were harvested 72 h after seeding and submitted to Western blotting for the 
analysis of MVP, Rad51 and Tubulin as loading control. (B) Subconfluent and very confluent 
A549 cells were trypsinized and reseeded in fresh medium under subconfluent conditions. Cells 
were harvested at different time points for the assessment of MVP expression. Subconfluent (C) 
and confluent (D) A549 cells were reseeded at subconfluent conditions in fresh medium or in 
conditioned medium from confluent cells. MVP and Rad51 protein levels were determined in 
lysates collected at the indicated time points. Actin was used as a loading control. WBs 19B-D 
were performed by Tamara Codilupi. 
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To assess the changes in the composition of the medium or secreted factors that were 
responsible for the upregulation of MVP expression, we performed additional experi-
ments to determine the influence of obvious factors such as pH or lactate concentration 
on the MVP expression level. The pH of strongly conditioned medium was determined 
to be around 6.7 and acidification was assumed to depend on secreted lactate, which 
accumulates in the medium over time. However, supplementation of subconfluent cells 
with medium that was adjusted to a pH of 6.7 or contained 10 mM lactate, did not 
accelerate induction of MVP in A549 cells (Figure 3.21A).  
Supposedly, conditioned medium contains a reduced amount of serum components, and 
the shortage of nutrients might eventually induce a stress response in cultured cells, 
leading to increased MVP expression. MVP indeed was shown to play a role in starva-
tion resistance [444, 335]. Thus, to probe for the effect of nutrient deprivation on MVP 
expression, A549 cells were subjected to 48 hours of serum starvation (medium contain-
ing 1 % serum), followed by a release into fresh medium. 48 hours of serum starvation 
also had no influence on MVP expression, nor did we observe any change in MVP 
expression upon release from starvation (see Figure 3.21B). 
A B 
 
Figure 3.21 Induction of MVP in A549 cells is not mediated by low pH or the accumulation of 
lactate, nor by serum starvation. (A) A549 cells were incubated in medium of pH 6.7 or in 
medium containing 10 mM lactate. Lysates were collected at 24 and 48 hours for the analyses of 
MVP expression by WB. The experiment was performed by Tamara Codilupi. (B) A549 cells 
were starved for 48 hours and were then released into fresh medium. Sampled were taken at the 
indicated time points after release. Control samples show the MVP expression level of non-
starved A549 cells. 
Apart from changes in the medium composition, autocrine factors might be involved in 
upregulation of MVP. In the experiments that involved large doses of radiation (see 
above, Figure 3.19A), the irradiated cells do not reach confluency, due to cell cycle 
arrest or cell death. Thus, the composition of the medium with regard to pH and lactate 
might be less affected under these conditions. On the other hand, it is known that irradi-
ation and other stress stimuli induce compensatory activation of intracellular signaling 
pathways such as mitogen-activated pathways involved in cell survival and repopulation 
[265, 445, 446]. Irradiation induces increased shedding of growth factors that are 
involved in epidermal growth factor receptor (EGFR) stimulation [264, 265, 447]. To 
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investigate an involvement of EGFR pathways in the upregulation of MVP, EGFR 
signaling was stimulated by epidermal growth factor (EGF). Interestingly, we observed 
that MVP was upregulated after EGF stimulation in a similar time frame as after irradia-
tion (see Figure 3.22). The induction of MVP by EGFR stimulation was slightly lower 
in A549 cells than in the human breast carcinoma cell line MDA-MB-231. In A549 
cells, upregulation of MVP over time was stronger, which might be due to a generally 
increased secretion of stimulatory factors.  
A B 
           
Figure 3.22 MVP expression is induced by stimulation with epidermal growth factor. A549 
cells (A) and MDA-MB-231 (B) were stimulated with 100 ng/ml EGF and MVP expression was 
assayed at the indicated time points by Western blotting. WBs were performed by Tamara 
Codilupi. 
Both cell lines carry an activating mutation in K-Ras downstream of EGFR [448, 449], 
which correlates with increased EGFR ligand production [271] and increased shedding 
of EGFR ligands by increased ADAM-17 activity [450]. However, we did not analyze 
the composition and the level of secreted growth factors to determine which specific 
growth factor might be responsible for the upregulation of MVP in A549 cells by the 
conditioned medium. Likewise, it would be interesting to test the hypothesis of a puta-
tive link between irradiation-induced growth factor shedding and the increase in MVP 
expression.  
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3.5 Discussion of the MVP Project 
The promising findings of the major vault protein (MVP) as a player in the DNA repair 
process of homologous recombination could not be confirmed and might have been an 
artefact of the siRNA technique used. Thus, the first part of the discussion will be dedi-
cated to the technique of RNAi. In the second part MVP as a player in stress response, 
such as in the response to ionizing radiation will be reconsidered and the regulation of 
MVP in response to stress factors will be discussed.  
3.5.1 The Puzzling World of RNAi 
At long last, we ended up with six siRNA sequences targeting the MVP, which all 
displayed different phenotypes in the non-small cell lung cancer cell line A549. Two of 
the first three siRNA sequences had been used in previous publications and the other 
three siRNA sequences had been designed by the company Ambion and had undergone 
selection by an algorithm to exclude sequences with possible nonspecific effects. 
Nonetheless, in our hands, the discrepancy between the effects evoked by the different 
sequences proofed to be a serious handicap for their use. These observations also raise 
the questions why in some cell systems nonspecific effects do not display, whereas in 
others, they do, and how these nonspecific effects could be prevented. In the following 
part, a brief overview on the RNAi mechanism and its scientific exploitation, will be 
followed by the review of “our” siRNA sequences in the context of the cell systems we 
worked with. Finally, the issue of off-target effects, and how they might arise will be 
addressed. 
3.5.1.1 A Brief Overview of the Discovery of RNA Interference, of Mechanisms of 
RNAi and of Its Endogenous Functions 
The suppression of gene expression by the ectopic introduction of nucleotide sequences 
has been first observed in plant science. Unexpectedly, ectopic expression of chalcone 
synthase (CHS) an enzyme involved in anthocyanin biosynthesis diminished en-
dogenous CHS expression in petunia petals [451]. Similar observations were made in 
Neurospora crassa a type of red bread mold; ectopic expression of carotenoids induced 
an albino phenotype [452]. Even though the authors found that the introduced sequences 
had randomly integrated into the genome and were able to disturb endogenous expres-
sion, the effect was lost over time.  
Before Andrew Fire and Craig C. Mello came across their findings that double-stranded 
RNA sequences were most efficient in suppression of genes [453], antisense technique 
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was used to downregulate protein expression in C. elegans. Antisense strands (single 
stranded RNA) were thought to bind to the messenger RNA and inhibit its translation. 
Curiously, Guo et al. found that not only the antisense RNA sequence, but also the 
sense sequence led to suppression of the target gene, the mechanism of which they were 
not able to explain [454]. Andrew Fire and Craig C. Mello observed similar results 
when the single stranded siRNA products were not purified by gel electrophoresis, but 
were merely treated with DNase to degrade the template. Purified RNA strands showed 
reduced RNAi potency. Thus, they suspected that the observed RNA interference 
actually came from the contamination with the template remnants when they observed 
that repression of gene expression by dsRNA was far more potent in C. elegans; only a 
few injected molecules were sufficient to induce the phenotype of the corresponding 
knockout animal. Eventually they were honored with the Nobel Prize in 2006 for their 
discovery of RNA interference. Fire and Mello also distinguished that the dsRNA-effect 
was propagated to cells distant from the injection site and was even handed down to 
later generations [453].  
At the same time, regulation of gene expression by endogenous antisense sequences 
became apparent, first in plants, then in prokaryotes and bacteriophages and later also in 
eukaryotic cells. Some antisense sequences were found to be transcribed from the 
noncoding strand of the same gene locus as the regulated gene [455]. These regulatory 
sequences overlap with a great part of the translated region or bind to the 5’ untranslated 
region (5’ UTR) to inhibit translation. On the other hand, another type of regulatory 
RNA sequences, so-called microRNAs (miRNAs) tend to bind the 3’ UTR region and 
are not direct antisense transcripts.  
The first miRNA named lin4 was discovered in C. elegans and regulates the lin14 
mRNA, a transcript of a separate locus [456, 457]. However, many miRNAs are 
transcribed from introns of coding genes [458, 459]. The transcripts of approximately 
70-80 nucleotides (nts) of length contain one to several hairpin structures, which are 
consequently separated by the RNAse III enzyme Drosha in the nucleus. Upon transport 
to the cytoplasm, the so-called pre-miRNA is further tailored by the RNAse III enzyme 
Dicer into a 21-25-nt long double stranded miRNA molecule, with a 2-nt overhang at 
each 3’ end. In the same way, endogenous siRNAs are processed by Dicer, though they 
derive from long sense-antisense transcripts.  
Both miRNAs and siRNAs act in a similar fashion to regulate protein expression. The 
processed double-stranded RNAs assemble into the RNA-induced silencing complex 
(RISC), which contains an Argonaute 2 (Ago2) protein. Ago2 selectively binds to the 
guide strand, which is distinguished by the lower 5’ stability of the RNA duplex  
[460–462]. The second strand is then released in the presence of inherent mismatches 
Discussion of the MVP Project 
126 
 
that are often attributed to miRNAs, or it is cleaved by the Ago2 “slicer” activity in case 
of a perfect match of the RNA duplex [463]. Similarly, in case of perfect match of the 
guide strand to the target sequence, the latter is cleaved by Ago2. MicroRNAs, other 
than siRNAs often imperfectly pair with their target sequence, which leads to 
repression, rather than to degradation of the targeted mRNA. However, some miRNAs 
such as miR-196, which is involved in HOX8B regulation, have been reported to match 
their target perfectly, leading to cleavage of the targeted transcript [464].  
Initially, the RNA silencing mechanism was thought to be mainly involved in host 
defense against viral infection, as observed in plants [465, 466]. Further investigations 
indicated that some viruses might have turned the stick around, by hijacking the RNA 
silencing machinery to manipulate the host cell (reviewed in [467]). By now, we know 
that RNA-dependent mechanisms are also involved in manifold endogenous regulation 
processes, and RNA molecules other than miRNAs and siRNAs have been identified 
with different origins and mode of actions (see Table 3.4 and [468]). Also the interest in 
long noncoding RNAs (lncRNAs) has returned with the technical developments that 
allow to study whole transcriptomes; it has been suggested that about 75% of the 
noncoding genome is transcribed and is surmised to be involved in gene regulation 
[469, 470].  
Table 3.4 Classes of regulatory RNAs identified in eukaryotic cells [471]. 
 
3.5.1.2 RNAi a Powerful Tool in Research 
In human and other mammalian cells, RNAi did not turn out to be a tool as powerful as 
in C. elegans, where siRNA molecules are amplified by RNA-dependent RNA 
polymerase (RdRP) enzymes [472–474] and silencing can spread among cells, and 
under circumstances are even transmitted to the next generation [453]. Nevertheless, 
RNAi has advanced to a widely used technique in scientific research to eliminate 
cellular proteins in order to study their function. Moreover, a lot of effort is put into 
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RNAi-based therapeutic approaches to treat various diseases such as cancer, viral 
infections and inflammatory diseases. However, the therapeutic application of RNAi 
and the challenges involved will not be discussed here. 
In research, three RNAi methods are commonly used: transient transfection with short 
interfering dsRNA sequences (siRNAs), stable expression of short hairpin RNAs 
(shRNAs) or miRNA-adapted shRNAs (miR-shRNAs) from transient or stably 
transfected plasmids. The siRNA technique has the advantage that it can be easily and 
quickly established, and therefore is the choice of method for screen-based investiga-
tions or for short-term experiments for the assessment of potential effects. A cellular 
model system that can be readily transfected is a prerequisite for siRNA. A big 
disadvantage of the siRNA-knockdown method to the more laborious shRNA and  
miR-shRNA approaches is the duration of the knockdown of the target. Based on our 
own experience, the protein knockdown manifests around 24 to 48 hours after transfec-
tion with siRNA and starts to wear off at latest around 96 hours after transfection. Thus, 
during an siRNA experiment, cells may not be given enough time for recovery from the 
transfection procedure and the short duration of the actual knockdown may not be suffi-
cient to investigate the scientific question. Knockdown by shRNA on the other hand can 
be stable over time upon integration of the vector plasmid into the host cell’s genome. 
In case of a very severe knockdown phenotype or if required by the experimental 
design, shRNA expression can be regulated by means of inducible promoter elements. 
The coupling of naturally occurring miRNA flanking regions to shRNA drives 
transcription by RNA polymerase (pol) II, which also transcribes most endogenous 
primary miRNA transcripts [475]. The use of an endogenous promoter may prevent 
overexpression of shRNAs that has been associated with cellular toxicity, presumably 
through oversaturation of cellular microRNA/short hairpin RNA pathways [476]. 
Moreover, miRNA-adapted transcripts can be designed to contain several miR-shRNAs 
facilitating the knockdown of multiple targets at the same time [477].  
3.5.1.3 Review of the siRNA Sequences siMVP#1-3 and Determination of Potential 
Indications for Off-Target Effects  
As described, we performed the knockdown of MVP by means of siRNA. Due to the 
great impact of MVP knockdown in A549 cells, a stable knockdown by shRNA was not 
an option. However, an inducible shRNA construct was considered for future extended 
experiments. 
The knockdown of MVP by siMVP#1 and siMVP#2 had a strong impact on cell via-
bility and proliferation in both cell lines, the non-small cell lung carcinoma cell line 
A549 and the human colon cancer cell line HCT116. This observed stagnation of the 
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proliferative activity will be referred to as MVP knockdown phenotype. Of note, 
siMVP#1 was more “toxic” than siMVP#2, which was not only reflected in a reduced 
plating efficiency, but also in a much stronger reduction of the S phase cell population. 
The depletion of S phase cells had not been observed to this extent in our previous 
studies, since different time points for cell cycle analyses and on differential transfec-
tion protocols and transfection agents were chosen [430]. For the current studies, a 
reverse transfection protocol was applied, using a specific transfection reagent adapted 
for siRNA transfection. This may have enhanced and prolonged downregulation of 
MVP. Instead of the 48-hour time point, cell cycle distribution was determined 72 hours 
after transfection, where the siMVP knockdown phenotype became most apparent.  
As mentioned above, the severity of the induced phenotype was different for the two 
siRNA sequences, siMVP#1 and siMVP#2, used and might have correlated with the 
efficiency of the MVP knockdown. To confirm the relationship we decided to use a 
third siRNA sequence against MVP and thus a published sequence that was declared 
efficient but non-toxic in HeLa cells was chosen [433]. Intriguingly, in A549 cells we 
were again confronted with a very strong MVP knockdown phenotype with almost 
completely abolished growth. To our surprise, siMVP#3-transfected A549 cells accu-
mulated in G1 phase, whereas siMVP#1 induced a strong G2 arrest and siMVP#2 
provoked a less marked G2 arrest. The difference between siMVP#3 and the other two 
sequences could hardly be explained by different knockdown efficiencies, and rein-
forced the requirement for validation of the siRNA sequences. 
Indications that indeed all three siRNAs (siMVP#1-3) introduced nonspecific effects 
can be deduced from the following experiment. To determine the relationship between 
the MVP expression level and the appearance of the siMVP knockdown phenotype, the 
siRNAs were applied in a gradient of concentrations. As a measure for the phenotype, 
we probed the Rad51 expression level. Rad51 repression was assumed to indirectly 
reflect reduced cell cycle progression upon MVP-directed siRNA treatment, or to be a 
direct consequence of MVP-regulated Rad51-transcription. Previous data suggested that 
Rad51 transcription might be induced by MVP in a PTEN-dependent way and would 
therefore be reduced upon MVP-depletion, eventually leading to a G2-arrest [430]. 
Even though we demonstrated that Rad51-depletion indeed arrest A549 cells in the G2 
phase of the cell cycle, the Rad51 expression levels in the siMVP-gradient experiments 
rather correlated with the amount of siRNA applied than with the MVP expression 
level. MVP levels were efficiently reduced even at low siRNA concentrations, whereas 
Rad51 levels gradually decreased with increasing siRNA concentrations for all three 
siMVP sequences. Thus, the MVP knockdown does not seem to be responsible for the 
loss of Rad51 expression. More likely, the results indicate that with rising siRNA 
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concentrations “toxicity” may increase, which leads to a gradual decrease in cell cycle 
progression and thus reduced Rad51 expression levels.  
Furthermore, not in all the cell lines we tested, MVP-depletion had an effect on the 
Rad51 expression level. But interestingly no MVP-Rad51 interrelationship could be 
observed in the MVP-knockout mouse model. Thus, a cancer type-dependent addiction 
to MVP-facilitated Rad51 transcription might exist. However, such a pronounced 
dependence of Rad51-transcription on MVP, which under normal circumstances seems 
to be “non-essential”, may be rather unlikely. Interestingly, cell lines harboring wild 
type p53 were clearly more prone to Rad51 repression. Transfection with each of the 
three siMVP sequences led to phosphorylation of p53, which in turn might affect cell 
cycle progression. Although not all siMVP sequences stimulated p53 to the same extent. 
Interestingly, stimulation of p53 was not apparent, if a mixture of all three siRNAs was 
applied instead of a single siMVP siRNA. These findings suggest the presence of 
differential toxic effects that are “diluted” by the siRNA pool. Moreover, increased p53 
activity upon MVP knockdown in cell culture or in the MVP-knockout mouse model 
has not been reported before, which supports the notion that nonspecific effects lead to 
p53 activation and may even be partially responsible for the siMVP knockdown pheno-
type. Possibly, a double knockout of MVP and p53 may help to understand the role of 
p53 in the induction of the phenotype. 
With all these findings, we could not overlook the possibility that all three siMVP 
sequences might be accompanied by nonspecific effects that interfere with the outcome 
of the experimental results. Especially in the research on radiation responses, an addi-
tional though nonspecific stimulation of p53 may falsify the treatment outcome and the 
cellular radiosensitivity. Obviously, the loss of Rad51, if not a result of MVP-depletion, 
may lead to wrong conclusions with regard to homologous recombination. If deregulat-
ed cell cycle progression is the result of nonspecific effects, we are confronted with the 
loss of Rad51 in the G2 phase, which we observed in siMVP#1 and siMVP#2-treated 
cells. In the G2 phase of the cell cycle, Rad51 normally is present and facilitates homol-
ogous recombination. However, Yamamoto et al. demonstrated that mRNA levels of 
Rad51 were already reduced in G2-M phase and they postulated that the high stability 
of Rad51 that they determined by a pulse chase experiment explains its presence in G2-
M phase [478]. Thus, it may be possible, that cells arrested in G2 over time show 
reduced Rad51 expression and lower Rad51 foci formation. 
The three additional siRNA sequences siMVP_A, B and C (sequences derived from 
Ambion) added even more variety to our MVP knockdown phenotypes. Interestingly, 
two of the sequences rather induced MVP, even though they were designed based on a 
very advanced algorithm. Finally, the third sequence, siMVP_C, showed efficient 
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downregulation of MVP and surprisingly had no effect on cell proliferation, providing 
evidence that MVP can be downregulated without deregulation of the cell cycle. There 
might exist the possibility that siMVP_C, in concert with the MVP knockdown, 
mediates a nonspecific effect leading to increased proliferation, which then counteracted 
the MVP knockdown phenotype. However, the phenotype of siMVP_C best resembles 
the previous findings in the MVP-knockout mouse model, without additional effect on 
cell proliferation, indicating that this sequence should be considered for future research 
on MVP.  
Intriguingly, nonspecific effects did not manifest in all cell lines in the same way. Some 
cell lines, for example the HeLa cells seemed to be “immune” to the siMVP#3-induced 
off-target effects and did not display any toxicity. Possibly, aggressive cancer cell lines 
do not react with cell cycle arrest, whereas others still do. Similarly, Fedorov et al. 
observed that the introduction of toxic siRNA sequences does not induce apoptosis to 
the same extent in all cell lines tested [479]. 
The siRNA technique may be a powerful tool to gain a first insight into the function of a 
protein. However, to our experience, nonspecific effects seem to be ubiquitously 
present. Thus, results obtained by siRNA technique should be considered with great 
care and require validation. 
3.5.1.4 Mechanisms of Potential Toxicities of RNAi  
With a careful design of the siRNAs, some but not all off-target effects may be avoided. 
As mentioned above, the guide strand is selected by the thermodynamically more insta-
ble 5’ end of the RNA duplex. Other than in miRNA processing, the passenger strand of 
the siRNA is cleaved once the guide strand has been recognized and is bound by Ago2 
[480]. For some siRNAs, the guide strand and for others the passenger strand were 
shown to mediate the off-target effects. Thus, potential off-target effects could derive 
from an ambiguous strand selection. Moreover, Jackson et al. demonstrated that a 
perfect match was not necessary for gene regulation and that a sequence with only 11 
complementary base pairs could induce gene silencing [481]. As mentioned above, 
miRNAs often incompletely match their target sequence. Specificity of miRNAs is 
determined by a “seed” sequence of 7 base pairs at position 2-8 that is complementary 
to a region in the 3’ UTR of the target mRNA [482–485]. It has been shown that 
miRNAs with the same “seed” sequence that are otherwise different can regulate trans-
lation of the same protein [486]. The Ago2/siRNA-complex does not differ from an 
Ago2/miRNA-complex and therefore may regulate genes other than the perfect match-
ing mRNA in a miRNA-like manner, introducing unforeseen off-target effects.  
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In the case of siMVP_A and siMVP_B, both of which did not lead to any reduction in 
the target gene, the passenger strand may have been selected. Modifications of the 
passenger sequence can ensure the entrance of only the guide strand into the RISC 
complex. The sequences for siMVP_A and B were derived from Ambion. However, 
Ambion sells chemically modified siRNAs, whereas we ordered unmodified siRNAs. 
Thus, the strand selection may not have been provided.  
Strand selection was considered by Brahmsen et al., to be the major determinant for the 
improvement of siRNA activity, as they performed a screen comparing different chemi-
cal modifications on siRNA performance [487]. In literature, numerous approaches 
have been investigated to enhance strand selection by the introduction of chemical 
modifications. As an example, 5’-phosphorylation is important for strand selection and, 
thus 5’-O-methylation of the passenger strand prevents phosphorylation of this strand 
and thus enhances specific selection of the guide strand [488]. Similarly, 5-nitroindole 
modification at position 15 of the siRNA passenger strand leads to reduction of off-
target effects without impairing the efficiency of the siRNA [489]. Chemical modifica-
tions were also investigated to reduce miRNA-like off-target effects. Jackson et al. 
introduced a 2′-O-methyl modification in position 2, which lowered the thermodynamic 
stability of the seed region (bp 2-8). As determined by microarray analyses the modified 
siRNAs affected a reduced number of genes, with similar efficiency in downregulating 
the target mRNA [490].  
Besides classic off-target effects that arise from nonspecific interactions with non-target 
mRNAs, some siRNA sequences evoke immune responses. However, the mechanism is 
not fully understood. Certain nucleic acid motifs have been associated with Toll-like 
receptor recognition, leading to the induction of interferons (IFNs) and inflammatory 
cytokines [491, 492]. This stimulation is predominantly triggered in immune cells and 
thus plays a role upon systemic application of RNAi. On the other hand, upregulation of 
the IFN-mediated pathways were also shown to take place in cell culture [493, 494]. 
Non-immune cells also dispose over a family of RNA sensors that recognize viral 
nucleic acids, including RIG-1, MDA-5 and LGP2 [495]. Whereas these sensors may 
recognize longer RNA duplexes and their interplay with siRNAs is not known, the 
dsRNA-dependent protein kinase (PKR) is stimulated by dsRNA of only 21 bps [493].  
To sum up, commercially available siRNAs are usually modified to enhance the speci-
ficity of the strand selection, and analogy of the seed region of the siRNA to known 
seed regions are avoided. Nevertheless, many carefully selected and modified siRNAs 
elicit nonspecific effects and the true knockdown-related changes may be difficult to 
discern. Nonspecific effects may be reduced with lowered siRNA concentrations. It is 
therefore advised to titrate the siRNA concentration and to use the lowest concentration 
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necessary. On the same bases, some companies work with pools of siRNAs, targeting 
different sequences of the same mRNA, which allows for the application of lower 
concentrations for each individual siRNA. This was also shown to reduce off-target 
effects in our case. However, for the investigation of a gene with unknown function, it 
is essential to use sequences “without” off-target effects. Thus, several siRNAs should 
be applied individually and the phenotypes should be skeptically compared with each 
other. Best is the validation of an siRNA-induced phenotype by a rescue experiment, 
where the knockdown protein is complemented by the ectopic expression of a siRNA-
resistant variant. However, as in the case of MVP, it is difficult to discern whether the 
ectopically expressed MVP assembles into functional vaults and thus an unsuccessful 
rescue may not always be proof for nonspecific effects. 
3.5.2 What Did We Learn about MVP? 
The precise function of MVP and vaults still has not been elucidated. Our own conclu-
sions on the role of MVP in DNA damage repair are limited due to the technical issues 
related to the siRNA technique we applied. However, we observed that MVP was 
induced after treatment with ionizing radiation and by other stress stimuli. Upregulation 
of MVP by osmotic stress, hypoxia and DNA damaging agents was previously 
described in literature. Thus, MVP may play a role in stress response or even stress 
resistance. Furthermore, we observed, that the expression level of MVP was partially 
regulated through autocrine and/or paracrine signaling. 
3.5.2.1 The Role of MVP in DNA Damage Repair 
With regard to the contribution of MVP to DNA repair or more precisely to homolo-
gous recombination (HR), we are not able to draw a final conclusion. We could not 
confirm the hypothesis of a putative MVP/PTEN/Rad51 axis. HCT116 PTEN-knockout 
cells showed a similar decrease of Rad51 levels as the parental HCT116 cell line, 
indicating that it is not the putative MVP-PTEN interaction that is responsible for 
reduced Rad51 expression we observed. Furthermore, the knockdown of MVP did not 
lead to Rad51 repression in all cell lines, but only in those that responded with a cell 
cycle arrest. This suggests that cell cycle deregulation, induced by off-target effects, but 
not MVP-depletion determines the Rad51 expression level. As mentioned before, not all 
cell lines are equally sensitive to the introduction of nonspecific effects [479], which 
may explain the differential manifestation of the knockdown phenotype. Independent of 
the siRNA-induced effects, we were not able to confirm the previous finding of a direct 
interaction of MVP with BRCA2/Rad51 by immunoprecipitation.  
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Nonetheless, we observed a dose-dependent upregulation of MVP in response to ioniz-
ing radiation. However, a strong increase of the MVP levels took place only at 72 hours 
after irradiation, suggesting a role in stress resistance rather than a direct involvement in 
DNA repair. Thus, investigations with regard to this late response may reveal more 
information about the role of MVP in radiation response.  
3.5.2.2 Is MVP a General Player in Stress Response? 
We found that not only treatment with ionizing radiation, but also the hypoxia-
mimicking agent DMOG, increasing cellular confluency or even transfection with 
certain siRNA sequences led to an increase in MVP expression. Several studies reported 
that MVP expression was upregulated in response to stress factors such as DNA-
damaging agents and ultraviolet rays [378], hyperosmotic stress [496], hyperthermia 
[497] and hypoxia [498]. MVP was also shown to be induced in virus-infected cell 
systems [499, 351] or in peripheral blood mononuclear cells (PBMCs) and in liver cells 
of hepatitis C virus (HCV) patients [500]. Steiner et al. showed that specifically inter-
feron gamma (IFNγ), which is mainly released by T-cells and natural killer (NK) cells 
upon viral infections, stimulated MVP expression on a transcriptional and translational 
level [330]. However, Guo et al. performed his experiments in Hep2 cells that do not 
produce IFNγ, indicating that there are different ways how viral infections induce MVP 
expression. Similar to viral genomes, siRNAs can trigger cellular responses to the 
foreign dsRNA, which may rely on specific RNA motifs. We observed did not investi-
gate the responsible mechanism leading to the induction of MVP expression in response 
to certain siRNA sequences, may it be similar to the viral infection of Hep2 cells or 
other mechanisms. Among the sequences that induced MVP were the “non-toxic” 
control siRNA, targeting luciferase, and the sequences siMVP_A and siMVP_C, which 
resulted in upregulation instead of a downregulation of MVP. Other control siRNAs, 
such as scramble_A and scramble_B did not induce MVP expression. Therefore, the 
transfection process alone cannot be the sole cause of MVP induction, nor the mere 
presence of double-stranded RNA. Thus, sequence-specific recognition by dsRNA 
sensors or nonspecific effects introduced by the siRNAs may be possible causes of the 
siRNA-dependent upregulation of MVP. 
In response to ionizing radiation (IR), we found that MVP was substantially upregulated 
at around 72 hours after irradiation. The knockdown of p53 by siRNA reduced radia-
tion-dependent induction of MVP, as had been demonstrated before in human diploid 
fibroblasts (HDFs) with regard to the senescence-induced increase of MVP [501]. 
Interestingly, also the basal MVP level was reduced upon p53-depletion, indicating that 
p53 might play a general role in the regulation of MVP expression. Most of the cancers 
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cells, for which we determined high MVP expression levels, harbored wild type p53. In 
senescent cells, phosphorylation of p53 is often increased [502], which may result in 
enhanced p53-transcriptional activity. However, this was not the case for the cancer cell 
lines we worked with. Eventually, a more sensitive and more comprehensive assay may 
be required to precisely determine the activity status of p53 in cancer cells. 
Of note, the MVP expression level was difficult to follow, since with increasing cell 
confluency MVP expression levels increased as well. This upregulation of MVP could 
be counteracted by replacing the medium with fresh medium or performing the experi-
ments at low cell densities. We learnt that it is the number of cells and conditioning of 
the supernatant and not the confluency itself that affected MVP expression. Thus, 
unknown factors released by the cells might induce MVP expression in an autocrine 
manner, which could explain that increasing the amount of medium, or replacing the 
medium, reduced the inductive stimuli. Moreover, cellular irradiation seemed to 
increase secretion of such stimulatory factors. MVP levels increased after irradiation 
with 10 Gy, even though the cell number remained low and 24-hour medium changes 
reduced the induction of MVP to a large extent. Furthermore, medium that was condi-
tioned for 48 hours by irradiated cells led to stronger induction of MVP in untreated 
cells, than conditioned medium from unirradiated cells. Though, again, to find the right 
control condition was difficult, because non-irradiated cells proliferate faster and the 
cell number critically influences the amount of factors released. Importantly, we could 
exclude that low pH and increasing lactate concentrations contribute to the induction of 
MVP expression. 
Stimulation of the EGFR receptor by EGF led to an increase in MVP expression in 
A549 cells. This cell line expresses aberrant, constitutively active Ras, which has been 
linked to increased release of EGFR ligands upon irradiation [269, 270]. Furthermore, 
ADAM metallopeptidase domain 17 (ADAM17), which is involved in the shedding of 
EGFR ligands, displayed increased activity in response to ionizing radiation (prelimi-
nary results obtained by Ashish Sharma, in our group). Thus, EGFR signaling may 
contribute to radiation-induced MVP expression. Further investigations are required to 
evaluate the importance of the EGFR in upregulation of MVP upon IR and to elucidate 
the precise mechanism leading to increased MVP expression. 
3.5.2.3 Conclusion  
Elucidation of the pathways involved in MVP upregulation by the different stimuli 
could be a next step. Our observations imply that secreted factors play a crucial role in 
the regulation of MVP expression. It would be interesting to know if and how the 
numerous stimuli that lead to the induction of MVP, converge on the signaling level. 
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Interferon γ has been proposed to act through the JAK/STAT pathway on MVP 
transcription, even though the main increase in the MVP protein level upon stimulation 
with IFNγ has been designated to an increased translation rate [330]. IFNγ, according to 
literature, is not released by solid cancer cells, though respective murine in vivo models 
could shed more light on the putative role of paracrine stimulation of MVP expression 
in cancer cells by IFNγ. 
We found that EGFR-stimulation resulted in an increased MVP expression and Johnson 
et al. showed that the MVP protein levels were significantly elevated in glioblastoma 
tumor xenografts expressing the constitutively active EGFRvIII compared to xenografts 
with wild type EGFR [503]. The exact mechanism by which EGFR leads to MVP 
upregulation is not known, but EGFR is also known to activate STAT proteins. 
Interestingly, combined activation of the JAK/STAT and EGFR signaling has been 
demonstrated to contribute to carcinogenesis [504] and both pathways were found to be 
constitutively active across most human hepatocellular carcinomas [505]. That MVP is 
not merely a silent passenger, upregulated by these two pathways, is indicated by two 
recent publications. Loetsch et al. determined a link between MVP and PI3K-signaling 
in a glioblastoma cell line. Their data suggest that MVP might interact with EGFR or a 
binding partner of EGFR, thus enhancing receptor stability or altering receptor recy-
cling [506]. And Losert et al. reported a link between MVP and resistance to the EGFR 
inhibitor gefitinib. They observed that in hepatocellular carcinoma cells, expression of 
MVP increased EGFR-independent phosphorylation of Akt, which might explain the 
increased resistance to EGFR-inhibitors in presence of MVP expression [507]. 
Probably, MVP not only confers apoptotic resistance to senescent human diploid 
fibroblast but also to cancers cells, essentially to those harboring wild type p53 and thus 
may contribute to early carcinogenesis.  
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